<?xml version="1.0" encoding="UTF-8"?><corpus cvsVersion="1.2" source="AIMed">  <document id="AIMed.d3" origId="11781834" set="test">    <sentence charOffset="0-131" id="AIMed.d3.s25" seqId="s25" text="Role of cyclin-dependent kinase inhibitors in the growth arrest at senescence in human prostate epithelial and uroepithelial cells.">      </sentence>    <sentence charOffset="132-278" id="AIMed.d3.s26" seqId="s26" text="Cellular senescence has been proposed to be an in vitro and in vivo block that cells must overcome in order to immortalize and become tumorigenic.">      </sentence>    <sentence charOffset="279-452" id="AIMed.d3.s27" seqId="s27" text="To characterize these pathways, we focused on changes in the cyclin-dependent kinase inhibitors and their binding partners that underlie the cell cycle arrest at senescence.">      </sentence>    <sentence charOffset="453-566" id="AIMed.d3.s28" seqId="s28" text="As a model, we utilized normal human prostate epithelial cell (HPEC) and human uroepithelial cell (HUC) cultures.">      </sentence>    <sentence charOffset="567-726" id="AIMed.d3.s29" seqId="s29" text="After 30-40 population doublings cells became growth-arrested in G0/1 with a threefold decrease in Cdk2-associated activity, a point defined as pre-senescence.">      <entity charOffset="99-103" id="AIMed.d3.s29.e0" seqId="e45" text="Cdk2" type="protein" />    </sentence>    <sentence charOffset="727-877" id="AIMed.d3.s30" seqId="s30" text="Temporally following this growth arrest, the cells develop a senescence morphology and express senescence-associated beta-galactosidase (SA-beta-gal).">      <entity charOffset="117-135" id="AIMed.d3.s30.e0" seqId="e46" text="beta-galactosidase" type="protein" />      <entity charOffset="95-135" id="AIMed.d3.s30.e1" seqId="e47" text="senescence-associated beta-galactosidase" type="protein" />      <entity charOffset="137-148" id="AIMed.d3.s30.e2" seqId="e48" text="SA-beta-gal" type="protein" />    </sentence>    <sentence charOffset="878-999" id="AIMed.d3.s31" seqId="s31" text="Levels of p16(INK4a) and p57(KIP2) rise in HUCs during progressive passages, whereas only p16 increases in HPEC cultures.">      <entity charOffset="10-13" id="AIMed.d3.s31.e0" seqId="e49" text="p16" type="protein" />      <entity charOffset="14-19" id="AIMed.d3.s31.e1" seqId="e50" text="INK4a" type="protein" />      <entity charOffset="25-28" id="AIMed.d3.s31.e2" seqId="e51" text="p57" type="protein" />      <entity charOffset="29-33" id="AIMed.d3.s31.e3" seqId="e52" text="KIP2" type="protein" />      <entity charOffset="90-93" id="AIMed.d3.s31.e4" seqId="e53" text="p16" type="protein" />    </sentence>    <sentence charOffset="1000-1083" id="AIMed.d3.s32" seqId="s32" text="The induced expression of p57, similar to p16, produces a senescent-like phenotype.">      <entity charOffset="26-29" id="AIMed.d3.s32.e0" seqId="e54" text="p57" type="protein" />      <entity charOffset="42-45" id="AIMed.d3.s32.e1" seqId="e55" text="p16" type="protein" />    </sentence>    <sentence charOffset="1084-1152" id="AIMed.d3.s33" seqId="s33" text="pRB, cyclin D, p19(INK4d) and p27(KIP1) decrease in both cell types.">      <entity charOffset="0-3" id="AIMed.d3.s33.e0" seqId="e56" text="pRB" type="protein" />      <entity charOffset="5-13" id="AIMed.d3.s33.e1" seqId="e57" text="cyclin D" type="protein" />      <entity charOffset="15-18" id="AIMed.d3.s33.e2" seqId="e58" text="p19" type="protein" />      <entity charOffset="19-24" id="AIMed.d3.s33.e3" seqId="e59" text="INK4d" type="protein" />      <entity charOffset="30-33" id="AIMed.d3.s33.e4" seqId="e60" text="p27" type="protein" />      <entity charOffset="34-38" id="AIMed.d3.s33.e5" seqId="e61" text="KIP1" type="protein" />    </sentence>    <sentence charOffset="1153-1338" id="AIMed.d3.s34" seqId="s34" text="We find that p53, p21(CIP1) and p15(INK4b) are transiently elevated in HPECs and HUCs at the pre-senescent growth arrest, then return to low proliferating levels at terminal senescence.">      <entity charOffset="13-16" id="AIMed.d3.s34.e0" seqId="e62" text="p53" type="protein" />      <entity charOffset="18-21" id="AIMed.d3.s34.e1" seqId="e63" text="p21" type="protein" />      <entity charOffset="22-26" id="AIMed.d3.s34.e2" seqId="e64" text="CIP1" type="protein" />      <entity charOffset="32-35" id="AIMed.d3.s34.e3" seqId="e65" text="p15" type="protein" />      <entity charOffset="36-41" id="AIMed.d3.s34.e4" seqId="e66" text="INK4b" type="protein" />    </sentence>    <sentence charOffset="1339-1537" id="AIMed.d3.s35" seqId="s35" text="Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.">      <entity charOffset="12-15" id="AIMed.d3.s35.e0" seqId="e67" text="p53" type="protein" />      <entity charOffset="17-20" id="AIMed.d3.s35.e1" seqId="e68" text="p21" type="protein" />      <entity charOffset="21-25" id="AIMed.d3.s35.e2" seqId="e69" text="CIP1" type="protein" />      <entity charOffset="28-31" id="AIMed.d3.s35.e3" seqId="e70" text="p15" type="protein" />      <entity charOffset="32-37" id="AIMed.d3.s35.e4" seqId="e71" text="INK4b" type="protein" />      <entity charOffset="40-43" id="AIMed.d3.s35.e5" seqId="e72" text="p16" type="protein" />      <entity charOffset="44-49" id="AIMed.d3.s35.e6" seqId="e73" text="INK4a" type="protein" />      <entity charOffset="56-59" id="AIMed.d3.s35.e7" seqId="e74" text="p57" type="protein" />      <entity charOffset="60-64" id="AIMed.d3.s35.e8" seqId="e75" text="KIP2" type="protein" />    </sentence>    <sentence charOffset="1538-1811" id="AIMed.d3.s36" seqId="s36" text="These results indicate: (i) the existence of a subset of growth inhibiting genes elevated at the onset of the senescence, (ii) a distinct class of genes involved in the maintenance of senescence, and (iii) the frequent inactivation of these pathways during immortalization.">      </sentence>  </document>  <document id="AIMed.d4" origId="11787467" set="test">    <sentence charOffset="0-109" id="AIMed.d4.s37" seqId="s37" text="Positive inotropic responses mediated by endothelin ET(A) and ET(B) receptors in human myocardial trabeculae.">      <entity charOffset="52-57" id="AIMed.d4.s37.e0" seqId="e76" text="ET(A)" type="protein" />      <entity charOffset="62-67" id="AIMed.d4.s37.e1" seqId="e77" text="ET(B)" type="protein" />    </sentence>    <sentence charOffset="110-308" id="AIMed.d4.s38" seqId="s38" text="The aim of the present study was to determine possible inotropic effects mediated by endothelin ET(A) and ET(B) receptors in human myocardial trabeculae from the right atrium and the left ventricle.">      <entity charOffset="96-101" id="AIMed.d4.s38.e0" seqId="e78" text="ET(A)" type="protein" />      <entity charOffset="106-111" id="AIMed.d4.s38.e1" seqId="e79" text="ET(B)" type="protein" />    </sentence>    <sentence charOffset="309-466" id="AIMed.d4.s39" seqId="s39" text="Isolated trabeculae from human hearts were paced at 1.0 Hz in tissue baths, and changes in isometric contractile force upon exposure to agonist were studied.">      </sentence>    <sentence charOffset="467-553" id="AIMed.d4.s40" seqId="s40" text="Endothelin-1 (ET-1) and ET-3 had a strong positive inotropic effect in all trabeculae.">      <entity charOffset="0-12" id="AIMed.d4.s40.e0" seqId="e80" text="Endothelin-1" type="protein" />      <entity charOffset="14-18" id="AIMed.d4.s40.e1" seqId="e81" text="ET-1" type="protein" />      <entity charOffset="24-28" id="AIMed.d4.s40.e2" seqId="e82" text="ET-3" type="protein" />    </sentence>    <sentence charOffset="554-664" id="AIMed.d4.s41" seqId="s41" text="ET-1 was significantly more potent than ET-3 in both atrial (P &lt; 0.001) and ventricular (P &lt; 0.05) trabeculae.">      <entity charOffset="0-4" id="AIMed.d4.s41.e0" seqId="e83" text="ET-1" type="protein" />      <entity charOffset="40-44" id="AIMed.d4.s41.e1" seqId="e84" text="ET-3" type="protein" />    </sentence>    <sentence charOffset="665-916" id="AIMed.d4.s42" seqId="s42" text="Preincubation with the ET(A) receptor antagonist FR139317 (1 microM) decreased significantly (P &lt; 0.005) the potency of ET- I in both atrial and ventricular trabeculae, without any significant changes in Emax (maximum effect obtained with an agonist).">      <entity charOffset="23-37" id="AIMed.d4.s42.e0" seqId="e85" text="ET(A) receptor" type="protein" />      <entity charOffset="120-125" id="AIMed.d4.s42.e1" seqId="e86" text="ET- I" type="protein" />    </sentence>    <sentence charOffset="917-1100" id="AIMed.d4.s43" seqId="s43" text="The ET(B) receptor agonist IRL 1620 had a positive inotropic effect only in some trabeculae, and the ET(B) receptor antagonist BQ 788 (1 microM) almost completely blocked this effect.">      <entity charOffset="4-18" id="AIMed.d4.s43.e0" seqId="e87" text="ET(B) receptor" type="protein" />      <entity charOffset="101-115" id="AIMed.d4.s43.e1" seqId="e88" text="ET(B) receptor" type="protein" />    </sentence>    <sentence charOffset="1101-1256" id="AIMed.d4.s44" seqId="s44" text="These results suggest that both ET(A) and ET(B) receptors mediate positive inotropic responses at both the atrial and ventricular level in the human heart.">      <entity charOffset="32-37" id="AIMed.d4.s44.e0" seqId="e89" text="ET(A)" type="protein" />      <entity charOffset="42-47" id="AIMed.d4.s44.e1" seqId="e90" text="ET(B)" type="protein" />    </sentence>  </document>  <document id="AIMed.d6" origId="11787815" set="test">    <sentence charOffset="0-51" id="AIMed.d6.s50" seqId="s50" text="Apoptotic proteins. p53 and c-myc related pathways.">      <entity charOffset="20-23" id="AIMed.d6.s50.e0" seqId="e95" text="p53" type="protein" />      <entity charOffset="28-33" id="AIMed.d6.s50.e1" seqId="e96" text="c-myc" type="protein" />    </sentence>    <sentence charOffset="52-158" id="AIMed.d6.s51" seqId="s51" text="c-Myc and p53 are two proteins that have critical roles in the regulation of apoptosis and the cell cycle.">      <entity charOffset="0-5" id="AIMed.d6.s51.e0" seqId="e97" text="c-Myc" type="protein" />      <entity charOffset="10-13" id="AIMed.d6.s51.e1" seqId="e98" text="p53" type="protein" />    </sentence>    <sentence charOffset="159-389" id="AIMed.d6.s52" seqId="s52" text="The authors review how these two proteins are thought to control the opposing events of proliferation and apoptosis and examine whether their well-documented biological roles in tumorigenesis can be applied to the vascular system.">      </sentence>  </document>  <document id="AIMed.d7" origId="11787847" set="test">    <sentence charOffset="0-117" id="AIMed.d7.s53" seqId="s53" text="A comparative study of E-cadherin and stromelysin-3 expression in de novo and ex adenoma carcinoma of the colorectum.">      <entity charOffset="23-33" id="AIMed.d7.s53.e0" seqId="e99" text="E-cadherin" type="protein" />      <entity charOffset="38-51" id="AIMed.d7.s53.e1" seqId="e100" text="stromelysin-3" type="protein" />    </sentence>    <sentence charOffset="118-285" id="AIMed.d7.s54" seqId="s54" text="An apparent exception to the colorectal adenoma-carcinoma carcinogenetic pathway is the so-called &quot;de novo&quot; carcinoma which has no evidence of adenoma in its vicinity.">      </sentence>    <sentence charOffset="286-512" id="AIMed.d7.s55" seqId="s55" text="Despite the fact that they are often quite small, these lesions appear to be more aggressive (i.e., greater likelihood of lymph-node metastases) than carcinomas that clearly arise from surrounding adenomas exadenoma carcinoma.">      </sentence>    <sentence charOffset="513-875" id="AIMed.d7.s56" seqId="s56" text="The purpose of the present comparative immunohistochemical study was to compare rates of cell adhesion molecule (E-cadherin) and protease [stromelysin-3 (ST-3)] expression in groups of de novo (n=64) and ex adenoma (n=42) lesions in order to see whether their more aggressive behavior is associated with decreased cell adhesion and increased protease expression.">      <entity charOffset="113-123" id="AIMed.d7.s56.e0" seqId="e101" text="E-cadherin" type="protein" />      <entity charOffset="139-152" id="AIMed.d7.s56.e1" seqId="e102" text="stromelysin-3" type="protein" />      <entity charOffset="154-158" id="AIMed.d7.s56.e2" seqId="e103" text="ST-3" type="protein" />    </sentence>    <sentence charOffset="876-1032" id="AIMed.d7.s57" seqId="s57" text="The rates of extensive ST-3 expression and decreased E-cadherin expression were significantly higher in the de novo group (P=0.014 and 0.005, respectively).">      <entity charOffset="23-27" id="AIMed.d7.s57.e0" seqId="e104" text="ST-3" type="protein" />      <entity charOffset="53-63" id="AIMed.d7.s57.e1" seqId="e105" text="E-cadherin" type="protein" />    </sentence>    <sentence charOffset="1033-1162" id="AIMed.d7.s58" seqId="s58" text="Histopathologically, the de novo group also had a significantly higher percentage of cases with an infiltrative invasion pattern.">      </sentence>    <sentence charOffset="1163-1303" id="AIMed.d7.s59" seqId="s59" text="These differences highlight the more aggressive phenotype of the de novo colorectal carcinoma and fit with their greater invasive potential.">      </sentence>  </document>  <document id="AIMed.d11" origId="11789762" set="test">    <sentence charOffset="0-118" id="AIMed.d11.s87" seqId="s87" text="Immunohistochemical analysis of epidermal growth factor receptor family members in stage I non-small cell lung cancer.">      </sentence>    <sentence charOffset="119-297" id="AIMed.d11.s88" seqId="s88" text="BACKGROUND: To elucidate the relationship between the expression of epidermal growth factor receptor family members (ErbB-1, neu/ErbB-2, ErbB-3, and ErbB-4) and tumor recurrence.">      <entity charOffset="117-123" id="AIMed.d11.s88.e0" seqId="e137" text="ErbB-1" type="protein" />      <entity charOffset="129-135" id="AIMed.d11.s88.e1" seqId="e138" text="ErbB-2" type="protein" />      <entity charOffset="137-143" id="AIMed.d11.s88.e2" seqId="e139" text="ErbB-3" type="protein" />      <entity charOffset="149-155" id="AIMed.d11.s88.e3" seqId="e140" text="ErbB-4" type="protein" />    </sentence>    <sentence charOffset="298-473" id="AIMed.d11.s89" seqId="s89" text="METHODS: We used immunohistochemistry to examine the expression of four epidermal growth factor receptor family members in 73 patients with stage I non-small cell lung cancer.">      </sentence>    <sentence charOffset="474-738" id="AIMed.d11.s90" seqId="s90" text="RESULTS: Using Cox univariate analysis, we determined that angiolymphatic tumor emboli and non-well-differentiated tumor cells were two significant conventional pathologic predictors of tumor recurrence, and that ErbB-1 and ErbB-3 were also significant predictors.">      <entity charOffset="213-219" id="AIMed.d11.s90.e0" seqId="e141" text="ErbB-1" type="protein" />      <entity charOffset="224-230" id="AIMed.d11.s90.e1" seqId="e142" text="ErbB-3" type="protein" />    </sentence>    <sentence charOffset="739-900" id="AIMed.d11.s91" seqId="s91" text="Co-expression of ErbB-1+, -3+, or expression of three or more epidermal growth factor receptor family members had a significant effect on lung cancer recurrence.">      <entity charOffset="17-23" id="AIMed.d11.s91.e0" seqId="e143" text="ErbB-1" type="protein" />    </sentence>    <sentence charOffset="901-1019" id="AIMed.d11.s92" seqId="s92" text="A stepwise multivariate Cox proportional hazards regression analysis provided a predictive model for tumor recurrence.">      </sentence>    <sentence charOffset="1020-1188" id="AIMed.d11.s93" seqId="s93" text="CONCLUSIONS: The present study shows that in patients with a non-well-differentiated tumor, overexpression of ErbB-3 is a useful marker for predicting tumor recurrence.">      <entity charOffset="110-116" id="AIMed.d11.s93.e0" seqId="e144" text="ErbB-3" type="protein" />    </sentence>    <sentence charOffset="1189-1306" id="AIMed.d11.s94" seqId="s94" text="The present study also confirmed that ErbB-1 expression increased in proportion to the loss of tumor differentiation.">      <entity charOffset="38-44" id="AIMed.d11.s94.e0" seqId="e145" text="ErbB-1" type="protein" />    </sentence>    <sentence charOffset="1307-1370" id="AIMed.d11.s95" seqId="s95" text="The correlation between ErbB-3 and distant metastasis was good.">      <entity charOffset="24-30" id="AIMed.d11.s95.e0" seqId="e146" text="ErbB-3" type="protein" />    </sentence>  </document>  <document id="AIMed.d13" origId="11790884" set="test">    <sentence charOffset="0-79" id="AIMed.d13.s107" seqId="s107" text="Potential cellular signatures of viral infections in human hematopoietic cells.">      </sentence>    <sentence charOffset="80-397" id="AIMed.d13.s108" seqId="s108" text="Expression profiling of cellular genes was performed using a 10,000 cDNA human gene array in order to identify expression changes following chronic infection of human hematopoietic cells with Kaposi's Sarcoma-associated Virus (KSHV) also known as Human Herpesvirus 8 (HHV8) and Human T cell leukemia virus-1 (HTLV-1).">      </sentence>    <sentence charOffset="398-651" id="AIMed.d13.s109" seqId="s109" text="We performed cell-free in vitro infection of primary bone marrow derived CD34+ cells using semi-purified HHV8 and a mature IL-2 dependent T cell line, KIT 225, using highly concentrated viral stocks prepared from an infectious molecular clone of HTLV-1.">      <entity charOffset="73-77" id="AIMed.d13.s109.e0" seqId="e161" text="CD34" type="protein" />      <entity charOffset="123-127" id="AIMed.d13.s109.e1" seqId="e162" text="IL-2" type="protein" />    </sentence>    <sentence charOffset="652-783" id="AIMed.d13.s110" seqId="s110" text="Thirty days post infection, mRNA was isolated from infected cultures and uninfected controls and submitted for microarray analysis.">      </sentence>    <sentence charOffset="784-921" id="AIMed.d13.s111" seqId="s111" text="More than 400 genes were differentially expressed more than two-fold following HHV8 infection of primary bone marrow derived CD34+ cells.">      <entity charOffset="125-129" id="AIMed.d13.s111.e0" seqId="e163" text="CD34" type="protein" />    </sentence>    <sentence charOffset="922-1085" id="AIMed.d13.s112" seqId="s112" text="Of these 400, interferon regulatory factor 4 (IRF4), cyclin B2, TBP-associated factor, eukaryotic elongation factor and pim 2 were up-regulated more than 3.5 fold.">      <entity charOffset="14-44" id="AIMed.d13.s112.e0" seqId="e164" text="interferon regulatory factor 4" type="protein" />      <entity charOffset="46-50" id="AIMed.d13.s112.e1" seqId="e165" text="IRF4" type="protein" />      <entity charOffset="53-62" id="AIMed.d13.s112.e2" seqId="e166" text="cyclin B2" type="protein" />      <entity charOffset="120-125" id="AIMed.d13.s112.e3" seqId="e167" text="pim 2" type="protein" />    </sentence>    <sentence charOffset="1086-1232" id="AIMed.d13.s113" seqId="s113" text="In contrast, less than 100 genes were differentially expressed more than two-fold following chronic infection of a mature T cell line with HTLV-1.">      </sentence>    <sentence charOffset="1233-1289" id="AIMed.d13.s114" seqId="s114" text="Of these, only cdc7 was up-regulated more than 3.5 fold.">      <entity charOffset="15-19" id="AIMed.d13.s114.e0" seqId="e168" text="cdc7" type="protein" />    </sentence>    <sentence charOffset="1290-1451" id="AIMed.d13.s115" seqId="s115" text="These data may provide insight into cellular signatures of infection useful for diagnosis of infection as well as potential targets for therapeutic intervention.">      </sentence>  </document>  <document id="AIMed.d19" origId="11795408" set="test">    <sentence charOffset="0-67" id="AIMed.d19.s159" seqId="s159" text="The genetics of host resistance and susceptibility to tuberculosis.">      </sentence>    <sentence charOffset="68-228" id="AIMed.d19.s160" seqId="s160" text="The study of human genomics has the potential to aid our understanding of the interindividual and interpopulation differences in susceptibility to tuberculosis.">      </sentence>    <sentence charOffset="229-334" id="AIMed.d19.s161" seqId="s161" text="Resistance to infection is affected by the ability of macrophages to phagocytose and destroy the bacilli.">      </sentence>    <sentence charOffset="335-531" id="AIMed.d19.s162" seqId="s162" text="Several genes are involved in this process, and two have been the focus of recent interest: the natural resistance-associated protein (NRAMP1) gene and the genes coding for the vitamin D receptor.">      <entity charOffset="96-133" id="AIMed.d19.s162.e0" seqId="e234" text="natural resistance-associated protein" type="protein" />      <entity charOffset="135-141" id="AIMed.d19.s162.e1" seqId="e235" text="NRAMP1" type="protein" />      <entity charOffset="177-195" id="AIMed.d19.s162.e2" seqId="e236" text="vitamin D receptor" type="protein" />    </sentence>    <sentence charOffset="532-688" id="AIMed.d19.s163" seqId="s163" text="Susceptibility genes have also been discovered--for example, one on the X chromosome that may explain the increased susceptibility of males to tuberculosis.">      </sentence>    <sentence charOffset="689-816" id="AIMed.d19.s164" seqId="s164" text="Studies have also focused on the variations in virulence of the bacillus in both its drug-susceptible and drug-resistant forms.">      </sentence>    <sentence charOffset="817-1025" id="AIMed.d19.s165" seqId="s165" text="These mechanisms must be understood in order to prevent, or combat, the emergence of a virulent, multidrug-resistant form of the bacillus that would be uncontrollable by means of today's treatment strategies.">      </sentence>  </document>  <document id="AIMed.d21" origId="11796738" set="test">    <sentence charOffset="0-92" id="AIMed.d21.s170" seqId="s170" text="Regulated trafficking of neurotransmitter transporters: common notes but different melodies.">      </sentence>    <sentence charOffset="93-232" id="AIMed.d21.s171" seqId="s171" text="The activity of biogenic amine and amino acid neurotransmitters is limited by presynaptic and astrocytic Na(+)-dependent transport systems.">      </sentence>    <sentence charOffset="233-422" id="AIMed.d21.s172" seqId="s172" text="Their functional importance is underscored by the observation that these transporters are the targets of broad classes of psychotherapeutic agents, including antidepressants and stimulants.">      </sentence>    <sentence charOffset="423-549" id="AIMed.d21.s173" seqId="s173" text="Early studies suggested that the activity of these transporters can be fine tuned by a number of different signaling pathways.">      </sentence>    <sentence charOffset="550-721" id="AIMed.d21.s174" seqId="s174" text="In the past five years, several groups have provided compelling evidence that changing the cell surface availability of these transporters contributes to this fine tuning.">      </sentence>    <sentence charOffset="722-939" id="AIMed.d21.s175" seqId="s175" text="This regulated trafficking can result in rapid (within minutes) increases or decreases in the plasma membrane expression of these transporters and is independent of transcriptional or translational control mechanisms.">      </sentence>    <sentence charOffset="940-1151" id="AIMed.d21.s176" seqId="s176" text="Many of the same signaling molecules, including protein kinase C (PKC), tyrosine kinase, phosphatidylinositol 3-kinase (P13-K), and protein phosphatase, regulate the transporters for different neurotransmitters.">      <entity charOffset="48-64" id="AIMed.d21.s176.e0" seqId="e243" text="protein kinase C" type="protein" />      <entity charOffset="66-69" id="AIMed.d21.s176.e1" seqId="e244" text="PKC" type="protein" />      <entity charOffset="72-118" id="AIMed.d21.s176.e2" seqId="e245" text="tyrosine kinase, phosphatidylinositol 3-kinase" type="protein" />      <entity charOffset="120-125" id="AIMed.d21.s176.e3" seqId="e246" text="P13-K" type="protein" />    </sentence>    <sentence charOffset="1152-1308" id="AIMed.d21.s177" seqId="s177" text="In addition to these classical receptor activated pathways, transporter substrates also regulate activity and cell surface expression of these transporters.">      </sentence>    <sentence charOffset="1309-1383" id="AIMed.d21.s178" seqId="s178" text="In fact, some of the transporters form complexes with signaling molecules.">      </sentence>    <sentence charOffset="1384-1637" id="AIMed.d21.s179" seqId="s179" text="Given the functional and genetic similarities of these transporters, it is not surprising that the same signaling molecules regulate their trafficking, but except for the molecules, the actual effects on individual transporters are remarkably different.">      </sentence>    <sentence charOffset="1638-1726" id="AIMed.d21.s180" seqId="s180" text="It is as if the same musical notes have been rearranged into several different melodies.">      </sentence>  </document>  <document id="AIMed.d24" origId="11800374" set="test">    <sentence charOffset="0-140" id="AIMed.d24.s196" seqId="s196" text="Instability of extracellular matrix gene expression in primary cell culture of fibroblasts from human vocal fold lamina propria and tracheal">      </sentence>    <sentence charOffset="141-254" id="AIMed.d24.s197" seqId="s197" text="scar.Primary fibroblast cell cultures were established from lamina propria of human vocal fold and tracheal scar.">      </sentence>    <sentence charOffset="255-425" id="AIMed.d24.s198" seqId="s198" text="There exists a crucial need to provide new tools for studying voice biology, and one of the first steps is the development of a human primary laryngeal cell culture bank.">      </sentence>    <sentence charOffset="426-641" id="AIMed.d24.s199" seqId="s199" text="Because cell lines can lose their differentiated phenotype in culture across passages, documentation of gene expression must be determined for passage populations, for us to have knowledge of cell behavior in vitro.">      </sentence>    <sentence charOffset="642-989" id="AIMed.d24.s200" seqId="s200" text="Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.">      <entity charOffset="78-91" id="AIMed.d24.s200.e0" seqId="e271" text="procollagen I" type="protein" />      <entity charOffset="93-104" id="AIMed.d24.s200.e1" seqId="e272" text="collagenase" type="protein" />      <entity charOffset="106-113" id="AIMed.d24.s200.e2" seqId="e273" text="elastin" type="protein" />      <entity charOffset="115-141" id="AIMed.d24.s200.e3" seqId="e274" text="hyaluronic acid synthase 2" type="protein" />      <entity charOffset="143-156" id="AIMed.d24.s200.e4" seqId="e275" text="hyaluronidase" type="protein" />      <entity charOffset="158-169" id="AIMed.d24.s200.e5" seqId="e276" text="fibronectin" type="protein" />      <entity charOffset="171-175" id="AIMed.d24.s200.e6" seqId="e277" text="cd44" type="protein" />      <entity charOffset="177-189" id="AIMed.d24.s200.e7" seqId="e278" text="fibromodulin" type="protein" />      <entity charOffset="195-202" id="AIMed.d24.s200.e8" seqId="e279" text="decorin" type="protein" />    </sentence>    <sentence charOffset="990-1218" id="AIMed.d24.s201" seqId="s201" text="Cytogenetic analysis demonstrated relative stability of the karyotypes across passages for the tracheal scar cell cultures, whereas the karyotypes of the normal lamina propria fibroblasts showed instability in in vitro cultures.">      </sentence>    <sentence charOffset="1219-1316" id="AIMed.d24.s202" seqId="s202" text="Recommendations for use of primary cell cultures for further studies of gene expression are made.">      </sentence>  </document>  <document id="AIMed.d28" origId="10074428" set="test">    <sentence charOffset="0-116" id="AIMed.d28.s232" seqId="s232" text="Identification of a new member of the tumor necrosis factor family and its receptor, a human ortholog of mouse GITR.">      </sentence>    <sentence charOffset="117-303" id="AIMed.d28.s233" seqId="s233" text="The tumor necrosis factor (TNF) and TNF receptor (TNFR) gene superfamilies regulate diverse biological functions, including cell proliferation, differentiation, and survival [1] [2] [3].">      </sentence>    <sentence charOffset="304-522" id="AIMed.d28.s234" seqId="s234" text="We have identified a new TNF-related ligand, designated human GITR ligand (hGITRL), and its human receptor (hGITR), an ortholog of the recently discovered murine glucocorticoid-induced TNFR-related (mGITR) protein [4].">      <entity charOffset="62-66" id="AIMed.d28.s234.e0" seqId="e329" text="GITR" type="protein" />      <entity charOffset="62-73" id="AIMed.d28.s234.e1" seqId="e330" text="GITR ligand" type="protein" />      <entity charOffset="75-81" id="AIMed.d28.s234.e2" seqId="e332" text="hGITRL" type="protein" />      <entity charOffset="108-113" id="AIMed.d28.s234.e3" seqId="e335" text="hGITR" type="protein" />      <entity charOffset="199-204" id="AIMed.d28.s234.e4" seqId="e338" text="mGITR" type="protein" />      <entity charOffset="162-213" id="AIMed.d28.s234.e5" seqId="e339" text="glucocorticoid-induced TNFR-related (mGITR) protein" type="protein" />      <interaction e1="AIMed.d28.s234.e0" e2="AIMed.d28.s234.e2" id="AIMed.d28.s234.i0" type="PPI" />      <interaction e1="AIMed.d28.s234.e1" e2="AIMed.d28.s234.e3" id="AIMed.d28.s234.i1" type="PPI" />      <interaction e1="AIMed.d28.s234.e2" e2="AIMed.d28.s234.e3" id="AIMed.d28.s234.i2" type="PPI" />    </sentence>    <sentence charOffset="523-620" id="AIMed.d28.s235" seqId="s235" text="The hGITRL gene mapped to chromosome 1q23, near the gene for the TNF homolog Fas/CD95 ligand [5].">      <entity charOffset="4-10" id="AIMed.d28.s235.e0" seqId="e340" text="hGITRL" type="protein" />      <entity charOffset="77-80" id="AIMed.d28.s235.e1" seqId="e341" text="Fas" type="protein" />      <entity charOffset="81-92" id="AIMed.d28.s235.e2" seqId="e342" text="CD95 ligand" type="protein" />    </sentence>    <sentence charOffset="621-723" id="AIMed.d28.s236" seqId="s236" text="The hGITR gene mapped to chromosome 1p36, near a cluster of five genes encoding TNFR homologs [1] [6].">      <entity charOffset="4-9" id="AIMed.d28.s236.e0" seqId="e343" text="hGITR" type="protein" />    </sentence>    <sentence charOffset="724-843" id="AIMed.d28.s237" seqId="s237" text="We found hGITRL mRNA in several peripheral tissues, and detected hGITRL protein on cultured vascular endothelial cells.">      <entity charOffset="9-15" id="AIMed.d28.s237.e0" seqId="e344" text="hGITRL" type="protein" />      <entity charOffset="65-71" id="AIMed.d28.s237.e1" seqId="e345" text="hGITRL" type="protein" />    </sentence>    <sentence charOffset="844-1019" id="AIMed.d28.s238" seqId="s238" text="The levels of hGITR mRNA in tissues were generally low; in peripheral blood T cells, however, antigen-receptor stimulation led to a substantial induction of hGITR transcripts.">      <entity charOffset="14-19" id="AIMed.d28.s238.e0" seqId="e346" text="hGITR" type="protein" />      <entity charOffset="157-162" id="AIMed.d28.s238.e1" seqId="e347" text="hGITR" type="protein" />    </sentence>    <sentence charOffset="1020-1262" id="AIMed.d28.s239" seqId="s239" text="Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti-apoptotic transcription factor NF-kappaB, via a pathway that appeared to involve TNFR-associated factor 2 (TRAF2) [7] and NF-kappaB-inducing kinase (NIK) [8].">      <entity charOffset="18-24" id="AIMed.d28.s239.e0" seqId="e348" text="hGITRL" type="protein" />      <entity charOffset="29-34" id="AIMed.d28.s239.e1" seqId="e349" text="hGITR" type="protein" />      <entity charOffset="115-124" id="AIMed.d28.s239.e2" seqId="e350" text="NF-kappaB" type="protein" />      <entity charOffset="165-189" id="AIMed.d28.s239.e3" seqId="e351" text="TNFR-associated factor 2" type="protein" />      <entity charOffset="191-196" id="AIMed.d28.s239.e4" seqId="e352" text="TRAF2" type="protein" />      <entity charOffset="206-215" id="AIMed.d28.s239.e5" seqId="e353" text="NF-kappaB" type="protein" />      <entity charOffset="206-231" id="AIMed.d28.s239.e6" seqId="e354" text="NF-kappaB-inducing kinase" type="protein" />      <entity charOffset="233-236" id="AIMed.d28.s239.e7" seqId="e355" text="NIK" type="protein" />    </sentence>    <sentence charOffset="1263-1371" id="AIMed.d28.s240" seqId="s240" text="Cotransfection of hGITRL and hGITR in Jurkat T leukemia cells inhibited antigen-receptor-induced cell death.">      <entity charOffset="18-24" id="AIMed.d28.s240.e0" seqId="e356" text="hGITRL" type="protein" />      <entity charOffset="29-34" id="AIMed.d28.s240.e1" seqId="e357" text="hGITR" type="protein" />    </sentence>    <sentence charOffset="1372-1452" id="AIMed.d28.s241" seqId="s241" text="Thus, hGITRL and hGITR may modulate T lymphocyte survival in peripheral tissues.">      <entity charOffset="6-12" id="AIMed.d28.s241.e0" seqId="e358" text="hGITRL" type="protein" />      <entity charOffset="17-22" id="AIMed.d28.s241.e1" seqId="e359" text="hGITR" type="protein" />    </sentence>  </document>  <document id="AIMed.d31" origId="10318773" set="test">    <sentence charOffset="0-114" id="AIMed.d31.s256" seqId="s256" text="A newly identified member of tumor necrosis factor receptor superfamily (TR6) suppresses LIGHT-mediated apoptosis.">      <entity charOffset="73-76" id="AIMed.d31.s256.e0" seqId="e413" text="TR6" type="protein" />      <entity charOffset="89-94" id="AIMed.d31.s256.e1" seqId="e414" text="LIGHT" type="protein" />    </sentence>    <sentence charOffset="115-213" id="AIMed.d31.s257" seqId="s257" text="TR6 (decoy receptor 3 (DcR3)) is a new member of the tumor necrosis factor receptor (TNFR) family.">      <entity charOffset="0-3" id="AIMed.d31.s257.e0" seqId="e415" text="TR6" type="protein" />      <entity charOffset="5-21" id="AIMed.d31.s257.e1" seqId="e416" text="decoy receptor 3" type="protein" />      <entity charOffset="23-27" id="AIMed.d31.s257.e2" seqId="e417" text="DcR3" type="protein" />    </sentence>    <sentence charOffset="214-284" id="AIMed.d31.s258" seqId="s258" text="TR6 mRNA is expressed in lung tissues and colon adenocarcinoma, SW480.">      <entity charOffset="0-3" id="AIMed.d31.s258.e0" seqId="e418" text="TR6" type="protein" />    </sentence>    <sentence charOffset="285-448" id="AIMed.d31.s259" seqId="s259" text="In addition, the expression of TR6 mRNA was shown in the endothelial cell line and induced by phorbol 12-myristate 13-acetate/ionomycin in Jurkat T leukemia cells.">      <entity charOffset="31-34" id="AIMed.d31.s259.e0" seqId="e419" text="TR6" type="protein" />    </sentence>    <sentence charOffset="449-565" id="AIMed.d31.s260" seqId="s260" text="The open reading frame of TR6 encodes 300 amino acids with a 29-residue signal sequence but no transmembrane region.">      <entity charOffset="26-29" id="AIMed.d31.s260.e0" seqId="e420" text="TR6" type="protein" />    </sentence>    <sentence charOffset="566-680" id="AIMed.d31.s261" seqId="s261" text="Using histidine-tagged recombinant TR6, we screened soluble forms of TNF-ligand proteins with immunoprecipitation.">      <entity charOffset="35-38" id="AIMed.d31.s261.e0" seqId="e421" text="TR6" type="protein" />    </sentence>    <sentence charOffset="681-825" id="AIMed.d31.s262" seqId="s262" text="Here, we demonstrate that TR6 specifically binds two cellular ligands, LIGHT (herpes virus entry mediator (HVEM)-L) and Fas ligand (FasL/CD95L).">      <entity charOffset="26-29" id="AIMed.d31.s262.e0" seqId="e422" text="TR6" type="protein" />      <entity charOffset="71-76" id="AIMed.d31.s262.e1" seqId="e428" text="LIGHT" type="protein" />      <entity charOffset="107-111" id="AIMed.d31.s262.e2" seqId="e430" text="HVEM" type="protein" />      <entity charOffset="78-114" id="AIMed.d31.s262.e3" seqId="e431" text="herpes virus entry mediator (HVEM)-L" type="protein" />      <entity charOffset="120-130" id="AIMed.d31.s262.e4" seqId="e433" text="Fas ligand" type="protein" />      <entity charOffset="132-136" id="AIMed.d31.s262.e5" seqId="e435" text="FasL" type="protein" />      <entity charOffset="137-142" id="AIMed.d31.s262.e6" seqId="e437" text="CD95L" type="protein" />      <interaction e1="AIMed.d31.s262.e0" e2="AIMed.d31.s262.e1" id="AIMed.d31.s262.i0" type="PPI" />      <interaction e1="AIMed.d31.s262.e0" e2="AIMed.d31.s262.e3" id="AIMed.d31.s262.i1" type="PPI" />      <interaction e1="AIMed.d31.s262.e0" e2="AIMed.d31.s262.e4" id="AIMed.d31.s262.i2" type="PPI" />      <interaction e1="AIMed.d31.s262.e0" e2="AIMed.d31.s262.e5" id="AIMed.d31.s262.i3" type="PPI" />      <interaction e1="AIMed.d31.s262.e0" e2="AIMed.d31.s262.e6" id="AIMed.d31.s262.i4" type="PPI" />    </sentence>    <sentence charOffset="826-926" id="AIMed.d31.s263" seqId="s263" text="These bindings were confirmed with HEK 293 EBNA cells transfected with LIGHT cDNA by flow cytometry.">      <entity charOffset="71-76" id="AIMed.d31.s263.e0" seqId="e439" text="LIGHT" type="protein" />    </sentence>    <sentence charOffset="927-982" id="AIMed.d31.s264" seqId="s264" text="TR6 inhibited LIGHT-induced cytotoxicity in HT29 cells.">      <entity charOffset="0-3" id="AIMed.d31.s264.e0" seqId="e440" text="TR6" type="protein" />      <entity charOffset="14-19" id="AIMed.d31.s264.e1" seqId="e441" text="LIGHT" type="protein" />    </sentence>    <sentence charOffset="983-1152" id="AIMed.d31.s265" seqId="s265" text="It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both lymphotoxin beta receptor (LTbetaR) and HVEM/TR2 receptors.">      <entity charOffset="23-28" id="AIMed.d31.s265.e0" seqId="e442" text="LIGHT" type="protein" />      <entity charOffset="110-126" id="AIMed.d31.s265.e1" seqId="e443" text="lymphotoxin beta" type="protein" />      <entity charOffset="110-135" id="AIMed.d31.s265.e2" seqId="e445" text="lymphotoxin beta receptor" type="protein" />      <entity charOffset="137-144" id="AIMed.d31.s265.e3" seqId="e446" text="LTbetaR" type="protein" />      <entity charOffset="150-154" id="AIMed.d31.s265.e4" seqId="e448" text="HVEM" type="protein" />      <entity charOffset="155-158" id="AIMed.d31.s265.e5" seqId="e449" text="TR2" type="protein" />      <interaction e1="AIMed.d31.s265.e1" e2="AIMed.d31.s265.e3" id="AIMed.d31.s265.i0" type="PPI" />    </sentence>    <sentence charOffset="1153-1293" id="AIMed.d31.s266" seqId="s266" text="Our data suggest that TR6 inhibits the interactions of LIGHT with HVEM/TR2 and LTbetaR, thereby suppressing LIGHT- mediated HT29 cell death.">      <entity charOffset="22-25" id="AIMed.d31.s266.e0" seqId="e450" text="TR6" type="protein" />      <entity charOffset="55-60" id="AIMed.d31.s266.e1" seqId="e451" text="LIGHT" type="protein" />      <entity charOffset="66-70" id="AIMed.d31.s266.e2" seqId="e455" text="HVEM" type="protein" />      <entity charOffset="71-74" id="AIMed.d31.s266.e3" seqId="e457" text="TR2" type="protein" />      <entity charOffset="79-86" id="AIMed.d31.s266.e4" seqId="e459" text="LTbetaR" type="protein" />      <entity charOffset="108-113" id="AIMed.d31.s266.e5" seqId="e461" text="LIGHT" type="protein" />      <interaction e1="AIMed.d31.s266.e1" e2="AIMed.d31.s266.e2" id="AIMed.d31.s266.i0" type="PPI" />      <interaction e1="AIMed.d31.s266.e1" e2="AIMed.d31.s266.e3" id="AIMed.d31.s266.i1" type="PPI" />      <interaction e1="AIMed.d31.s266.e1" e2="AIMed.d31.s266.e4" id="AIMed.d31.s266.i2" type="PPI" />    </sentence>    <sentence charOffset="1294-1386" id="AIMed.d31.s267" seqId="s267" text="Thus, TR6 may play a regulatory role for suppressing in FasL- and LIGHT-mediated cell death.">      <entity charOffset="6-9" id="AIMed.d31.s267.e0" seqId="e462" text="TR6" type="protein" />      <entity charOffset="56-60" id="AIMed.d31.s267.e1" seqId="e463" text="FasL" type="protein" />      <entity charOffset="66-71" id="AIMed.d31.s267.e2" seqId="e464" text="LIGHT" type="protein" />    </sentence>  </document>  <document id="AIMed.d34" origId="10369872" set="test">    <sentence charOffset="0-98" id="AIMed.d34.s284" seqId="s284" text="Presenilins interact with Rab11, a small GTPase involved in the regulation of vesicular transport.">      <entity charOffset="26-31" id="AIMed.d34.s284.e0" seqId="e554" text="Rab11" type="protein" />    </sentence>    <sentence charOffset="99-215" id="AIMed.d34.s285" seqId="s285" text="Presenilin 1 (PS1) mutations account for the majority of early-onset dominant cases of familial Alzheimer's disease.">      <entity charOffset="0-12" id="AIMed.d34.s285.e0" seqId="e555" text="Presenilin 1" type="protein" />      <entity charOffset="14-17" id="AIMed.d34.s285.e1" seqId="e556" text="PS1" type="protein" />    </sentence>    <sentence charOffset="216-374" id="AIMed.d34.s286" seqId="s286" text="Presenilins (PSs) are located in many intra-cellular compartments such as the endoplasmic reticulum, Golgi apparatus, nuclear region and vesicular structures.">      </sentence>    <sentence charOffset="375-543" id="AIMed.d34.s287" seqId="s287" text="These proteins include from seven to nine putative transmembrane domains, with the N- and C-terminal ends and a large hydrophilic loop orientated towards the cytoplasm.">      </sentence>    <sentence charOffset="544-682" id="AIMed.d34.s288" seqId="s288" text="We report an interaction between the human PS1 or PS2 hydrophilic loop and Rab11, a small GTPase belonging to the Ras-related superfamily.">      <entity charOffset="43-46" id="AIMed.d34.s288.e0" seqId="e557" text="PS1" type="protein" />      <entity charOffset="50-53" id="AIMed.d34.s288.e1" seqId="e559" text="PS2" type="protein" />      <entity charOffset="75-80" id="AIMed.d34.s288.e2" seqId="e561" text="Rab11" type="protein" />      <interaction e1="AIMed.d34.s288.e0" e2="AIMed.d34.s288.e2" id="AIMed.d34.s288.i0" type="PPI" />      <interaction e1="AIMed.d34.s288.e1" e2="AIMed.d34.s288.e2" id="AIMed.d34.s288.i1" type="PPI" />    </sentence>    <sentence charOffset="683-823" id="AIMed.d34.s289" seqId="s289" text="Interaction domains were mapped to codons 374-400 for PS1 and to codons 106-179 for Rab11, a region including the fourth GTP-binding domain.">      <entity charOffset="54-57" id="AIMed.d34.s289.e0" seqId="e564" text="PS1" type="protein" />      <entity charOffset="84-89" id="AIMed.d34.s289.e1" seqId="e566" text="Rab11" type="protein" />      <interaction e1="AIMed.d34.s289.e0" e2="AIMed.d34.s289.e1" id="AIMed.d34.s289.i0" type="PPI" />    </sentence>    <sentence charOffset="824-1010" id="AIMed.d34.s290" seqId="s290" text="Considering the implication of Rab proteins in vesicular transport pathways, the PS-Rab11 inter-action suggests that PSs might be involved in amyloid precursor protein vesicular routing.">      <entity charOffset="84-89" id="AIMed.d34.s290.e0" seqId="e568" text="Rab11" type="protein" />    </sentence>  </document>  <document id="AIMed.d38" origId="10488147" set="test">    <sentence charOffset="0-115" id="AIMed.d38.s320" seqId="s320" text="Molecular cloning of a novel human CC chemokine (Eotaxin-3) that is a functional ligand of CC chemokine receptor 3.">      <entity charOffset="49-58" id="AIMed.d38.s320.e0" seqId="e669" text="Eotaxin-3" type="protein" />      <entity charOffset="91-114" id="AIMed.d38.s320.e1" seqId="e671" text="CC chemokine receptor 3" type="protein" />      <interaction e1="AIMed.d38.s320.e0" e2="AIMed.d38.s320.e1" id="AIMed.d38.s320.i0" type="PPI" />    </sentence>    <sentence charOffset="116-362" id="AIMed.d38.s321" seqId="s321" text="Previously, we mapped the novel CC chemokine myeloid progenitor inhibitory factor 2 (MPIF-2)/eotaxin-2 to chromosome 7q11.23 (Nomiyama, H., Osborne, L. R., Imai, T., Kusuda, J., Miura, R., Tsui, L.-C., and Yoshie, O. (1998) Genomics 49, 339-340).">      <entity charOffset="45-83" id="AIMed.d38.s321.e0" seqId="e673" text="myeloid progenitor inhibitory factor 2" type="protein" />      <entity charOffset="85-91" id="AIMed.d38.s321.e1" seqId="e674" text="MPIF-2" type="protein" />      <entity charOffset="93-102" id="AIMed.d38.s321.e2" seqId="e675" text="eotaxin-2" type="protein" />    </sentence>    <sentence charOffset="363-497" id="AIMed.d38.s322" seqId="s322" text="Since chemokine genes tend to be clustered, unknown chemokines may be present in the vicinity of those mapped to new chromosomal loci.">      </sentence>    <sentence charOffset="498-666" id="AIMed.d38.s323" seqId="s323" text="Prompted by this hypothesis, we analyzed the genomic region containing the gene for MPIF-2/eotaxin-2 (SCYA24) and have identified a novel CC chemokine termed eotaxin-3.">      <entity charOffset="84-90" id="AIMed.d38.s323.e0" seqId="e676" text="MPIF-2" type="protein" />      <entity charOffset="91-100" id="AIMed.d38.s323.e1" seqId="e677" text="eotaxin-2" type="protein" />      <entity charOffset="102-108" id="AIMed.d38.s323.e2" seqId="e678" text="SCYA24" type="protein" />      <entity charOffset="158-167" id="AIMed.d38.s323.e3" seqId="e679" text="eotaxin-3" type="protein" />    </sentence>    <sentence charOffset="667-790" id="AIMed.d38.s324" seqId="s324" text="The genes for MPIF-2/eotaxin-2 (SCYA24) and eotaxin-3 (SCYA26) are localized within a region of approximately 40 kilobases.">      <entity charOffset="14-20" id="AIMed.d38.s324.e0" seqId="e680" text="MPIF-2" type="protein" />      <entity charOffset="21-30" id="AIMed.d38.s324.e1" seqId="e681" text="eotaxin-2" type="protein" />      <entity charOffset="32-38" id="AIMed.d38.s324.e2" seqId="e682" text="SCYA24" type="protein" />      <entity charOffset="44-53" id="AIMed.d38.s324.e3" seqId="e683" text="eotaxin-3" type="protein" />      <entity charOffset="55-61" id="AIMed.d38.s324.e4" seqId="e684" text="SCYA26" type="protein" />    </sentence>    <sentence charOffset="791-885" id="AIMed.d38.s325" seqId="s325" text="By Northern blot analysis, eotaxin-3 mRNA was constitutively expressed in the heart and ovary.">      <entity charOffset="27-36" id="AIMed.d38.s325.e0" seqId="e685" text="eotaxin-3" type="protein" />    </sentence>    <sentence charOffset="886-961" id="AIMed.d38.s326" seqId="s326" text="We have generated recombinant eotaxin-3 in a baculovirus expression system.">      <entity charOffset="30-39" id="AIMed.d38.s326.e0" seqId="e686" text="eotaxin-3" type="protein" />    </sentence>    <sentence charOffset="962-1103" id="AIMed.d38.s327" seqId="s327" text="Eotaxin-3 induced transient calcium mobilization specifically in CC chemokine receptor 3 (CCR3)-expressing L1.2 cells with an EC(50) of 3 nM.">      <entity charOffset="0-9" id="AIMed.d38.s327.e0" seqId="e687" text="Eotaxin-3" type="protein" />      <entity charOffset="65-88" id="AIMed.d38.s327.e1" seqId="e688" text="CC chemokine receptor 3" type="protein" />      <entity charOffset="90-94" id="AIMed.d38.s327.e2" seqId="e689" text="CCR3" type="protein" />    </sentence>    <sentence charOffset="1104-1207" id="AIMed.d38.s328" seqId="s328" text="Eotaxin-3 competed the binding of (125)I-eotaxin to CCR3-expressing L1.2 cells with an IC(50) of 13 nM.">      <entity charOffset="0-9" id="AIMed.d38.s328.e0" seqId="e690" text="Eotaxin-3" type="protein" />      <entity charOffset="39-48" id="AIMed.d38.s328.e1" seqId="e692" text="I-eotaxin" type="protein" />      <entity charOffset="52-56" id="AIMed.d38.s328.e2" seqId="e694" text="CCR3" type="protein" />      <interaction e1="AIMed.d38.s328.e0" e2="AIMed.d38.s328.e2" id="AIMed.d38.s328.i0" type="PPI" />      <interaction e1="AIMed.d38.s328.e1" e2="AIMed.d38.s328.e2" id="AIMed.d38.s328.i1" type="PPI" />    </sentence>    <sentence charOffset="1208-1311" id="AIMed.d38.s329" seqId="s329" text="Eotaxin-3 was chemotactic for normal peripheral blood eosinophils and basophils at high concentrations.">      <entity charOffset="0-9" id="AIMed.d38.s329.e0" seqId="e697" text="Eotaxin-3" type="protein" />    </sentence>    <sentence charOffset="1312-1378" id="AIMed.d38.s330" seqId="s330" text="Collectively, eotaxin-3 is yet another functional ligand for CCR3.">      <entity charOffset="14-23" id="AIMed.d38.s330.e0" seqId="e698" text="eotaxin-3" type="protein" />      <entity charOffset="61-65" id="AIMed.d38.s330.e1" seqId="e700" text="CCR3" type="protein" />      <interaction e1="AIMed.d38.s330.e0" e2="AIMed.d38.s330.e1" id="AIMed.d38.s330.i0" type="PPI" />    </sentence>    <sentence charOffset="1379-1491" id="AIMed.d38.s331" seqId="s331" text="The potency of eotaxin-3 as a CCR3 ligand seems, however, to be approximately 10-fold less than that of eotaxin.">      <entity charOffset="15-24" id="AIMed.d38.s331.e0" seqId="e702" text="eotaxin-3" type="protein" />      <entity charOffset="30-34" id="AIMed.d38.s331.e1" seqId="e704" text="CCR3" type="protein" />      <entity charOffset="104-111" id="AIMed.d38.s331.e2" seqId="e707" text="eotaxin" type="protein" />      <interaction e1="AIMed.d38.s331.e0" e2="AIMed.d38.s331.e1" id="AIMed.d38.s331.i0" type="PPI" />      <interaction e1="AIMed.d38.s331.e1" e2="AIMed.d38.s331.e2" id="AIMed.d38.s331.i1" type="PPI" />    </sentence>    <sentence charOffset="1492-1645" id="AIMed.d38.s332" seqId="s332" text="Identification of eotaxin-3 will further promote our understanding of the control of eosinophil trafficking and other CCR3-mediated biological phenomena.">      <entity charOffset="18-27" id="AIMed.d38.s332.e0" seqId="e709" text="eotaxin-3" type="protein" />      <entity charOffset="118-122" id="AIMed.d38.s332.e1" seqId="e710" text="CCR3" type="protein" />    </sentence>    <sentence charOffset="1646-1752" id="AIMed.d38.s333" seqId="s333" text="The strategy used in this study may also be applicable to identification of other unknown chemokine genes.">      </sentence>  </document>  <document id="AIMed.d45" origId="10860730" set="test">    <sentence charOffset="0-104" id="AIMed.d45.s389" seqId="s389" text="Design, characterization, and structure of a biologically active single-chain mutant of human IFN-gamma.">      <entity charOffset="94-103" id="AIMed.d45.s389.e0" seqId="e929" text="IFN-gamma" type="protein" />    </sentence>    <sentence charOffset="105-263" id="AIMed.d45.s390" seqId="s390" text="A mutant form of human interferon-gamma (IFN-gamma SC1) that binds one IFN-gamma receptor alpha chain (IFN-gamma R alpha) has been designed and characterized.">      <entity charOffset="23-39" id="AIMed.d45.s390.e0" seqId="e930" text="interferon-gamma" type="protein" />      <entity charOffset="41-50" id="AIMed.d45.s390.e1" seqId="e931" text="IFN-gamma" type="protein" />      <entity charOffset="41-54" id="AIMed.d45.s390.e2" seqId="e932" text="IFN-gamma SC1" type="protein" />      <entity charOffset="71-80" id="AIMed.d45.s390.e3" seqId="e935" text="IFN-gamma" type="protein" />      <entity charOffset="71-89" id="AIMed.d45.s390.e4" seqId="e936" text="IFN-gamma receptor" type="protein" />      <entity charOffset="71-101" id="AIMed.d45.s390.e5" seqId="e937" text="IFN-gamma receptor alpha chain" type="protein" />      <entity charOffset="103-112" id="AIMed.d45.s390.e6" seqId="e939" text="IFN-gamma" type="protein" />      <entity charOffset="103-120" id="AIMed.d45.s390.e7" seqId="e940" text="IFN-gamma R alpha" type="protein" />      <interaction e1="AIMed.d45.s390.e2" e2="AIMed.d45.s390.e5" id="AIMed.d45.s390.i0" type="PPI" />      <interaction e1="AIMed.d45.s390.e2" e2="AIMed.d45.s390.e7" id="AIMed.d45.s390.i1" type="PPI" />    </sentence>    <sentence charOffset="264-440" id="AIMed.d45.s391" seqId="s391" text="IFN-gamma SC1 was derived by linking the two peptide chains of the IFN-gamma dimer by a seven-residue linker and changing His111 in the first chain to an aspartic acid residue.">      <entity charOffset="0-9" id="AIMed.d45.s391.e0" seqId="e942" text="IFN-gamma" type="protein" />      <entity charOffset="0-13" id="AIMed.d45.s391.e1" seqId="e943" text="IFN-gamma SC1" type="protein" />      <entity charOffset="67-76" id="AIMed.d45.s391.e2" seqId="e944" text="IFN-gamma" type="protein" />    </sentence>    <sentence charOffset="441-604" id="AIMed.d45.s392" seqId="s392" text="Isothermal titration calorimetry shows that IFN-gamma SC1 forms a 1:1 complex with its high-affinity receptor (IFN-gamma R alpha) with an affinity of 27(+/- 9) nM.">      <entity charOffset="44-53" id="AIMed.d45.s392.e0" seqId="e947" text="IFN-gamma" type="protein" />      <entity charOffset="44-57" id="AIMed.d45.s392.e1" seqId="e948" text="IFN-gamma SC1" type="protein" />      <entity charOffset="111-120" id="AIMed.d45.s392.e2" seqId="e950" text="IFN-gamma" type="protein" />      <entity charOffset="111-128" id="AIMed.d45.s392.e3" seqId="e951" text="IFN-gamma R alpha" type="protein" />      <interaction e1="AIMed.d45.s392.e1" e2="AIMed.d45.s392.e3" id="AIMed.d45.s392.i0" type="PPI" />    </sentence>    <sentence charOffset="605-741" id="AIMed.d45.s393" seqId="s393" text="The crystal structure of IFN-gamma SC1 has been determined at 2.9 A resolution from crystals grown in 1.4 M citrate solutions at pH 7.6.">      <entity charOffset="25-34" id="AIMed.d45.s393.e0" seqId="e953" text="IFN-gamma" type="protein" />      <entity charOffset="25-38" id="AIMed.d45.s393.e1" seqId="e954" text="IFN-gamma SC1" type="protein" />    </sentence>    <sentence charOffset="742-944" id="AIMed.d45.s394" seqId="s394" text="Comparison of the wild-type receptor-binding domain and the Asp111-containing domain of IFN-gamma SC1 show that they are structurally equivalent but have very different electrostatic surface potentials.">      <entity charOffset="88-97" id="AIMed.d45.s394.e0" seqId="e955" text="IFN-gamma" type="protein" />      <entity charOffset="88-101" id="AIMed.d45.s394.e1" seqId="e956" text="IFN-gamma SC1" type="protein" />    </sentence>    <sentence charOffset="945-1100" id="AIMed.d45.s395" seqId="s395" text="As a result, surface charge rather than structural changes is likely responsible for the inability of the His111--&gt;Asp domain of to bind IFN-gamma R alpha.">      <entity charOffset="137-154" id="AIMed.d45.s395.e0" seqId="e957" text="IFN-gamma R alpha" type="protein" />    </sentence>    <sentence charOffset="1101-1270" id="AIMed.d45.s396" seqId="s396" text="The AB loops of IFN-gamma SC1 adopt conformations similar to the ordered loops of IFN-gamma observed in the crystal structure of the IFN-gamma/IFN-gamma R alpha complex.">      <entity charOffset="16-29" id="AIMed.d45.s396.e0" seqId="e958" text="IFN-gamma SC1" type="protein" />      <entity charOffset="82-91" id="AIMed.d45.s396.e1" seqId="e959" text="IFN-gamma" type="protein" />      <entity charOffset="133-142" id="AIMed.d45.s396.e2" seqId="e960" text="IFN-gamma" type="protein" />      <entity charOffset="143-152" id="AIMed.d45.s396.e3" seqId="e962" text="IFN-gamma" type="protein" />      <entity charOffset="143-160" id="AIMed.d45.s396.e4" seqId="e963" text="IFN-gamma R alpha" type="protein" />      <interaction e1="AIMed.d45.s396.e2" e2="AIMed.d45.s396.e4" id="AIMed.d45.s396.i0" type="PPI" />    </sentence>    <sentence charOffset="1271-1391" id="AIMed.d45.s397" seqId="s397" text="Thus, IFN-gamma R alpha binding does not result in a large conformational change in the AB loop as previously suggested.">      <entity charOffset="6-15" id="AIMed.d45.s397.e0" seqId="e965" text="IFN-gamma" type="protein" />      <entity charOffset="6-23" id="AIMed.d45.s397.e1" seqId="e966" text="IFN-gamma R alpha" type="protein" />    </sentence>    <sentence charOffset="1392-1571" id="AIMed.d45.s398" seqId="s398" text="The structure also reveals the final six C-terminal amino acid residues of IFN-gamma SC1 (residues 253-258) that have not been observed in any other reported IFN-gamma structures.">      <entity charOffset="75-84" id="AIMed.d45.s398.e0" seqId="e967" text="IFN-gamma" type="protein" />      <entity charOffset="75-88" id="AIMed.d45.s398.e1" seqId="e968" text="IFN-gamma SC1" type="protein" />      <entity charOffset="158-167" id="AIMed.d45.s398.e2" seqId="e969" text="IFN-gamma" type="protein" />    </sentence>    <sentence charOffset="1572-1724" id="AIMed.d45.s399" seqId="s399" text="Despite binding to only one IFN-gamma R alpha, IFN-gamma SC1 is biologically active in cell proliferation, MHC class I induction, and anti-viral assays.">      <entity charOffset="28-37" id="AIMed.d45.s399.e0" seqId="e970" text="IFN-gamma" type="protein" />      <entity charOffset="28-45" id="AIMed.d45.s399.e1" seqId="e971" text="IFN-gamma R alpha" type="protein" />      <entity charOffset="47-60" id="AIMed.d45.s399.e2" seqId="e973" text="IFN-gamma SC1" type="protein" />      <interaction e1="AIMed.d45.s399.e1" e2="AIMed.d45.s399.e2" id="AIMed.d45.s399.i0" type="PPI" />    </sentence>    <sentence charOffset="1725-1891" id="AIMed.d45.s400" seqId="s400" text="This suggests that one domain of IFN-gamma is sufficient to recruit IFN-gamma R alpha and IFN-gamma R beta into a complex competent for eliciting biological activity.">      <entity charOffset="33-42" id="AIMed.d45.s400.e0" seqId="e975" text="IFN-gamma" type="protein" />      <entity charOffset="68-77" id="AIMed.d45.s400.e1" seqId="e978" text="IFN-gamma" type="protein" />      <entity charOffset="68-85" id="AIMed.d45.s400.e2" seqId="e979" text="IFN-gamma R alpha" type="protein" />      <entity charOffset="90-99" id="AIMed.d45.s400.e3" seqId="e981" text="IFN-gamma" type="protein" />      <entity charOffset="90-106" id="AIMed.d45.s400.e4" seqId="e982" text="IFN-gamma R beta" type="protein" />      <interaction e1="AIMed.d45.s400.e0" e2="AIMed.d45.s400.e2" id="AIMed.d45.s400.i0" type="PPI" />      <interaction e1="AIMed.d45.s400.e0" e2="AIMed.d45.s400.e4" id="AIMed.d45.s400.i1" type="PPI" />    </sentence>    <sentence charOffset="1892-2050" id="AIMed.d45.s401" seqId="s401" text="The current data are consistent with the main role of the IFN-gamma dimer being to decrease the dissociation constant of IFN-gamma for its cellular receptors.">      <entity charOffset="58-67" id="AIMed.d45.s401.e0" seqId="e983" text="IFN-gamma" type="protein" />      <entity charOffset="121-130" id="AIMed.d45.s401.e1" seqId="e986" text="IFN-gamma" type="protein" />    </sentence>  </document>  <document id="AIMed.d55" origId="11470772" set="test">    <sentence charOffset="0-143" id="AIMed.d55.s481" seqId="s481" text="Human CC chemokine liver-expressed chemokine/CCL16 is a functional ligand for CCR1, CCR2 and CCR5, and constitutively expressed by hepatocytes.">      <entity charOffset="6-44" id="AIMed.d55.s481.e0" seqId="e1226" text="CC chemokine liver-expressed chemokine" type="protein" />      <entity charOffset="45-50" id="AIMed.d55.s481.e1" seqId="e1230" text="CCL16" type="protein" />      <entity charOffset="78-82" id="AIMed.d55.s481.e2" seqId="e1234" text="CCR1" type="protein" />      <entity charOffset="84-88" id="AIMed.d55.s481.e3" seqId="e1237" text="CCR2" type="protein" />      <entity charOffset="93-97" id="AIMed.d55.s481.e4" seqId="e1240" text="CCR5" type="protein" />      <interaction e1="AIMed.d55.s481.e0" e2="AIMed.d55.s481.e2" id="AIMed.d55.s481.i0" type="PPI" />      <interaction e1="AIMed.d55.s481.e0" e2="AIMed.d55.s481.e3" id="AIMed.d55.s481.i1" type="PPI" />      <interaction e1="AIMed.d55.s481.e0" e2="AIMed.d55.s481.e4" id="AIMed.d55.s481.i2" type="PPI" />      <interaction e1="AIMed.d55.s481.e1" e2="AIMed.d55.s481.e2" id="AIMed.d55.s481.i3" type="PPI" />      <interaction e1="AIMed.d55.s481.e1" e2="AIMed.d55.s481.e3" id="AIMed.d55.s481.i4" type="PPI" />      <interaction e1="AIMed.d55.s481.e1" e2="AIMed.d55.s481.e4" id="AIMed.d55.s481.i5" type="PPI" />    </sentence>    <sentence charOffset="144-241" id="AIMed.d55.s482" seqId="s482" text="Liver-expressed chemokine (LEC)/CCL16 is a human CC chemokine selectively expressed in the liver.">      <entity charOffset="0-25" id="AIMed.d55.s482.e0" seqId="e1243" text="Liver-expressed chemokine" type="protein" />      <entity charOffset="27-30" id="AIMed.d55.s482.e1" seqId="e1244" text="LEC" type="protein" />      <entity charOffset="32-37" id="AIMed.d55.s482.e2" seqId="e1245" text="CCL16" type="protein" />    </sentence>    <sentence charOffset="242-422" id="AIMed.d55.s483" seqId="s483" text="Here, we investigated its receptor usage by calcium mobilization and chemotactic assays using mouse L1.2 pre-B cell lines stably expressing a panel of 12 human chemokine receptors.">      </sentence>    <sentence charOffset="423-524" id="AIMed.d55.s484" seqId="s484" text="At relatively high concentrations, LEC induced calcium mobilization and chemotaxis via CCR1 and CCR2.">      <entity charOffset="35-38" id="AIMed.d55.s484.e0" seqId="e1246" text="LEC" type="protein" />      <entity charOffset="87-91" id="AIMed.d55.s484.e1" seqId="e1249" text="CCR1" type="protein" />      <entity charOffset="96-100" id="AIMed.d55.s484.e2" seqId="e1251" text="CCR2" type="protein" />      <interaction e1="AIMed.d55.s484.e0" e2="AIMed.d55.s484.e1" id="AIMed.d55.s484.i0" type="PPI" />      <interaction e1="AIMed.d55.s484.e0" e2="AIMed.d55.s484.e2" id="AIMed.d55.s484.i1" type="PPI" />    </sentence>    <sentence charOffset="525-597" id="AIMed.d55.s485" seqId="s485" text="LEC also induced calcium mobilization, but marginal chemotaxis via CCR5.">      <entity charOffset="0-3" id="AIMed.d55.s485.e0" seqId="e1253" text="LEC" type="protein" />      <entity charOffset="67-71" id="AIMed.d55.s485.e1" seqId="e1255" text="CCR5" type="protein" />      <interaction e1="AIMed.d55.s485.e0" e2="AIMed.d55.s485.e1" id="AIMed.d55.s485.i0" type="PPI" />    </sentence>    <sentence charOffset="598-688" id="AIMed.d55.s486" seqId="s486" text="Consistently, LEC was found to bind to CCR1, CCR2 and CCR5 with relatively low affinities.">      <entity charOffset="14-17" id="AIMed.d55.s486.e0" seqId="e1257" text="LEC" type="protein" />      <entity charOffset="39-43" id="AIMed.d55.s486.e1" seqId="e1261" text="CCR1" type="protein" />      <entity charOffset="45-49" id="AIMed.d55.s486.e2" seqId="e1263" text="CCR2" type="protein" />      <entity charOffset="54-58" id="AIMed.d55.s486.e3" seqId="e1265" text="CCR5" type="protein" />      <interaction e1="AIMed.d55.s486.e0" e2="AIMed.d55.s486.e1" id="AIMed.d55.s486.i0" type="PPI" />      <interaction e1="AIMed.d55.s486.e0" e2="AIMed.d55.s486.e2" id="AIMed.d55.s486.i1" type="PPI" />      <interaction e1="AIMed.d55.s486.e0" e2="AIMed.d55.s486.e3" id="AIMed.d55.s486.i2" type="PPI" />    </sentence>    <sentence charOffset="689-742" id="AIMed.d55.s487" seqId="s487" text="The binding of LEC to CCR8 was much less significant.">      <entity charOffset="15-18" id="AIMed.d55.s487.e0" seqId="e1267" text="LEC" type="protein" />      <entity charOffset="22-26" id="AIMed.d55.s487.e1" seqId="e1269" text="CCR8" type="protein" />      <interaction e1="AIMed.d55.s487.e0" e2="AIMed.d55.s487.e1" id="AIMed.d55.s487.i0" type="PPI" />    </sentence>    <sentence charOffset="743-914" id="AIMed.d55.s488" seqId="s488" text="In spite of its binding to CCR5, LEC was unable to inhibit infection of an R5-type HIV-1 to activated human peripheral blood mononuclear cells even at high concentrations.">      <entity charOffset="27-31" id="AIMed.d55.s488.e0" seqId="e1271" text="CCR5" type="protein" />      <entity charOffset="33-36" id="AIMed.d55.s488.e1" seqId="e1273" text="LEC" type="protein" />      <interaction e1="AIMed.d55.s488.e0" e2="AIMed.d55.s488.e1" id="AIMed.d55.s488.i0" type="PPI" />    </sentence>    <sentence charOffset="915-995" id="AIMed.d55.s489" seqId="s489" text="In human liver sections, hepatocytes were strongly stained by anti-LEC antibody.">      </sentence>    <sentence charOffset="996-1078" id="AIMed.d55.s490" seqId="s490" text="HepG2, a human hepatocarcinoma cell line, was found to constitutively express LEC.">      <entity charOffset="78-81" id="AIMed.d55.s490.e0" seqId="e1275" text="LEC" type="protein" />    </sentence>    <sentence charOffset="1079-1194" id="AIMed.d55.s491" seqId="s491" text="LEC was also present in the plasma samples from healthy adult donors at relatively high concentrations (0.3--4 nM).">      <entity charOffset="0-3" id="AIMed.d55.s491.e0" seqId="e1276" text="LEC" type="protein" />    </sentence>    <sentence charOffset="1195-1339" id="AIMed.d55.s492" seqId="s492" text="Taken together, LEC is a new low-affinity functional ligand for CCR1, CCR2 and CCR5, and is constitutively expressed by liver parenchymal cells.">      <entity charOffset="16-19" id="AIMed.d55.s492.e0" seqId="e1277" text="LEC" type="protein" />      <entity charOffset="64-68" id="AIMed.d55.s492.e1" seqId="e1281" text="CCR1" type="protein" />      <entity charOffset="70-74" id="AIMed.d55.s492.e2" seqId="e1283" text="CCR2" type="protein" />      <entity charOffset="79-83" id="AIMed.d55.s492.e3" seqId="e1285" text="CCR5" type="protein" />      <interaction e1="AIMed.d55.s492.e0" e2="AIMed.d55.s492.e1" id="AIMed.d55.s492.i0" type="PPI" />      <interaction e1="AIMed.d55.s492.e0" e2="AIMed.d55.s492.e2" id="AIMed.d55.s492.i1" type="PPI" />      <interaction e1="AIMed.d55.s492.e0" e2="AIMed.d55.s492.e3" id="AIMed.d55.s492.i2" type="PPI" />    </sentence>    <sentence charOffset="1340-1447" id="AIMed.d55.s493" seqId="s493" text="The presence of LEC in normal plasma at relatively high concentrations may modulate inflammatory responses.">      <entity charOffset="16-19" id="AIMed.d55.s493.e0" seqId="e1287" text="LEC" type="protein" />    </sentence>  </document>  <document id="AIMed.d62" origId="1396586" set="test">    <sentence charOffset="0-61" id="AIMed.d62.s540" seqId="s540" text="Crystal structure of human platelet-derived growth factor BB.">      <entity charOffset="27-60" id="AIMed.d62.s540.e0" seqId="e1419" text="platelet-derived growth factor BB" type="protein" />    </sentence>    <sentence charOffset="62-234" id="AIMed.d62.s541" seqId="s541" text="The crystal structure of the homodimeric BB isoform of human recombinant platelet-derived growth factor (PDGF-BB) has been determined by X-ray analysis to 3.0 A resolution.">      <entity charOffset="41-103" id="AIMed.d62.s541.e0" seqId="e1420" text="BB isoform of human recombinant platelet-derived growth factor" type="protein" />      <entity charOffset="105-112" id="AIMed.d62.s541.e1" seqId="e1423" text="PDGF-BB" type="protein" />    </sentence>    <sentence charOffset="235-410" id="AIMed.d62.s542" seqId="s542" text="The polypeptide chain is folded into two highly twisted antiparallel pairs of beta-strands and contains an unusual knotted arrangement of three intramolecular disulfide bonds.">      </sentence>    <sentence charOffset="411-563" id="AIMed.d62.s543" seqId="s543" text="Dimerization leads to the clustering of three surface loops at each end of the elongated dimer, which most probably form the receptor recognition sites.">      </sentence>  </document>  <document id="AIMed.d66" origId="1833068" set="test">    <sentence charOffset="0-85" id="AIMed.d66.s562" seqId="s562" text="Human cyclin E, a new cyclin that interacts with two members of the CDC2 gene family.">      <entity charOffset="6-14" id="AIMed.d66.s562.e0" seqId="e1491" text="cyclin E" type="protein" />      <entity charOffset="68-72" id="AIMed.d66.s562.e1" seqId="e1492" text="CDC2" type="protein" />    </sentence>    <sentence charOffset="86-196" id="AIMed.d66.s563" seqId="s563" text="A new human cyclin, named cyclin E, was isolated by complementation of a triple cln deletion in S. cerevisiae.">      <entity charOffset="26-34" id="AIMed.d66.s563.e0" seqId="e1493" text="cyclin E" type="protein" />    </sentence>    <sentence charOffset="197-332" id="AIMed.d66.s564" seqId="s564" text="Cyclin E showed genetic interactions with the CDC28 gene, suggesting that it functioned at START by interacting with the CDC28 protein.">      <entity charOffset="0-8" id="AIMed.d66.s564.e0" seqId="e1494" text="Cyclin E" type="protein" />      <entity charOffset="46-51" id="AIMed.d66.s564.e1" seqId="e1497" text="CDC28" type="protein" />      <entity charOffset="121-126" id="AIMed.d66.s564.e2" seqId="e1499" text="CDC28" type="protein" />      <interaction e1="AIMed.d66.s564.e0" e2="AIMed.d66.s564.e1" id="AIMed.d66.s564.i0" type="PPI" />      <interaction e1="AIMed.d66.s564.e0" e2="AIMed.d66.s564.e2" id="AIMed.d66.s564.i1" type="PPI" />    </sentence>    <sentence charOffset="333-453" id="AIMed.d66.s565" seqId="s565" text="Two human genes were identified that could interact with cyclin E to perform START in yeast containing a cdc28 mutation.">      <entity charOffset="57-65" id="AIMed.d66.s565.e0" seqId="e1501" text="cyclin E" type="protein" />      <entity charOffset="105-110" id="AIMed.d66.s565.e1" seqId="e1502" text="cdc28" type="protein" />    </sentence>    <sentence charOffset="454-524" id="AIMed.d66.s566" seqId="s566" text="One was CDC2-HS, and the second was the human homolog of Xenopus CDK2.">      <entity charOffset="8-12" id="AIMed.d66.s566.e0" seqId="e1503" text="CDC2" type="protein" />      <entity charOffset="8-15" id="AIMed.d66.s566.e1" seqId="e1504" text="CDC2-HS" type="protein" />      <entity charOffset="65-69" id="AIMed.d66.s566.e2" seqId="e1505" text="CDK2" type="protein" />    </sentence>    <sentence charOffset="525-711" id="AIMed.d66.s567" seqId="s567" text="Cyclin E produced in E. coli bound and activated the CDC2 protein in extracts from human G1 cells, and antibodies against cyclin E immunoprecipitated a histone H1 kinase from HeLa cells.">      <entity charOffset="0-8" id="AIMed.d66.s567.e0" seqId="e1506" text="Cyclin E" type="protein" />      <entity charOffset="53-57" id="AIMed.d66.s567.e1" seqId="e1508" text="CDC2" type="protein" />      <entity charOffset="122-130" id="AIMed.d66.s567.e2" seqId="e1510" text="cyclin E" type="protein" />      <interaction e1="AIMed.d66.s567.e0" e2="AIMed.d66.s567.e1" id="AIMed.d66.s567.i0" type="PPI" />    </sentence>    <sentence charOffset="712-823" id="AIMed.d66.s568" seqId="s568" text="The interactions between cyclin E and CDC2, or CDK2, may be important at the G1 to S transition in human cells.">      <entity charOffset="25-33" id="AIMed.d66.s568.e0" seqId="e1511" text="cyclin E" type="protein" />      <entity charOffset="38-42" id="AIMed.d66.s568.e1" seqId="e1514" text="CDC2" type="protein" />      <entity charOffset="47-51" id="AIMed.d66.s568.e2" seqId="e1516" text="CDK2" type="protein" />      <interaction e1="AIMed.d66.s568.e0" e2="AIMed.d66.s568.e1" id="AIMed.d66.s568.i0" type="PPI" />      <interaction e1="AIMed.d66.s568.e0" e2="AIMed.d66.s568.e2" id="AIMed.d66.s568.i1" type="PPI" />    </sentence>  </document>  <document id="AIMed.d72" origId="2005966" set="test">    <sentence charOffset="0-100" id="AIMed.d72.s609" seqId="s609" text="A cellular protein that competes with SV40 T antigen for binding to the retinoblastoma gene product.">      <entity charOffset="38-52" id="AIMed.d72.s609.e0" seqId="e1615" text="SV40 T antigen" type="protein" />      <entity charOffset="72-86" id="AIMed.d72.s609.e1" seqId="e1616" text="retinoblastoma" type="protein" />    </sentence>    <sentence charOffset="101-273" id="AIMed.d72.s610" seqId="s610" text="Tumour-suppressor genes, such as the human retinoblastoma susceptibility gene (Rb), are widely recognized as being vital in the control of cell growth and tumour formation.">      <entity charOffset="43-77" id="AIMed.d72.s610.e0" seqId="e1617" text="retinoblastoma susceptibility gene" type="protein" />      <entity charOffset="79-81" id="AIMed.d72.s610.e1" seqId="e1618" text="Rb" type="protein" />    </sentence>    <sentence charOffset="274-407" id="AIMed.d72.s611" seqId="s611" text="This role is indicated, in part, by the suppression of tumorigenicity of human tumour cells after retrovirus-mediated Rb replacement.">      <entity charOffset="118-120" id="AIMed.d72.s611.e0" seqId="e1619" text="Rb" type="protein" />    </sentence>    <sentence charOffset="408-682" id="AIMed.d72.s612" seqId="s612" text="How Rb acts to bring about this suppression is not clear but one clue is that the Rb protein forms complexes with the transforming oncoproteins of several DNA tumour viruses, and that two regions of Rb essential for such binding frequently contain mutations in tumour cells.">      <entity charOffset="4-6" id="AIMed.d72.s612.e0" seqId="e1620" text="Rb" type="protein" />      <entity charOffset="82-84" id="AIMed.d72.s612.e1" seqId="e1621" text="Rb" type="protein" />      <entity charOffset="199-201" id="AIMed.d72.s612.e2" seqId="e1622" text="Rb" type="protein" />    </sentence>    <sentence charOffset="683-825" id="AIMed.d72.s613" seqId="s613" text="These observations suggest that endogenous cellular proteins might exist that bind to the same regions of Rb and thereby mediate its function.">      <entity charOffset="106-108" id="AIMed.d72.s613.e0" seqId="e1623" text="Rb" type="protein" />    </sentence>    <sentence charOffset="826-958" id="AIMed.d72.s614" seqId="s614" text="We report here the identification of one such human cellular Rb-associated protein of relative molecular mass 46,000 (46K) (RbAP46).">      <entity charOffset="61-63" id="AIMed.d72.s614.e0" seqId="e1624" text="Rb" type="protein" />      <entity charOffset="61-82" id="AIMed.d72.s614.e1" seqId="e1625" text="Rb-associated protein" type="protein" />      <entity charOffset="124-130" id="AIMed.d72.s614.e2" seqId="e1626" text="RbAP46" type="protein" />    </sentence>    <sentence charOffset="959-1291" id="AIMed.d72.s615" seqId="s615" text="Two lines of evidence support the notion that RbAP46 and simian virus 40 T antigen have homologous Rb-binding properties: first, several mutated Rb proteins that failed to bind to T also did not associate with RbAP46; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with RbAP46 for binding to Rb.">      <entity charOffset="46-52" id="AIMed.d72.s615.e0" seqId="e1627" text="RbAP46" type="protein" />      <entity charOffset="57-82" id="AIMed.d72.s615.e1" seqId="e1629" text="simian virus 40 T antigen" type="protein" />      <entity charOffset="99-101" id="AIMed.d72.s615.e2" seqId="e1631" text="Rb" type="protein" />      <entity charOffset="145-147" id="AIMed.d72.s615.e3" seqId="e1634" text="Rb" type="protein" />      <entity charOffset="210-216" id="AIMed.d72.s615.e4" seqId="e1635" text="RbAP46" type="protein" />      <entity charOffset="307-313" id="AIMed.d72.s615.e5" seqId="e1636" text="RbAP46" type="protein" />      <entity charOffset="329-331" id="AIMed.d72.s615.e6" seqId="e1637" text="Rb" type="protein" />      <interaction e1="AIMed.d72.s615.e0" e2="AIMed.d72.s615.e2" id="AIMed.d72.s615.i0" type="PPI" />      <interaction e1="AIMed.d72.s615.e1" e2="AIMed.d72.s615.e2" id="AIMed.d72.s615.i1" type="PPI" />    </sentence>    <sentence charOffset="1292-1457" id="AIMed.d72.s616" seqId="s616" text="The apparent targeting of the RbAP46-Rb interaction by oncoproteins of DNA tumour viruses strongly suggests that formation of this complex is functionally important.">      <entity charOffset="30-36" id="AIMed.d72.s616.e0" seqId="e1638" text="RbAP46" type="protein" />      <entity charOffset="37-39" id="AIMed.d72.s616.e1" seqId="e1640" text="Rb" type="protein" />      <interaction e1="AIMed.d72.s616.e0" e2="AIMed.d72.s616.e1" id="AIMed.d72.s616.i0" type="PPI" />    </sentence>  </document>  <document id="AIMed.d84" origId="7559507" set="test">    <sentence charOffset="0-178" id="AIMed.d84.s711" seqId="s711" text="Evidence for a differential interaction of SHC and the insulin receptor substrate-1 (IRS-1) with the insulin-like growth factor-I (IGF-I) receptor in the yeast two-hybrid system.">      <entity charOffset="43-46" id="AIMed.d84.s711.e0" seqId="e1913" text="SHC" type="protein" />      <entity charOffset="55-83" id="AIMed.d84.s711.e1" seqId="e1914" text="insulin receptor substrate-1" type="protein" />      <entity charOffset="85-90" id="AIMed.d84.s711.e2" seqId="e1916" text="IRS-1" type="protein" />      <entity charOffset="101-129" id="AIMed.d84.s711.e3" seqId="e1918" text="insulin-like growth factor-I" type="protein" />      <entity charOffset="131-136" id="AIMed.d84.s711.e4" seqId="e1919" text="IGF-I" type="protein" />      <entity charOffset="101-146" id="AIMed.d84.s711.e5" seqId="e1920" text="insulin-like growth factor-I (IGF-I) receptor" type="protein" />      <interaction e1="AIMed.d84.s711.e1" e2="AIMed.d84.s711.e5" id="AIMed.d84.s711.i0" type="PPI" />      <interaction e1="AIMed.d84.s711.e2" e2="AIMed.d84.s711.e5" id="AIMed.d84.s711.i1" type="PPI" />    </sentence>    <sentence charOffset="179-487" id="AIMed.d84.s712" seqId="s712" text="Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).">      <entity charOffset="147-175" id="AIMed.d84.s712.e0" seqId="e1923" text="insulin-like growth factor-I" type="protein" />      <entity charOffset="147-184" id="AIMed.d84.s712.e1" seqId="e1924" text="insulin-like growth factor-I receptor" type="protein" />      <entity charOffset="186-192" id="AIMed.d84.s712.e2" seqId="e1928" text="IGF-IR" type="protein" />      <entity charOffset="202-218" id="AIMed.d84.s712.e3" seqId="e1932" text="insulin receptor" type="protein" />      <entity charOffset="220-222" id="AIMed.d84.s712.e4" seqId="e1936" text="IR" type="protein" />      <entity charOffset="256-262" id="AIMed.d84.s712.e5" seqId="e1940" text="p52Shc" type="protein" />      <entity charOffset="271-287" id="AIMed.d84.s712.e6" seqId="e1945" text="insulin receptor" type="protein" />      <entity charOffset="271-299" id="AIMed.d84.s712.e7" seqId="e1946" text="insulin receptor substrate-1" type="protein" />      <entity charOffset="301-306" id="AIMed.d84.s712.e8" seqId="e1951" text="IRS-1" type="protein" />      <interaction e1="AIMed.d84.s712.e1" e2="AIMed.d84.s712.e5" id="AIMed.d84.s712.i0" type="PPI" />      <interaction e1="AIMed.d84.s712.e1" e2="AIMed.d84.s712.e7" id="AIMed.d84.s712.i1" type="PPI" />      <interaction e1="AIMed.d84.s712.e1" e2="AIMed.d84.s712.e8" id="AIMed.d84.s712.i2" type="PPI" />      <interaction e1="AIMed.d84.s712.e2" e2="AIMed.d84.s712.e5" id="AIMed.d84.s712.i3" type="PPI" />      <interaction e1="AIMed.d84.s712.e2" e2="AIMed.d84.s712.e7" id="AIMed.d84.s712.i4" type="PPI" />      <interaction e1="AIMed.d84.s712.e2" e2="AIMed.d84.s712.e8" id="AIMed.d84.s712.i5" type="PPI" />      <interaction e1="AIMed.d84.s712.e3" e2="AIMed.d84.s712.e5" id="AIMed.d84.s712.i6" type="PPI" />      <interaction e1="AIMed.d84.s712.e3" e2="AIMed.d84.s712.e7" id="AIMed.d84.s712.i7" type="PPI" />      <interaction e1="AIMed.d84.s712.e3" e2="AIMed.d84.s712.e8" id="AIMed.d84.s712.i8" type="PPI" />      <interaction e1="AIMed.d84.s712.e4" e2="AIMed.d84.s712.e5" id="AIMed.d84.s712.i9" type="PPI" />      <interaction e1="AIMed.d84.s712.e4" e2="AIMed.d84.s712.e7" id="AIMed.d84.s712.i10" type="PPI" />      <interaction e1="AIMed.d84.s712.e4" e2="AIMed.d84.s712.e8" id="AIMed.d84.s712.i11" type="PPI" />    </sentence>    <sentence charOffset="488-585" id="AIMed.d84.s713" seqId="s713" text="We also mapped the specific domains of the IGF-IR and p52Shc participating in these interactions.">      <entity charOffset="43-49" id="AIMed.d84.s713.e0" seqId="e1956" text="IGF-IR" type="protein" />      <entity charOffset="54-60" id="AIMed.d84.s713.e1" seqId="e1957" text="p52Shc" type="protein" />    </sentence>    <sentence charOffset="586-1036" id="AIMed.d84.s714" seqId="s714" text="Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.">      <entity charOffset="83-89" id="AIMed.d84.s714.e0" seqId="e1958" text="IGF-IR" type="protein" />      <entity charOffset="128-134" id="AIMed.d84.s714.e1" seqId="e1961" text="p52Shc" type="protein" />      <entity charOffset="139-144" id="AIMed.d84.s714.e2" seqId="e1963" text="IRS-1" type="protein" />      <entity charOffset="151-157" id="AIMed.d84.s714.e3" seqId="e1965" text="p52Shc" type="protein" />      <entity charOffset="162-167" id="AIMed.d84.s714.e4" seqId="e1967" text="IRS-1" type="protein" />      <entity charOffset="180-186" id="AIMed.d84.s714.e5" seqId="e1969" text="IGF-IR" type="protein" />      <entity charOffset="238-244" id="AIMed.d84.s714.e6" seqId="e1972" text="p52Shc" type="protein" />      <entity charOffset="246-251" id="AIMed.d84.s714.e7" seqId="e1973" text="IRS-1" type="protein" />      <entity charOffset="338-344" id="AIMed.d84.s714.e8" seqId="e1975" text="IGF-IR" type="protein" />      <entity charOffset="384-390" id="AIMed.d84.s714.e9" seqId="e1977" text="p52Shc" type="protein" />      <entity charOffset="432-434" id="AIMed.d84.s714.e10" seqId="e1980" text="IR" type="protein" />      <entity charOffset="443-449" id="AIMed.d84.s714.e11" seqId="e1982" text="IGF-IR" type="protein" />      <interaction e1="AIMed.d84.s714.e0" e2="AIMed.d84.s714.e1" id="AIMed.d84.s714.i0" type="PPI" />      <interaction e1="AIMed.d84.s714.e0" e2="AIMed.d84.s714.e2" id="AIMed.d84.s714.i1" type="PPI" />      <interaction e1="AIMed.d84.s714.e3" e2="AIMed.d84.s714.e5" id="AIMed.d84.s714.i2" type="PPI" />      <interaction e1="AIMed.d84.s714.e4" e2="AIMed.d84.s714.e5" id="AIMed.d84.s714.i3" type="PPI" />      <interaction e1="AIMed.d84.s714.e7" e2="AIMed.d84.s714.e8" id="AIMed.d84.s714.i4" type="PPI" />      <interaction e1="AIMed.d84.s714.e9" e2="AIMed.d84.s714.e10" id="AIMed.d84.s714.i5" type="PPI" />      <interaction e1="AIMed.d84.s714.e9" e2="AIMed.d84.s714.e11" id="AIMed.d84.s714.i6" type="PPI" />    </sentence>    <sentence charOffset="1037-1300" id="AIMed.d84.s715" seqId="s715" text="We propose that (i) the IGF-IR and the IR share at least in part the same molecular mechanism underlying their interplay with their two substrates, p52Shc and IRS-1, and (ii) IRS-1 interacts with the IGF-IR in a fashion that is different from that used by p52Shc.">      <entity charOffset="24-30" id="AIMed.d84.s715.e0" seqId="e1984" text="IGF-IR" type="protein" />      <entity charOffset="39-41" id="AIMed.d84.s715.e1" seqId="e1987" text="IR" type="protein" />      <entity charOffset="148-154" id="AIMed.d84.s715.e2" seqId="e1990" text="p52Shc" type="protein" />      <entity charOffset="159-164" id="AIMed.d84.s715.e3" seqId="e1993" text="IRS-1" type="protein" />      <entity charOffset="175-180" id="AIMed.d84.s715.e4" seqId="e1996" text="IRS-1" type="protein" />      <entity charOffset="200-206" id="AIMed.d84.s715.e5" seqId="e1998" text="IGF-IR" type="protein" />      <entity charOffset="256-262" id="AIMed.d84.s715.e6" seqId="e2001" text="p52Shc" type="protein" />      <interaction e1="AIMed.d84.s715.e0" e2="AIMed.d84.s715.e2" id="AIMed.d84.s715.i0" type="PPI" />      <interaction e1="AIMed.d84.s715.e0" e2="AIMed.d84.s715.e3" id="AIMed.d84.s715.i1" type="PPI" />      <interaction e1="AIMed.d84.s715.e1" e2="AIMed.d84.s715.e2" id="AIMed.d84.s715.i2" type="PPI" />      <interaction e1="AIMed.d84.s715.e1" e2="AIMed.d84.s715.e3" id="AIMed.d84.s715.i3" type="PPI" />      <interaction e1="AIMed.d84.s715.e4" e2="AIMed.d84.s715.e5" id="AIMed.d84.s715.i4" type="PPI" />      <interaction e1="AIMed.d84.s715.e5" e2="AIMed.d84.s715.e6" id="AIMed.d84.s715.i5" type="PPI" />    </sentence>    <sentence charOffset="1301-1417" id="AIMed.d84.s716" seqId="s716" text="Finally, our data highlight the crucial role of the juxtamembrane domain in signaling by both the IR and the IGF-IR.">      <entity charOffset="98-100" id="AIMed.d84.s716.e0" seqId="e2003" text="IR" type="protein" />      <entity charOffset="109-115" id="AIMed.d84.s716.e1" seqId="e2004" text="IGF-IR" type="protein" />    </sentence>  </document>  <document id="AIMed.d86" origId="7565735" set="test">    <sentence charOffset="0-67" id="AIMed.d86.s724" seqId="s724" text="Correlation of two-hybrid affinity data with in vitro measurements.">      </sentence>    <sentence charOffset="68-197" id="AIMed.d86.s725" seqId="s725" text="Since their introduction, the interaction trap and other two-hybrid systems have been used to study protein-protein interactions.">      </sentence>    <sentence charOffset="198-410" id="AIMed.d86.s726" seqId="s726" text="Despite their general use, little is known about the extent to which the degree of protein interaction determined by two-hybrid approaches parallels the degree of interaction determined by biochemical techniques.">      </sentence>    <sentence charOffset="411-515" id="AIMed.d86.s727" seqId="s727" text="In this study, we used a set of lexAop-LEU2 and lexAop-lacZ reporters to calibrate the interaction trap.">      </sentence>    <sentence charOffset="516-688" id="AIMed.d86.s728" seqId="s728" text="For the calibration, we used two sets of proteins, the Myc-Max-Mxi1 helix-loop-helix proteins, and wild-type and dimerization-defective versions of the lambda cI repressor.">      <entity charOffset="55-58" id="AIMed.d86.s728.e0" seqId="e2024" text="Myc" type="protein" />      <entity charOffset="59-62" id="AIMed.d86.s728.e1" seqId="e2025" text="Max" type="protein" />      <entity charOffset="63-67" id="AIMed.d86.s728.e2" seqId="e2026" text="Mxi1" type="protein" />    </sentence>    <sentence charOffset="689-1036" id="AIMed.d86.s729" seqId="s729" text="Our results indicate that the strength of interaction as predicted by the two-hybrid approach generally correlates with that determined in vitro, permitting discrimination of high-, intermediate-, and low-affinity interactions, but there was no single reporter for which the amount of gene expression linearly reflected affinity measured in vitro.">      </sentence>    <sentence charOffset="1037-1123" id="AIMed.d86.s730" seqId="s730" text="However, some reporters showed thresholds and only responded to stronger interactions.">      </sentence>    <sentence charOffset="1124-1241" id="AIMed.d86.s731" seqId="s731" text="Finally, some interactions were subject to directionality, and their apparent strength depended on the reporter used.">      </sentence>    <sentence charOffset="1242-1357" id="AIMed.d86.s732" seqId="s732" text="Taken together, our results provide a cautionary framework for interpreting affinities from two-hybrid experiments.">      </sentence>  </document>  <document id="AIMed.d88" origId="7589456" set="test">    <sentence charOffset="0-100" id="AIMed.d88.s742" seqId="s742" text="Interaction of the protein nucleobindin with G alpha i2, as revealed by the yeast two-hybrid system.">      <entity charOffset="27-39" id="AIMed.d88.s742.e0" seqId="e2099" text="nucleobindin" type="protein" />      <entity charOffset="45-55" id="AIMed.d88.s742.e1" seqId="e2101" text="G alpha i2" type="protein" />      <interaction e1="AIMed.d88.s742.e0" e2="AIMed.d88.s742.e1" id="AIMed.d88.s742.i0" type="PPI" />    </sentence>    <sentence charOffset="101-256" id="AIMed.d88.s743" seqId="s743" text="The heterotrimeric G protein, G alpha i2, transduces signals from seven membrane spanning receptors to effectors such as adenylyl cyclase and ion channels.">      <entity charOffset="30-40" id="AIMed.d88.s743.e0" seqId="e2103" text="G alpha i2" type="protein" />    </sentence>    <sentence charOffset="257-400" id="AIMed.d88.s744" seqId="s744" text="The purpose of this study was to identify these or other cellular proteins that interact with G alpha i2 by use of the yeast two-hybrid system.">      <entity charOffset="94-104" id="AIMed.d88.s744.e0" seqId="e2104" text="G alpha i2" type="protein" />    </sentence>    <sentence charOffset="401-486" id="AIMed.d88.s745" seqId="s745" text="A human B cell cDNA library was screened by this system using full length G alpha i2.">      <entity charOffset="74-84" id="AIMed.d88.s745.e0" seqId="e2105" text="G alpha i2" type="protein" />    </sentence>    <sentence charOffset="487-524" id="AIMed.d88.s746" seqId="s746" text="Four positive colonies were obtained.">      </sentence>    <sentence charOffset="525-738" id="AIMed.d88.s747" seqId="s747" text="Two of the four were identified as nucleobindin, a calcium binding protein and a putative antigen to which anti-nuclear antibodies are generated in mice with a disorder that resembles systemic lupus erythematosus.">      <entity charOffset="35-47" id="AIMed.d88.s747.e0" seqId="e2106" text="nucleobindin" type="protein" />    </sentence>    <sentence charOffset="739-882" id="AIMed.d88.s748" seqId="s748" text="Nucleobindin has a leucine zipper, EF hands, and a signal peptide sequence and is thought to localize to the nucleus as well as being secreted.">      <entity charOffset="0-12" id="AIMed.d88.s748.e0" seqId="e2107" text="Nucleobindin" type="protein" />    </sentence>    <sentence charOffset="883-1021" id="AIMed.d88.s749" seqId="s749" text="The specificity of intehraction between G alpha i2 and nucleobindin was confirmed by an in vitro binding assay using recombinant proteins.">      <entity charOffset="40-50" id="AIMed.d88.s749.e0" seqId="e2108" text="G alpha i2" type="protein" />      <entity charOffset="55-67" id="AIMed.d88.s749.e1" seqId="e2110" text="nucleobindin" type="protein" />      <interaction e1="AIMed.d88.s749.e0" e2="AIMed.d88.s749.e1" id="AIMed.d88.s749.i0" type="PPI" />    </sentence>    <sentence charOffset="1022-1173" id="AIMed.d88.s750" seqId="s750" text="Transfection of G alpha i2 and nucleobindin in COS cells increased G alpha i2 expression relative to cells transfected with G alpha i2 and mock vector.">      <entity charOffset="16-26" id="AIMed.d88.s750.e0" seqId="e2112" text="G alpha i2" type="protein" />      <entity charOffset="31-43" id="AIMed.d88.s750.e1" seqId="e2113" text="nucleobindin" type="protein" />      <entity charOffset="67-77" id="AIMed.d88.s750.e2" seqId="e2114" text="G alpha i2" type="protein" />      <entity charOffset="124-134" id="AIMed.d88.s750.e3" seqId="e2115" text="G alpha i2" type="protein" />    </sentence>    <sentence charOffset="1174-1308" id="AIMed.d88.s751" seqId="s751" text="Our results indicate that the yeast two-hybrid system provides a means to identify novel proteins that interact with G alpha proteins.">      </sentence>    <sentence charOffset="1309-1365" id="AIMed.d88.s752" seqId="s752" text="Nucleobindin appears to represent one of those proteins.">      <entity charOffset="0-12" id="AIMed.d88.s752.e0" seqId="e2116" text="Nucleobindin" type="protein" />    </sentence>  </document>  <document id="AIMed.d106" origId="7744247" set="test">    <sentence charOffset="0-100" id="AIMed.d106.s893" seqId="s893" text="Raf1 interaction with Cdc25 phosphatase ties mitogenic signal transduction to cell cycle activation.">      <entity charOffset="0-4" id="AIMed.d106.s893.e0" seqId="e2586" text="Raf1" type="protein" />      <entity charOffset="22-39" id="AIMed.d106.s893.e1" seqId="e2588" text="Cdc25 phosphatase" type="protein" />      <interaction e1="AIMed.d106.s893.e0" e2="AIMed.d106.s893.e1" id="AIMed.d106.s893.i0" type="PPI" />    </sentence>    <sentence charOffset="101-191" id="AIMed.d106.s894" seqId="s894" text="The Ras and Raf1 proto-oncogenes transduce extracellular signals that promote cell growth.">      <entity charOffset="4-7" id="AIMed.d106.s894.e0" seqId="e2590" text="Ras" type="protein" />      <entity charOffset="12-16" id="AIMed.d106.s894.e1" seqId="e2591" text="Raf1" type="protein" />    </sentence>    <sentence charOffset="192-345" id="AIMed.d106.s895" seqId="s895" text="Cdc25 phosphatases activate the cell division cycle by dephosphorylation of critical threonine and tyrosine residues within the cyclin-dependent kinases.">      </sentence>    <sentence charOffset="346-458" id="AIMed.d106.s896" seqId="s896" text="We show here that Cdc25 phosphatase associates with raf1 in somatic mammalian cells and in meiotic frog oocytes.">      <entity charOffset="18-35" id="AIMed.d106.s896.e0" seqId="e2592" text="Cdc25 phosphatase" type="protein" />      <entity charOffset="52-56" id="AIMed.d106.s896.e1" seqId="e2594" text="raf1" type="protein" />      <interaction e1="AIMed.d106.s896.e0" e2="AIMed.d106.s896.e1" id="AIMed.d106.s896.i0" type="PPI" />    </sentence>    <sentence charOffset="459-543" id="AIMed.d106.s897" seqId="s897" text="Furthermore, Cdc25 phosphatase can be activated in vitro in a Raf1-dependent manner.">      <entity charOffset="13-30" id="AIMed.d106.s897.e0" seqId="e2596" text="Cdc25 phosphatase" type="protein" />      <entity charOffset="62-66" id="AIMed.d106.s897.e1" seqId="e2598" text="Raf1" type="protein" />      <interaction e1="AIMed.d106.s897.e0" e2="AIMed.d106.s897.e1" id="AIMed.d106.s897.i0" type="PPI" />    </sentence>    <sentence charOffset="544-649" id="AIMed.d106.s898" seqId="s898" text="We suggest that activation of the cell cycle by the Ras/Raf1 pathways might be mediated in part by Cdc25.">      <entity charOffset="52-55" id="AIMed.d106.s898.e0" seqId="e2600" text="Ras" type="protein" />      <entity charOffset="56-60" id="AIMed.d106.s898.e1" seqId="e2601" text="Raf1" type="protein" />      <entity charOffset="99-104" id="AIMed.d106.s898.e2" seqId="e2602" text="Cdc25" type="protein" />    </sentence>  </document>  <document id="AIMed.d107" origId="7782277" set="test">    <sentence charOffset="0-88" id="AIMed.d107.s899" seqId="s899" text="A direct interaction between G-protein beta gamma subunits and the Raf-1 protein kinase.">      <entity charOffset="29-49" id="AIMed.d107.s899.e0" seqId="e2603" text="G-protein beta gamma" type="protein" />      <entity charOffset="67-87" id="AIMed.d107.s899.e1" seqId="e2605" text="Raf-1 protein kinase" type="protein" />      <interaction e1="AIMed.d107.s899.e0" e2="AIMed.d107.s899.e1" id="AIMed.d107.s899.i0" type="PPI" />    </sentence>    <sentence charOffset="89-209" id="AIMed.d107.s900" seqId="s900" text="Raf-1 is a serine/threonine protein kinase positioned downstream of Ras in the mitogen-activated protein kinase cascade.">      <entity charOffset="0-5" id="AIMed.d107.s900.e0" seqId="e2607" text="Raf-1" type="protein" />      <entity charOffset="68-71" id="AIMed.d107.s900.e1" seqId="e2608" text="Ras" type="protein" />      <entity charOffset="79-111" id="AIMed.d107.s900.e2" seqId="e2609" text="mitogen-activated protein kinase" type="protein" />    </sentence>    <sentence charOffset="210-431" id="AIMed.d107.s901" seqId="s901" text="Using a yeast two-hybrid strategy to identify other proteins that interact with and potentially regulate Raf-1, we isolated a clone encoding the carboxyl-terminal half of the G beta 2 subunit of heterotrimeric G-proteins.">      <entity charOffset="105-110" id="AIMed.d107.s901.e0" seqId="e2610" text="Raf-1" type="protein" />      <entity charOffset="175-191" id="AIMed.d107.s901.e1" seqId="e2612" text="G beta 2 subunit" type="protein" />      <interaction e1="AIMed.d107.s901.e0" e2="AIMed.d107.s901.e1" id="AIMed.d107.s901.i0" type="PPI" />    </sentence>    <sentence charOffset="432-562" id="AIMed.d107.s902" seqId="s902" text="In vitro, purified G beta gamma subunits specifically bound to a GST fusion protein encoding amino acids 1-330 of Raf-1 (Raf/330).">      <entity charOffset="19-31" id="AIMed.d107.s902.e0" seqId="e2614" text="G beta gamma" type="protein" />      <entity charOffset="114-119" id="AIMed.d107.s902.e1" seqId="e2617" text="Raf-1" type="protein" />      <entity charOffset="121-128" id="AIMed.d107.s902.e2" seqId="e2619" text="Raf/330" type="protein" />      <interaction e1="AIMed.d107.s902.e0" e2="AIMed.d107.s902.e1" id="AIMed.d107.s902.i0" type="PPI" />      <interaction e1="AIMed.d107.s902.e0" e2="AIMed.d107.s902.e2" id="AIMed.d107.s902.i1" type="PPI" />    </sentence>    <sentence charOffset="563-737" id="AIMed.d107.s903" seqId="s903" text="Binding assays with truncation mutants of GST-Raf indicate that the region located between amino acids 136 and 239 is a primary determinant for interaction with G beta gamma.">      <entity charOffset="46-49" id="AIMed.d107.s903.e0" seqId="e2621" text="Raf" type="protein" />      <entity charOffset="161-173" id="AIMed.d107.s903.e1" seqId="e2622" text="G beta gamma" type="protein" />    </sentence>    <sentence charOffset="738-949" id="AIMed.d107.s904" seqId="s904" text="In competition experiments, the carboxyl terminus of beta-adrenergic receptor kinase (beta ARK) blocked the binding of G beta gamma to Raf/330; however, the Raf-1-binding proteins, Ras and 14-3-3, had no effect.">      <entity charOffset="53-84" id="AIMed.d107.s904.e0" seqId="e2623" text="beta-adrenergic receptor kinase" type="protein" />      <entity charOffset="86-94" id="AIMed.d107.s904.e1" seqId="e2624" text="beta ARK" type="protein" />      <entity charOffset="119-131" id="AIMed.d107.s904.e2" seqId="e2625" text="G beta gamma" type="protein" />      <entity charOffset="135-142" id="AIMed.d107.s904.e3" seqId="e2627" text="Raf/330" type="protein" />      <entity charOffset="157-162" id="AIMed.d107.s904.e4" seqId="e2629" text="Raf-1" type="protein" />      <entity charOffset="181-184" id="AIMed.d107.s904.e5" seqId="e2631" text="Ras" type="protein" />      <interaction e1="AIMed.d107.s904.e2" e2="AIMed.d107.s904.e3" id="AIMed.d107.s904.i0" type="PPI" />      <interaction e1="AIMed.d107.s904.e4" e2="AIMed.d107.s904.e5" id="AIMed.d107.s904.i1" type="PPI" />    </sentence>    <sentence charOffset="950-1155" id="AIMed.d107.s905" seqId="s905" text="Scatchard analysis of in vitro binding between Raf/330 and G beta gamma revealed an affinity of interaction (Kd = 163 +/- 36 nM), similar to that seen between G beta gamma and beta ARK (Kd = 87 +/- 24 nM).">      <entity charOffset="47-54" id="AIMed.d107.s905.e0" seqId="e2633" text="Raf/330" type="protein" />      <entity charOffset="59-71" id="AIMed.d107.s905.e1" seqId="e2635" text="G beta gamma" type="protein" />      <entity charOffset="159-171" id="AIMed.d107.s905.e2" seqId="e2637" text="G beta gamma" type="protein" />      <entity charOffset="176-184" id="AIMed.d107.s905.e3" seqId="e2639" text="beta ARK" type="protein" />      <interaction e1="AIMed.d107.s905.e0" e2="AIMed.d107.s905.e1" id="AIMed.d107.s905.i0" type="PPI" />      <interaction e1="AIMed.d107.s905.e2" e2="AIMed.d107.s905.e3" id="AIMed.d107.s905.i1" type="PPI" />    </sentence>    <sentence charOffset="1156-1431" id="AIMed.d107.s906" seqId="s906" text="The formation of native heterotrimeric G alpha beta gamma complexes, as measured by pertussis toxin ADP-ribosylation of G alpha, could be disrupted by increasing amounts of Raf/330, with an EC50 of approximately 200 nM, in close agreement with the estimated binding affinity.">      <entity charOffset="39-57" id="AIMed.d107.s906.e0" seqId="e2641" text="G alpha beta gamma" type="protein" />      <entity charOffset="173-180" id="AIMed.d107.s906.e1" seqId="e2642" text="Raf/330" type="protein" />    </sentence>    <sentence charOffset="1432-1571" id="AIMed.d107.s907" seqId="s907" text="In vivo complexes of Raf-1 and G beta gamma were isolated from human embryonic kidney 293-T cells transfected with epitope-tagged G beta 2.">      <entity charOffset="21-26" id="AIMed.d107.s907.e0" seqId="e2643" text="Raf-1" type="protein" />      <entity charOffset="31-43" id="AIMed.d107.s907.e1" seqId="e2645" text="G beta gamma" type="protein" />      <entity charOffset="130-138" id="AIMed.d107.s907.e2" seqId="e2647" text="G beta 2" type="protein" />      <interaction e1="AIMed.d107.s907.e0" e2="AIMed.d107.s907.e1" id="AIMed.d107.s907.i0" type="PPI" />    </sentence>    <sentence charOffset="1572-1781" id="AIMed.d107.s908" seqId="s908" text="The identification and characterization of this novel interaction raises several possibilities for signaling cross-talk between growth factor receptors and those receptors coupled to heterotrimeric G-proteins.">      </sentence>  </document>  <document id="AIMed.d111" origId="7829531" set="test">    <sentence charOffset="0-213" id="AIMed.d111.s930" seqId="s930" text="Mutagenesis of the regulatory subunit (RII beta) of cAMP-dependent protein kinase II beta reveals hydrophobic amino acids that are essential for RII beta dimerization and/or anchoring RII beta to the cytoskeleton.">      <entity charOffset="39-47" id="AIMed.d111.s930.e0" seqId="e2742" text="RII beta" type="protein" />      <entity charOffset="52-89" id="AIMed.d111.s930.e1" seqId="e2743" text="cAMP-dependent protein kinase II beta" type="protein" />      <entity charOffset="145-153" id="AIMed.d111.s930.e2" seqId="e2744" text="RII beta" type="protein" />      <entity charOffset="184-192" id="AIMed.d111.s930.e3" seqId="e2747" text="RII beta" type="protein" />    </sentence>    <sentence charOffset="214-430" id="AIMed.d111.s931" seqId="s931" text="In neurons cAMP-dependent protein kinase II beta (PKAII beta) is sequestered in the dendritic cytoskeleton because the regulatory subunit (RII beta) of the enzyme is tightly bound by A Kinase Anchor Proteins (AKAPs).">      <entity charOffset="11-48" id="AIMed.d111.s931.e0" seqId="e2748" text="cAMP-dependent protein kinase II beta" type="protein" />      <entity charOffset="50-60" id="AIMed.d111.s931.e1" seqId="e2749" text="PKAII beta" type="protein" />      <entity charOffset="139-147" id="AIMed.d111.s931.e2" seqId="e2750" text="RII beta" type="protein" />    </sentence>    <sentence charOffset="431-542" id="AIMed.d111.s932" seqId="s932" text="The prototypic neuronal anchor protein AKAP75 has a COOH-terminal 22-residue RII beta binding (tethering) site.">      <entity charOffset="39-45" id="AIMed.d111.s932.e0" seqId="e2751" text="AKAP75" type="protein" />      <entity charOffset="77-85" id="AIMed.d111.s932.e1" seqId="e2753" text="RII beta" type="protein" />      <interaction e1="AIMed.d111.s932.e0" e2="AIMed.d111.s932.e1" id="AIMed.d111.s932.i0" type="PPI" />    </sentence>    <sentence charOffset="543-686" id="AIMed.d111.s933" seqId="s933" text="A key feature of the tethering site is that several amino acids with large aliphatic side chains mediate the high-affinity binding of RII beta.">      <entity charOffset="134-142" id="AIMed.d111.s933.e0" seqId="e2755" text="RII beta" type="protein" />    </sentence>    <sentence charOffset="687-882" id="AIMed.d111.s934" seqId="s934" text="Mutagenesis, recombinant protein expression, and physicochemical characterization were used to investigate the structural basis for the homodimerization and AKAP75 binding activities of RII beta.">      <entity charOffset="157-163" id="AIMed.d111.s934.e0" seqId="e2756" text="AKAP75" type="protein" />      <entity charOffset="186-194" id="AIMed.d111.s934.e1" seqId="e2758" text="RII beta" type="protein" />      <interaction e1="AIMed.d111.s934.e0" e2="AIMed.d111.s934.e1" id="AIMed.d111.s934.i0" type="PPI" />    </sentence>    <sentence charOffset="883-981" id="AIMed.d111.s935" seqId="s935" text="Several crucial residues are located in an NH2-terminal region that encompasses amino acids 13-36.">      </sentence>    <sentence charOffset="982-1083" id="AIMed.d111.s936" seqId="s936" text="Substitution of Ala for Leu13 or Phe36 generates monomeric RII beta subunits that cannot bind AKAP75.">      <entity charOffset="59-67" id="AIMed.d111.s936.e0" seqId="e2762" text="RII beta" type="protein" />      <entity charOffset="94-100" id="AIMed.d111.s936.e1" seqId="e2763" text="AKAP75" type="protein" />    </sentence>    <sentence charOffset="1084-1284" id="AIMed.d111.s937" seqId="s937" text="The results are not due to general misfolding since mutant RII beta monomers bind cAMP and inhibit the catalytic subunit of PKAII beta with the same affinity and efficacy as wild-type RII beta dimers.">      <entity charOffset="59-67" id="AIMed.d111.s937.e0" seqId="e2764" text="RII beta" type="protein" />      <entity charOffset="124-134" id="AIMed.d111.s937.e1" seqId="e2765" text="PKAII beta" type="protein" />      <entity charOffset="184-192" id="AIMed.d111.s937.e2" seqId="e2766" text="RII beta" type="protein" />    </sentence>    <sentence charOffset="1285-1445" id="AIMed.d111.s938" seqId="s938" text="Moreover, substitution of Ala for Leu12, Val20, Leu21, Phe31, Leu33, or Leu39 and replacement of Leu13 with Ile or Val did not impair the dimerization reaction.">      </sentence>    <sentence charOffset="1446-1571" id="AIMed.d111.s939" seqId="s939" text="Evidently, large hydrophobic side chains of Leu13 and Phe36 play pivotal roles in stabilizing RII beta-RII beta interactions.">      <entity charOffset="94-102" id="AIMed.d111.s939.e0" seqId="e2769" text="RII beta" type="protein" />      <entity charOffset="103-111" id="AIMed.d111.s939.e1" seqId="e2771" text="RII beta" type="protein" />      <interaction e1="AIMed.d111.s939.e0" e2="AIMed.d111.s939.e1" id="AIMed.d111.s939.i0" type="PPI" />    </sentence>    <sentence charOffset="1572-1724" id="AIMed.d111.s940" seqId="s940" text="A secondary consequence of destabilizing RII beta dimers is the loss of intracellular targeting/anchoring capacity because monomers fail to bind AKAP75.">      <entity charOffset="41-49" id="AIMed.d111.s940.e0" seqId="e2773" text="RII beta" type="protein" />      <entity charOffset="145-151" id="AIMed.d111.s940.e1" seqId="e2776" text="AKAP75" type="protein" />    </sentence>    <sentence charOffset="1725-1833" id="AIMed.d111.s941" seqId="s941" text="Other NH2-terminal residues directly modulate the affinity of RII beta dimers for the AKAP75 tethering site.">      <entity charOffset="62-70" id="AIMed.d111.s941.e0" seqId="e2777" text="RII beta" type="protein" />      <entity charOffset="86-92" id="AIMed.d111.s941.e1" seqId="e2781" text="AKAP75" type="protein" />      <interaction e1="AIMed.d111.s941.e0" e2="AIMed.d111.s941.e1" id="AIMed.d111.s941.i0" type="PPI" />    </sentence>    <sentence charOffset="1834-1977" id="AIMed.d111.s942" seqId="s942" text="Replacement of Val20-Leu21 with Ala-Ala produced a dimeric RII beta protein that binds AKAP75 approximately 4% as avidly as wild-type RII beta.">      <entity charOffset="59-67" id="AIMed.d111.s942.e0" seqId="e2783" text="RII beta" type="protein" />      <entity charOffset="87-93" id="AIMed.d111.s942.e1" seqId="e2785" text="AKAP75" type="protein" />      <entity charOffset="134-142" id="AIMed.d111.s942.e2" seqId="e2787" text="RII beta" type="protein" />      <interaction e1="AIMed.d111.s942.e0" e2="AIMed.d111.s942.e1" id="AIMed.d111.s942.i0" type="PPI" />    </sentence>    <sentence charOffset="1978-2123" id="AIMed.d111.s943" seqId="s943" text="It is possible that the aliphatic side chains of Val20 and Leu21 interact with the essential Leu and Ile residues in the AKAP75 tethering region.">      <entity charOffset="121-127" id="AIMed.d111.s943.e0" seqId="e2788" text="AKAP75" type="protein" />    </sentence>  </document>  <document id="AIMed.d133" origId="8137421" set="test">    <sentence charOffset="0-115" id="AIMed.d133.s1132" seqId="s1132" text="JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain.">      <entity charOffset="0-4" id="AIMed.d133.s1132.e0" seqId="e3427" text="JNK1" type="protein" />      <entity charOffset="50-56" id="AIMed.d133.s1132.e1" seqId="e3429" text="Ha-Ras" type="protein" />      <entity charOffset="91-96" id="AIMed.d133.s1132.e2" seqId="e3430" text="c-Jun" type="protein" />      <interaction e1="AIMed.d133.s1132.e0" e2="AIMed.d133.s1132.e2" id="AIMed.d133.s1132.i0" type="PPI" />    </sentence>    <sentence charOffset="116-267" id="AIMed.d133.s1133" seqId="s1133" text="The ultraviolet (UV) response of mammalian cells is characterized by a rapid and selective increase in gene expression mediated by AP-1 and NF-kappa B.">      <entity charOffset="131-135" id="AIMed.d133.s1133.e0" seqId="e3432" text="AP-1" type="protein" />      <entity charOffset="140-150" id="AIMed.d133.s1133.e1" seqId="e3433" text="NF-kappa B" type="protein" />    </sentence>    <sentence charOffset="268-404" id="AIMed.d133.s1134" seqId="s1134" text="The effect on AP-1 transcriptional activity results, in part, from enhanced phosphorylation of the c-Jun NH2-terminal activation domain.">      <entity charOffset="14-18" id="AIMed.d133.s1134.e0" seqId="e3434" text="AP-1" type="protein" />      <entity charOffset="99-104" id="AIMed.d133.s1134.e1" seqId="e3435" text="c-Jun" type="protein" />    </sentence>    <sentence charOffset="405-598" id="AIMed.d133.s1135" seqId="s1135" text="Here, we describe the molecular cloning and characterization of JNK1, a distant relative of the MAP kinase group that is activated by dual phosphorylation at Thr and Tyr during the UV response.">      <entity charOffset="64-68" id="AIMed.d133.s1135.e0" seqId="e3436" text="JNK1" type="protein" />      <entity charOffset="96-106" id="AIMed.d133.s1135.e1" seqId="e3437" text="MAP kinase" type="protein" />    </sentence>    <sentence charOffset="599-690" id="AIMed.d133.s1136" seqId="s1136" text="Significantly, Ha-Ras partially activates JNK1 and potentiates the activation caused by UV.">      <entity charOffset="15-21" id="AIMed.d133.s1136.e0" seqId="e3438" text="Ha-Ras" type="protein" />      <entity charOffset="42-46" id="AIMed.d133.s1136.e1" seqId="e3440" text="JNK1" type="protein" />      <interaction e1="AIMed.d133.s1136.e0" e2="AIMed.d133.s1136.e1" id="AIMed.d133.s1136.i0" type="PPI" />    </sentence>    <sentence charOffset="691-781" id="AIMed.d133.s1137" seqId="s1137" text="JNK1 binds to the c-Jun transactivation domain and phosphorylates it on Ser-63 and Ser-73.">      <entity charOffset="0-4" id="AIMed.d133.s1137.e0" seqId="e3442" text="JNK1" type="protein" />      <entity charOffset="18-23" id="AIMed.d133.s1137.e1" seqId="e3444" text="c-Jun" type="protein" />      <interaction e1="AIMed.d133.s1137.e0" e2="AIMed.d133.s1137.e1" id="AIMed.d133.s1137.i0" type="PPI" />    </sentence>    <sentence charOffset="782-900" id="AIMed.d133.s1138" seqId="s1138" text="Thus, JNK1 is a component of a novel signal transduction pathway that is activated by oncoproteins and UV irradiation.">      <entity charOffset="6-10" id="AIMed.d133.s1138.e0" seqId="e3446" text="JNK1" type="protein" />    </sentence>    <sentence charOffset="901-994" id="AIMed.d133.s1139" seqId="s1139" text="These properties indicate that JNK1 activation may play an important role in tumor promotion.">      <entity charOffset="31-35" id="AIMed.d133.s1139.e0" seqId="e3447" text="JNK1" type="protein" />    </sentence>  </document>  <document id="AIMed.d134" origId="8139691" set="test">    <sentence charOffset="0-61" id="AIMed.d134.s1140" seqId="s1140" text="B61 is a ligand for the ECK receptor protein-tyrosine kinase.">      <entity charOffset="0-3" id="AIMed.d134.s1140.e0" seqId="e3448" text="B61" type="protein" />      <entity charOffset="24-27" id="AIMed.d134.s1140.e1" seqId="e3450" text="ECK" type="protein" />      <entity charOffset="24-60" id="AIMed.d134.s1140.e2" seqId="e3451" text="ECK receptor protein-tyrosine kinase" type="protein" />      <interaction e1="AIMed.d134.s1140.e0" e2="AIMed.d134.s1140.e2" id="AIMed.d134.s1140.i0" type="PPI" />    </sentence>    <sentence charOffset="62-223" id="AIMed.d134.s1141" seqId="s1141" text="A protein ligand for the ECK receptor protein-tyrosine kinase has been isolated by using the extracellular domain (ECK-X) of the receptor as an affinity reagent.">      <entity charOffset="25-28" id="AIMed.d134.s1141.e0" seqId="e3453" text="ECK" type="protein" />      <entity charOffset="25-61" id="AIMed.d134.s1141.e1" seqId="e3454" text="ECK receptor protein-tyrosine kinase" type="protein" />      <entity charOffset="115-118" id="AIMed.d134.s1141.e2" seqId="e3455" text="ECK" type="protein" />    </sentence>    <sentence charOffset="224-390" id="AIMed.d134.s1142" seqId="s1142" text="Initially, concentrated cell culture supernatants were screened for receptor binding activity using immobilized ECK-X in a surface plasmon resonance detection system.">      <entity charOffset="112-115" id="AIMed.d134.s1142.e0" seqId="e3456" text="ECK" type="protein" />    </sentence>    <sentence charOffset="391-670" id="AIMed.d134.s1143" seqId="s1143" text="Subsequently, supernatants from selected cell lines were fractionated directly by receptor affinity chromatography, resulting in the single-step purification of B61, a protein previously identified as the product of an early response gene induced by tumour necrosis factor-alpha.">      <entity charOffset="161-164" id="AIMed.d134.s1143.e0" seqId="e3457" text="B61" type="protein" />      <entity charOffset="250-278" id="AIMed.d134.s1143.e1" seqId="e3458" text="tumour necrosis factor-alpha" type="protein" />    </sentence>    <sentence charOffset="671-813" id="AIMed.d134.s1144" seqId="s1144" text="We report here that recombinant B61 induces autophosphorylation of ECK in intact cells, consistent with B61 being an authentic ligand for ECK.">      <entity charOffset="32-35" id="AIMed.d134.s1144.e0" seqId="e3459" text="B61" type="protein" />      <entity charOffset="67-70" id="AIMed.d134.s1144.e1" seqId="e3461" text="ECK" type="protein" />      <entity charOffset="104-107" id="AIMed.d134.s1144.e2" seqId="e3463" text="B61" type="protein" />      <entity charOffset="138-141" id="AIMed.d134.s1144.e3" seqId="e3465" text="ECK" type="protein" />      <interaction e1="AIMed.d134.s1144.e0" e2="AIMed.d134.s1144.e1" id="AIMed.d134.s1144.i0" type="PPI" />      <interaction e1="AIMed.d134.s1144.e2" e2="AIMed.d134.s1144.e3" id="AIMed.d134.s1144.i1" type="PPI" />    </sentence>    <sentence charOffset="814-1024" id="AIMed.d134.s1145" seqId="s1145" text="ECK is a member of a large orphan receptor protein-tyrosine kinase family headed by EPH, and we suggest that ligands for other members of this family will be related to B61, and can be isolated in the same way.">      <entity charOffset="0-3" id="AIMed.d134.s1145.e0" seqId="e3467" text="ECK" type="protein" />      <entity charOffset="169-172" id="AIMed.d134.s1145.e1" seqId="e3468" text="B61" type="protein" />    </sentence>  </document>  <document id="AIMed.d140" origId="8242750" set="test">    <sentence charOffset="0-75" id="AIMed.d140.s1180" seqId="s1180" text="Cdi1, a human G1 and S phase protein phosphatase that associates with Cdk2.">      <entity charOffset="0-4" id="AIMed.d140.s1180.e0" seqId="e3568" text="Cdi1" type="protein" />      <entity charOffset="70-74" id="AIMed.d140.s1180.e1" seqId="e3570" text="Cdk2" type="protein" />      <interaction e1="AIMed.d140.s1180.e0" e2="AIMed.d140.s1180.e1" id="AIMed.d140.s1180.i0" type="PPI" />    </sentence>    <sentence charOffset="76-219" id="AIMed.d140.s1181" seqId="s1181" text="We used the interaction trap, a yeast genetic selection for interacting proteins, to isolate human cyclin-dependent kinase interactor 1 (Cdi1).">      <entity charOffset="99-135" id="AIMed.d140.s1181.e0" seqId="e3572" text="cyclin-dependent kinase interactor 1" type="protein" />      <entity charOffset="137-141" id="AIMed.d140.s1181.e1" seqId="e3573" text="Cdi1" type="protein" />    </sentence>    <sentence charOffset="220-332" id="AIMed.d140.s1182" seqId="s1182" text="In yeast, Cdi1 interacts with cyclin-dependent kinases, including human Cdc2, Cdk2, and Cdk3, but not with Cdk4.">      <entity charOffset="10-14" id="AIMed.d140.s1182.e0" seqId="e3574" text="Cdi1" type="protein" />      <entity charOffset="72-76" id="AIMed.d140.s1182.e1" seqId="e3578" text="Cdc2" type="protein" />      <entity charOffset="78-82" id="AIMed.d140.s1182.e2" seqId="e3580" text="Cdk2" type="protein" />      <entity charOffset="88-92" id="AIMed.d140.s1182.e3" seqId="e3582" text="Cdk3" type="protein" />      <entity charOffset="107-111" id="AIMed.d140.s1182.e4" seqId="e3584" text="Cdk4" type="protein" />      <interaction e1="AIMed.d140.s1182.e0" e2="AIMed.d140.s1182.e1" id="AIMed.d140.s1182.i0" type="PPI" />      <interaction e1="AIMed.d140.s1182.e0" e2="AIMed.d140.s1182.e2" id="AIMed.d140.s1182.i1" type="PPI" />      <interaction e1="AIMed.d140.s1182.e0" e2="AIMed.d140.s1182.e3" id="AIMed.d140.s1182.i2" type="PPI" />    </sentence>    <sentence charOffset="333-442" id="AIMed.d140.s1183" seqId="s1183" text="In HeLa cells, Cdi1 is expressed at the G1 to S transition, and the protein forms stable complexes with Cdk2.">      <entity charOffset="15-19" id="AIMed.d140.s1183.e0" seqId="e3585" text="Cdi1" type="protein" />      <entity charOffset="104-108" id="AIMed.d140.s1183.e1" seqId="e3587" text="Cdk2" type="protein" />      <interaction e1="AIMed.d140.s1183.e0" e2="AIMed.d140.s1183.e1" id="AIMed.d140.s1183.i0" type="PPI" />    </sentence>    <sentence charOffset="443-531" id="AIMed.d140.s1184" seqId="s1184" text="Cdi1 bears weak sequence similarity to known tyrosine and dual specificity phosphatases.">      <entity charOffset="0-4" id="AIMed.d140.s1184.e0" seqId="e3589" text="Cdi1" type="protein" />    </sentence>    <sentence charOffset="532-696" id="AIMed.d140.s1185" seqId="s1185" text="In vitro, Cdi1 removes phosphate from tyrosine residues in model substrates, but a mutant protein that bears a lesion in the putative active site cysteine does not.">      <entity charOffset="10-14" id="AIMed.d140.s1185.e0" seqId="e3590" text="Cdi1" type="protein" />    </sentence>    <sentence charOffset="697-845" id="AIMed.d140.s1186" seqId="s1186" text="Overexpression of wild-type Cdi1 delays progression through the cell cycle in yeast and HeLa cells; delay is dependent on Cdi1 phosphatase activity.">      <entity charOffset="28-32" id="AIMed.d140.s1186.e0" seqId="e3591" text="Cdi1" type="protein" />      <entity charOffset="122-126" id="AIMed.d140.s1186.e1" seqId="e3592" text="Cdi1" type="protein" />    </sentence>    <sentence charOffset="846-968" id="AIMed.d140.s1187" seqId="s1187" text="These experiments identify Cdi1 as a novel type of protein phosphatase that forms complexes with cyclin-dependent kinases.">      <entity charOffset="27-31" id="AIMed.d140.s1187.e0" seqId="e3593" text="Cdi1" type="protein" />    </sentence>  </document>  <document id="AIMed.d149" origId="8491186" set="test">    <sentence charOffset="0-147" id="AIMed.d149.s1262" seqId="s1262" text="The SH2/SH3 domain-containing protein GRB2 interacts with tyrosine-phosphorylated IRS1 and Shc: implications for insulin control of ras signalling.">      <entity charOffset="38-42" id="AIMed.d149.s1262.e0" seqId="e3820" text="GRB2" type="protein" />      <entity charOffset="82-86" id="AIMed.d149.s1262.e1" seqId="e3823" text="IRS1" type="protein" />      <entity charOffset="91-94" id="AIMed.d149.s1262.e2" seqId="e3825" text="Shc" type="protein" />      <entity charOffset="132-135" id="AIMed.d149.s1262.e3" seqId="e3827" text="ras" type="protein" />      <interaction e1="AIMed.d149.s1262.e0" e2="AIMed.d149.s1262.e1" id="AIMed.d149.s1262.i0" type="PPI" />      <interaction e1="AIMed.d149.s1262.e0" e2="AIMed.d149.s1262.e2" id="AIMed.d149.s1262.i1" type="PPI" />    </sentence>    <sentence charOffset="148-293" id="AIMed.d149.s1263" seqId="s1263" text="GRB2, a small protein comprising one SH2 domain and two SH3 domains, represents the human homologue of the Caenorhabditis elegans protein, sem-5.">      <entity charOffset="0-4" id="AIMed.d149.s1263.e0" seqId="e3828" text="GRB2" type="protein" />      <entity charOffset="139-144" id="AIMed.d149.s1263.e1" seqId="e3829" text="sem-5" type="protein" />    </sentence>    <sentence charOffset="294-429" id="AIMed.d149.s1264" seqId="s1264" text="Both GRB2 and sem-5 have been implicated in a highly conserved mechanism that regulates p21ras signalling by receptor tyrosine kinases.">      <entity charOffset="5-9" id="AIMed.d149.s1264.e0" seqId="e3830" text="GRB2" type="protein" />      <entity charOffset="14-19" id="AIMed.d149.s1264.e1" seqId="e3831" text="sem-5" type="protein" />      <entity charOffset="88-94" id="AIMed.d149.s1264.e2" seqId="e3832" text="p21ras" type="protein" />    </sentence>    <sentence charOffset="430-552" id="AIMed.d149.s1265" seqId="s1265" text="In this report we show that in response to insulin, GRB2 forms a stable complex with two tyrosine-phosphorylated proteins.">      <entity charOffset="43-50" id="AIMed.d149.s1265.e0" seqId="e3833" text="insulin" type="protein" />      <entity charOffset="52-56" id="AIMed.d149.s1265.e1" seqId="e3834" text="GRB2" type="protein" />    </sentence>    <sentence charOffset="553-678" id="AIMed.d149.s1266" seqId="s1266" text="One protein is the major insulin receptor substrate IRS-1 and the second is the SH2 domain-containing oncogenic protein, Shc.">      <entity charOffset="52-57" id="AIMed.d149.s1266.e0" seqId="e3835" text="IRS-1" type="protein" />      <entity charOffset="121-124" id="AIMed.d149.s1266.e1" seqId="e3836" text="Shc" type="protein" />    </sentence>    <sentence charOffset="679-882" id="AIMed.d149.s1267" seqId="s1267" text="The interactions between GRB2 and these two proteins require ligand activation of the insulin receptor and are mediated by the binding of the SH2 domain of GRB2 to phosphotyrosines on both IRS-1 and Shc.">      <entity charOffset="25-29" id="AIMed.d149.s1267.e0" seqId="e3837" text="GRB2" type="protein" />      <entity charOffset="86-102" id="AIMed.d149.s1267.e1" seqId="e3838" text="insulin receptor" type="protein" />      <entity charOffset="156-160" id="AIMed.d149.s1267.e2" seqId="e3839" text="GRB2" type="protein" />      <entity charOffset="189-194" id="AIMed.d149.s1267.e3" seqId="e3842" text="IRS-1" type="protein" />      <entity charOffset="199-202" id="AIMed.d149.s1267.e4" seqId="e3844" text="Shc" type="protein" />      <interaction e1="AIMed.d149.s1267.e2" e2="AIMed.d149.s1267.e3" id="AIMed.d149.s1267.i0" type="PPI" />      <interaction e1="AIMed.d149.s1267.e2" e2="AIMed.d149.s1267.e4" id="AIMed.d149.s1267.i1" type="PPI" />    </sentence>    <sentence charOffset="883-1052" id="AIMed.d149.s1268" seqId="s1268" text="Although GRB2 associates with IRS-1 and Shc, it is not tyrosine-phosphorylated after insulin stimulation, implying that GRB2 is not a substrate for the insulin receptor.">      <entity charOffset="9-13" id="AIMed.d149.s1268.e0" seqId="e3846" text="GRB2" type="protein" />      <entity charOffset="30-35" id="AIMed.d149.s1268.e1" seqId="e3849" text="IRS-1" type="protein" />      <entity charOffset="40-43" id="AIMed.d149.s1268.e2" seqId="e3851" text="Shc" type="protein" />      <entity charOffset="85-92" id="AIMed.d149.s1268.e3" seqId="e3853" text="insulin" type="protein" />      <entity charOffset="120-124" id="AIMed.d149.s1268.e4" seqId="e3854" text="GRB2" type="protein" />      <interaction e1="AIMed.d149.s1268.e0" e2="AIMed.d149.s1268.e1" id="AIMed.d149.s1268.i0" type="PPI" />      <interaction e1="AIMed.d149.s1268.e0" e2="AIMed.d149.s1268.e2" id="AIMed.d149.s1268.i1" type="PPI" />    </sentence>    <sentence charOffset="1053-1215" id="AIMed.d149.s1269" seqId="s1269" text="Furthermore, we have identified a short sequence motif (YV/IN) present in IRS-1, EGFR and Shc, which specifically binds the SH2 domain of GRB2 with high affinity.">      <entity charOffset="74-79" id="AIMed.d149.s1269.e0" seqId="e3855" text="IRS-1" type="protein" />      <entity charOffset="81-85" id="AIMed.d149.s1269.e1" seqId="e3857" text="EGFR" type="protein" />      <entity charOffset="90-93" id="AIMed.d149.s1269.e2" seqId="e3859" text="Shc" type="protein" />      <entity charOffset="138-142" id="AIMed.d149.s1269.e3" seqId="e3861" text="GRB2" type="protein" />      <interaction e1="AIMed.d149.s1269.e0" e2="AIMed.d149.s1269.e3" id="AIMed.d149.s1269.i0" type="PPI" />      <interaction e1="AIMed.d149.s1269.e1" e2="AIMed.d149.s1269.e3" id="AIMed.d149.s1269.i1" type="PPI" />      <interaction e1="AIMed.d149.s1269.e2" e2="AIMed.d149.s1269.e3" id="AIMed.d149.s1269.i2" type="PPI" />    </sentence>    <sentence charOffset="1216-1466" id="AIMed.d149.s1270" seqId="s1270" text="Interestingly, both GRB2 and phosphatidylinositol-3 (PI-3) kinase can simultaneously bind distinct tyrosine phosphorylated regions on the same IRS-1 molecule, suggesting a mechanism whereby IRS-1 could provide the core for a large signalling complex.">      <entity charOffset="20-24" id="AIMed.d149.s1270.e0" seqId="e3865" text="GRB2" type="protein" />      <entity charOffset="29-65" id="AIMed.d149.s1270.e1" seqId="e3867" text="phosphatidylinositol-3 (PI-3) kinase" type="protein" />      <entity charOffset="143-148" id="AIMed.d149.s1270.e2" seqId="e3869" text="IRS-1" type="protein" />      <entity charOffset="190-195" id="AIMed.d149.s1270.e3" seqId="e3872" text="IRS-1" type="protein" />      <interaction e1="AIMed.d149.s1270.e0" e2="AIMed.d149.s1270.e2" id="AIMed.d149.s1270.i0" type="PPI" />      <interaction e1="AIMed.d149.s1270.e1" e2="AIMed.d149.s1270.e2" id="AIMed.d149.s1270.i1" type="PPI" />    </sentence>    <sentence charOffset="1467-1622" id="AIMed.d149.s1271" seqId="s1271" text="We propose a model whereby insulin stimulation leads to formation of multiple protein--protein interactions between GRB2 and the two targets IRS-1 and Shc.">      <entity charOffset="116-120" id="AIMed.d149.s1271.e0" seqId="e3873" text="GRB2" type="protein" />      <entity charOffset="141-146" id="AIMed.d149.s1271.e1" seqId="e3876" text="IRS-1" type="protein" />      <entity charOffset="151-154" id="AIMed.d149.s1271.e2" seqId="e3878" text="Shc" type="protein" />      <interaction e1="AIMed.d149.s1271.e0" e2="AIMed.d149.s1271.e1" id="AIMed.d149.s1271.i0" type="PPI" />      <interaction e1="AIMed.d149.s1271.e0" e2="AIMed.d149.s1271.e2" id="AIMed.d149.s1271.i1" type="PPI" />    </sentence>    <sentence charOffset="1623-1739" id="AIMed.d149.s1272" seqId="s1272" text="These interactions may play a crucial role in activation of p21ras and the control of downstream effector molecules.">      <entity charOffset="60-66" id="AIMed.d149.s1272.e0" seqId="e3880" text="p21ras" type="protein" />    </sentence>  </document>  <document id="AIMed.d155" origId="8598932" set="test">    <sentence charOffset="0-46" id="AIMed.d155.s1315" seqId="s1315" text="A histone octamer-like structure within TFIID.">      <entity charOffset="40-45" id="AIMed.d155.s1315.e0" seqId="e4058" text="TFIID" type="protein" />    </sentence>    <sentence charOffset="47-389" id="AIMed.d155.s1316" seqId="s1316" text="The general transcription factor TFIID nucleates initiation complex formation through direct core promoter binding, commits promoters within chromatin to transcription, and mediates the action of transcriptional activators, a phenomenon that may correlate with enhanced TFIID recruitment or conformational changes in TFIID-promoter complexes.">      <entity charOffset="33-38" id="AIMed.d155.s1316.e0" seqId="e4059" text="TFIID" type="protein" />      <entity charOffset="270-275" id="AIMed.d155.s1316.e1" seqId="e4060" text="TFIID" type="protein" />      <entity charOffset="317-322" id="AIMed.d155.s1316.e2" seqId="e4061" text="TFIID" type="protein" />    </sentence>    <sentence charOffset="390-759" id="AIMed.d155.s1317" seqId="s1317" text="Molecular studies of the multiprotein TFIID complex have identified a primary TATA binding subunit (TBP), TBP-associated factors (TAFs) that interact with and mediate the function of activators and intersubunit interactions but have yielded relatively little insight into the structural organization of the complex or the actual mechanism of transcriptional activation.">      <entity charOffset="38-43" id="AIMed.d155.s1317.e0" seqId="e4062" text="TFIID" type="protein" />      <entity charOffset="78-98" id="AIMed.d155.s1317.e1" seqId="e4063" text="TATA binding subunit" type="protein" />      <entity charOffset="100-103" id="AIMed.d155.s1317.e2" seqId="e4064" text="TBP" type="protein" />    </sentence>    <sentence charOffset="760-905" id="AIMed.d155.s1318" seqId="s1318" text="Here we present biochemical evidence for the structural relevance of histone homologies in the human TFIID subunits hTAF80, hTAF31 and hTAF20/15.">      <entity charOffset="101-106" id="AIMed.d155.s1318.e0" seqId="e4065" text="TFIID" type="protein" />      <entity charOffset="116-122" id="AIMed.d155.s1318.e1" seqId="e4066" text="hTAF80" type="protein" />      <entity charOffset="124-130" id="AIMed.d155.s1318.e2" seqId="e4067" text="hTAF31" type="protein" />      <entity charOffset="135-144" id="AIMed.d155.s1318.e3" seqId="e4068" text="hTAF20/15" type="protein" />    </sentence>    <sentence charOffset="906-1080" id="AIMed.d155.s1319" seqId="s1319" text="Together with analyses of native TFIID complexes and accompanying crystallographic studies, the results suggest that there is a histone octamer-like TAF complex within TFIID.">      <entity charOffset="33-38" id="AIMed.d155.s1319.e0" seqId="e4069" text="TFIID" type="protein" />      <entity charOffset="168-173" id="AIMed.d155.s1319.e1" seqId="e4070" text="TFIID" type="protein" />    </sentence>  </document>  <document id="AIMed.d156" origId="8599092" set="test">    <sentence charOffset="0-58" id="AIMed.d156.s1320" seqId="s1320" text="IRAK: a kinase associated with the interleukin-1 receptor.">      <entity charOffset="0-4" id="AIMed.d156.s1320.e0" seqId="e4071" text="IRAK" type="protein" />      <entity charOffset="35-57" id="AIMed.d156.s1320.e1" seqId="e4073" text="interleukin-1 receptor" type="protein" />      <interaction e1="AIMed.d156.s1320.e0" e2="AIMed.d156.s1320.e1" id="AIMed.d156.s1320.i0" type="PPI" />    </sentence>    <sentence charOffset="59-166" id="AIMed.d156.s1321" seqId="s1321" text="The pleiotropic biological activities of interleukin-1 (IL-1) are mediated by its type I receptor (IL-1RI).">      <entity charOffset="41-54" id="AIMed.d156.s1321.e0" seqId="e4075" text="interleukin-1" type="protein" />      <entity charOffset="56-60" id="AIMed.d156.s1321.e1" seqId="e4078" text="IL-1" type="protein" />      <entity charOffset="99-105" id="AIMed.d156.s1321.e2" seqId="e4081" text="IL-1RI" type="protein" />      <interaction e1="AIMed.d156.s1321.e0" e2="AIMed.d156.s1321.e2" id="AIMed.d156.s1321.i0" type="PPI" />      <interaction e1="AIMed.d156.s1321.e1" e2="AIMed.d156.s1321.e2" id="AIMed.d156.s1321.i1" type="PPI" />    </sentence>    <sentence charOffset="167-325" id="AIMed.d156.s1322" seqId="s1322" text="When the ligand binds, IL-1RI initiates a signaling cascade that results in the activation of the transcription regulator nuclear factor kappa B (NF-kappa B).">      <entity charOffset="23-29" id="AIMed.d156.s1322.e0" seqId="e4085" text="IL-1RI" type="protein" />      <entity charOffset="122-144" id="AIMed.d156.s1322.e1" seqId="e4086" text="nuclear factor kappa B" type="protein" />      <entity charOffset="146-156" id="AIMed.d156.s1322.e2" seqId="e4087" text="NF-kappa B" type="protein" />    </sentence>    <sentence charOffset="326-456" id="AIMed.d156.s1323" seqId="s1323" text="A protein kinase designated IRAK (IL-1 receptor-associated kinase) was purified, and its complementary DNA was molecularly cloned.">      <entity charOffset="28-32" id="AIMed.d156.s1323.e0" seqId="e4088" text="IRAK" type="protein" />      <entity charOffset="34-38" id="AIMed.d156.s1323.e1" seqId="e4089" text="IL-1" type="protein" />      <entity charOffset="34-65" id="AIMed.d156.s1323.e2" seqId="e4090" text="IL-1 receptor-associated kinase" type="protein" />    </sentence>    <sentence charOffset="457-637" id="AIMed.d156.s1324" seqId="s1324" text="When human embryonic kidney cells (cell line 293) over-expressing IL-1RI or HeLa cells were exposed to IL-1, IRAK rapidly associated with the IL-1RI complex and was phosphorylated.">      <entity charOffset="66-72" id="AIMed.d156.s1324.e0" seqId="e4091" text="IL-1RI" type="protein" />      <entity charOffset="103-107" id="AIMed.d156.s1324.e1" seqId="e4092" text="IL-1" type="protein" />      <entity charOffset="109-113" id="AIMed.d156.s1324.e2" seqId="e4093" text="IRAK" type="protein" />      <entity charOffset="142-148" id="AIMed.d156.s1324.e3" seqId="e4095" text="IL-1RI" type="protein" />      <interaction e1="AIMed.d156.s1324.e2" e2="AIMed.d156.s1324.e3" id="AIMed.d156.s1324.i0" type="PPI" />    </sentence>    <sentence charOffset="638-807" id="AIMed.d156.s1325" seqId="s1325" text="The primary amino acid sequence of IRAK shares similarity with that of pelle,a protein kinase that is essential for the activation of a NF-kappa B homolog in Drosophila.">      <entity charOffset="35-39" id="AIMed.d156.s1325.e0" seqId="e4097" text="IRAK" type="protein" />      <entity charOffset="136-146" id="AIMed.d156.s1325.e1" seqId="e4098" text="NF-kappa B" type="protein" />    </sentence>  </document>  <document id="AIMed.d170" origId="8676437" set="test">    <sentence charOffset="0-94" id="AIMed.d170.s1434" seqId="s1434" text="Elimination of false negative results in the two-hybrid system in the phagocyte NADPH oxidase.">      <entity charOffset="80-93" id="AIMed.d170.s1434.e0" seqId="e4437" text="NADPH oxidase" type="protein" />    </sentence>    <sentence charOffset="95-194" id="AIMed.d170.s1435" seqId="s1435" text="The yeast two-hybrid system is finding increased use in the study of interactions between proteins.">      </sentence>    <sentence charOffset="195-366" id="AIMed.d170.s1436" seqId="s1436" text="In this method, two polypeptides are expressed in yeast as fusion proteins to a transcriptional activator DNA-binding domain (bd) and activating domain (ad), respectively.">      </sentence>    <sentence charOffset="367-490" id="AIMed.d170.s1437" seqId="s1437" text="Interaction between the two polypeptides reconstitutes function of a transactivator which controls expression of reporters.">      </sentence>    <sentence charOffset="491-724" id="AIMed.d170.s1438" seqId="s1438" text="The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 (comprised of subunits p22-phox and gp91-phox) and three cytosol proteins (p47-phox, p67-phox, and p21rac) that translocate to membrane and bind to cytochrome b558.">      <entity charOffset="14-27" id="AIMed.d170.s1438.e0" seqId="e4438" text="NADPH oxidase" type="protein" />      <entity charOffset="53-68" id="AIMed.d170.s1438.e1" seqId="e4439" text="cytochrome b558" type="protein" />      <entity charOffset="92-100" id="AIMed.d170.s1438.e2" seqId="e4440" text="p22-phox" type="protein" />      <entity charOffset="105-114" id="AIMed.d170.s1438.e3" seqId="e4442" text="gp91-phox" type="protein" />      <entity charOffset="144-152" id="AIMed.d170.s1438.e4" seqId="e4444" text="p47-phox" type="protein" />      <entity charOffset="154-162" id="AIMed.d170.s1438.e5" seqId="e4447" text="p67-phox" type="protein" />      <entity charOffset="168-174" id="AIMed.d170.s1438.e6" seqId="e4450" text="p21rac" type="protein" />      <entity charOffset="217-232" id="AIMed.d170.s1438.e7" seqId="e4452" text="cytochrome b558" type="protein" />      <interaction e1="AIMed.d170.s1438.e2" e2="AIMed.d170.s1438.e3" id="AIMed.d170.s1438.i0" type="PPI" />      <interaction e1="AIMed.d170.s1438.e4" e2="AIMed.d170.s1438.e5" id="AIMed.d170.s1438.i1" type="PPI" />      <interaction e1="AIMed.d170.s1438.e4" e2="AIMed.d170.s1438.e7" id="AIMed.d170.s1438.i2" type="PPI" />      <interaction e1="AIMed.d170.s1438.e5" e2="AIMed.d170.s1438.e7" id="AIMed.d170.s1438.i3" type="PPI" />      <interaction e1="AIMed.d170.s1438.e6" e2="AIMed.d170.s1438.e7" id="AIMed.d170.s1438.i4" type="PPI" />    </sentence>    <sentence charOffset="725-858" id="AIMed.d170.s1439" seqId="s1439" text="This is the first report to demonstrate that two of cytosolic components of cytochrome b558, p47-phox binding to p67-phox each other.">      <entity charOffset="76-91" id="AIMed.d170.s1439.e0" seqId="e4456" text="cytochrome b558" type="protein" />      <entity charOffset="93-101" id="AIMed.d170.s1439.e1" seqId="e4457" text="p47-phox" type="protein" />      <entity charOffset="113-121" id="AIMed.d170.s1439.e2" seqId="e4459" text="p67-phox" type="protein" />      <interaction e1="AIMed.d170.s1439.e1" e2="AIMed.d170.s1439.e2" id="AIMed.d170.s1439.i0" type="PPI" />    </sentence>    <sentence charOffset="859-966" id="AIMed.d170.s1440" seqId="s1440" text="We encountered several methodological problems in the two-hybrid system which are the focus of this report.">      </sentence>  </document>  <document id="AIMed.d178" origId="8822197" set="test">    <sentence charOffset="0-67" id="AIMed.d178.s1506" seqId="s1506" text="Formation of p27-CDK complexes during the human mitotic cell cycle.">      <entity charOffset="13-16" id="AIMed.d178.s1506.e0" seqId="e4745" text="p27" type="protein" />    </sentence>    <sentence charOffset="68-183" id="AIMed.d178.s1507" seqId="s1507" text="In eukaryotic cells, the coordinated activation of different cyclin-dependent kinases regulates entry into S-phase.">      </sentence>    <sentence charOffset="184-343" id="AIMed.d178.s1508" seqId="s1508" text="In vitro and in nonproliferating cells, p27 associates with and inhibits cyclin/cycin-dependent kinase (CDK) holoenzymes containing either CDK4, CDK6, or CDK2.">      <entity charOffset="40-43" id="AIMed.d178.s1508.e0" seqId="e4746" text="p27" type="protein" />      <entity charOffset="139-143" id="AIMed.d178.s1508.e1" seqId="e4750" text="CDK4" type="protein" />      <entity charOffset="145-149" id="AIMed.d178.s1508.e2" seqId="e4752" text="CDK6" type="protein" />      <entity charOffset="154-158" id="AIMed.d178.s1508.e3" seqId="e4754" text="CDK2" type="protein" />      <interaction e1="AIMed.d178.s1508.e0" e2="AIMed.d178.s1508.e1" id="AIMed.d178.s1508.i0" type="PPI" />      <interaction e1="AIMed.d178.s1508.e0" e2="AIMed.d178.s1508.e2" id="AIMed.d178.s1508.i1" type="PPI" />      <interaction e1="AIMed.d178.s1508.e0" e2="AIMed.d178.s1508.e3" id="AIMed.d178.s1508.i2" type="PPI" />    </sentence>    <sentence charOffset="344-567" id="AIMed.d178.s1509" seqId="s1509" text="Although many different types of proliferating cells contain p27 protein, neither the interactions of p27 with cyclin/CDK complexes nor the consequences of this interaction during the mitotic cycle have been fully explored.">      <entity charOffset="61-64" id="AIMed.d178.s1509.e0" seqId="e4756" text="p27" type="protein" />      <entity charOffset="102-105" id="AIMed.d178.s1509.e1" seqId="e4757" text="p27" type="protein" />    </sentence>    <sentence charOffset="568-652" id="AIMed.d178.s1510" seqId="s1510" text="We report that, in MANCA cells, the amount of p27 is constant during the cell cycle.">      <entity charOffset="46-49" id="AIMed.d178.s1510.e0" seqId="e4758" text="p27" type="protein" />    </sentence>    <sentence charOffset="653-729" id="AIMed.d178.s1511" seqId="s1511" text="In addition, p27 associates with three different CDKs: CDK2, CDK4, and CDK6.">      <entity charOffset="13-16" id="AIMed.d178.s1511.e0" seqId="e4759" text="p27" type="protein" />      <entity charOffset="55-59" id="AIMed.d178.s1511.e1" seqId="e4763" text="CDK2" type="protein" />      <entity charOffset="61-65" id="AIMed.d178.s1511.e2" seqId="e4765" text="CDK4" type="protein" />      <entity charOffset="71-75" id="AIMed.d178.s1511.e3" seqId="e4767" text="CDK6" type="protein" />      <interaction e1="AIMed.d178.s1511.e0" e2="AIMed.d178.s1511.e1" id="AIMed.d178.s1511.i0" type="PPI" />      <interaction e1="AIMed.d178.s1511.e0" e2="AIMed.d178.s1511.e2" id="AIMed.d178.s1511.i1" type="PPI" />      <interaction e1="AIMed.d178.s1511.e0" e2="AIMed.d178.s1511.e3" id="AIMed.d178.s1511.i2" type="PPI" />    </sentence>    <sentence charOffset="730-828" id="AIMed.d178.s1512" seqId="s1512" text="Furthermore, the amount of p27 is significantly lower than the amount of cyclin D3 in these cells.">      <entity charOffset="27-30" id="AIMed.d178.s1512.e0" seqId="e4769" text="p27" type="protein" />      <entity charOffset="73-82" id="AIMed.d178.s1512.e1" seqId="e4770" text="cyclin D3" type="protein" />    </sentence>    <sentence charOffset="829-1105" id="AIMed.d178.s1513" seqId="s1513" text="The amount of CDK4 and CDK6 associated with p27 does not change in a cell cycle-dependent fashion; in contrast, the amount of CDK2 associated with p27 is lowest in early G1 cells and increases to a maximum in mid-G1 phase, reaching a steady-state level in late G1-phase cells.">      <entity charOffset="14-18" id="AIMed.d178.s1513.e0" seqId="e4771" text="CDK4" type="protein" />      <entity charOffset="23-27" id="AIMed.d178.s1513.e1" seqId="e4773" text="CDK6" type="protein" />      <entity charOffset="44-47" id="AIMed.d178.s1513.e2" seqId="e4775" text="p27" type="protein" />      <entity charOffset="126-130" id="AIMed.d178.s1513.e3" seqId="e4778" text="CDK2" type="protein" />      <entity charOffset="147-150" id="AIMed.d178.s1513.e4" seqId="e4780" text="p27" type="protein" />      <interaction e1="AIMed.d178.s1513.e0" e2="AIMed.d178.s1513.e2" id="AIMed.d178.s1513.i0" type="PPI" />      <interaction e1="AIMed.d178.s1513.e1" e2="AIMed.d178.s1513.e2" id="AIMed.d178.s1513.i1" type="PPI" />      <interaction e1="AIMed.d178.s1513.e3" e2="AIMed.d178.s1513.e4" id="AIMed.d178.s1513.i2" type="PPI" />    </sentence>    <sentence charOffset="1106-1218" id="AIMed.d178.s1514" seqId="s1514" text="After mid-G1 phase, the amount of each p27/CDK complex remains constant through the remainder of the cell cycle.">      <entity charOffset="39-42" id="AIMed.d178.s1514.e0" seqId="e4782" text="p27" type="protein" />    </sentence>    <sentence charOffset="1219-1272" id="AIMed.d178.s1515" seqId="s1515" text="p27-immunoprecipitates contain an Rb-kinase activity.">      <entity charOffset="0-3" id="AIMed.d178.s1515.e0" seqId="e4783" text="p27" type="protein" />    </sentence>    <sentence charOffset="1273-1511" id="AIMed.d178.s1516" seqId="s1516" text="The substrate specificity, the expression pattern of this kinase, and the ability to deplete 50% of this kinase activity with a CDK6-specific antibody suggest that the CDK6 protein mediates, in part, the p27-associated Rb-kinase activity.">      <entity charOffset="128-132" id="AIMed.d178.s1516.e0" seqId="e4784" text="CDK6" type="protein" />      <entity charOffset="168-172" id="AIMed.d178.s1516.e1" seqId="e4785" text="CDK6" type="protein" />      <entity charOffset="204-207" id="AIMed.d178.s1516.e2" seqId="e4786" text="p27" type="protein" />      <entity charOffset="219-221" id="AIMed.d178.s1516.e3" seqId="e4787" text="Rb" type="protein" />    </sentence>    <sentence charOffset="1512-1599" id="AIMed.d178.s1517" seqId="s1517" text="In contrast, p27 complexes containing CDK2 are incapable of phosphorylating histone H1.">      <entity charOffset="13-16" id="AIMed.d178.s1517.e0" seqId="e4788" text="p27" type="protein" />      <entity charOffset="38-42" id="AIMed.d178.s1517.e1" seqId="e4790" text="CDK2" type="protein" />      <entity charOffset="76-86" id="AIMed.d178.s1517.e2" seqId="e4792" text="histone H1" type="protein" />      <interaction e1="AIMed.d178.s1517.e0" e2="AIMed.d178.s1517.e1" id="AIMed.d178.s1517.i0" type="PPI" />    </sentence>    <sentence charOffset="1600-1733" id="AIMed.d178.s1518" seqId="s1518" text="These data are consistent with a model wherein cyclin D/CDK complexes sequester the CDK2-dependent kinase inhibitory activity of p27.">      <entity charOffset="47-55" id="AIMed.d178.s1518.e0" seqId="e4793" text="cyclin D" type="protein" />      <entity charOffset="84-88" id="AIMed.d178.s1518.e1" seqId="e4794" text="CDK2" type="protein" />      <entity charOffset="129-132" id="AIMed.d178.s1518.e2" seqId="e4795" text="p27" type="protein" />    </sentence>  </document>  <document id="AIMed.d181" origId="8875926" set="test">    <sentence charOffset="0-84" id="AIMed.d181.s1538" seqId="s1538" text="Structure of the p53 tumor suppressor bound to the ankyrin and SH3 domains of 53BP2.">      <entity charOffset="17-20" id="AIMed.d181.s1538.e0" seqId="e4914" text="p53" type="protein" />      <entity charOffset="78-83" id="AIMed.d181.s1538.e1" seqId="e4916" text="53BP2" type="protein" />      <interaction e1="AIMed.d181.s1538.e0" e2="AIMed.d181.s1538.e1" id="AIMed.d181.s1538.i0" type="PPI" />    </sentence>    <sentence charOffset="85-255" id="AIMed.d181.s1539" seqId="s1539" text="Mutations in the p53 tumor suppressor are among the most frequently observed genetic alterations in human cancer and map to the 200-amino acid core domain of the protein.">      <entity charOffset="17-20" id="AIMed.d181.s1539.e0" seqId="e4918" text="p53" type="protein" />    </sentence>    <sentence charOffset="256-379" id="AIMed.d181.s1540" seqId="s1540" text="The core domain contains the sequence-specific DNA binding activity and the in vitro 53BP2 protein binding activity of p53.">      <entity charOffset="85-90" id="AIMed.d181.s1540.e0" seqId="e4919" text="53BP2" type="protein" />      <entity charOffset="119-122" id="AIMed.d181.s1540.e1" seqId="e4921" text="p53" type="protein" />      <interaction e1="AIMed.d181.s1540.e0" e2="AIMed.d181.s1540.e1" id="AIMed.d181.s1540.i0" type="PPI" />    </sentence>    <sentence charOffset="380-816" id="AIMed.d181.s1541" seqId="s1541" text="The crystal structure of the p53 core domain bound to the 53BP2 protein, which contains an SH3 (Src homology 3) domain and four ankyrin repeats, revealed that (i) the SH3 domain binds the L3 loop of p53 in a manner distinct from that of previously characterized SH3-polyproline peptide complexes, and (ii) an ankyrin repeat, which forms an L-shaped structure consisting of a beta hairpin and two alpha helices, binds the L2 loop of p53.">      <entity charOffset="29-32" id="AIMed.d181.s1541.e0" seqId="e4923" text="p53" type="protein" />      <entity charOffset="58-63" id="AIMed.d181.s1541.e1" seqId="e4925" text="53BP2" type="protein" />      <entity charOffset="199-202" id="AIMed.d181.s1541.e2" seqId="e4927" text="p53" type="protein" />      <entity charOffset="432-435" id="AIMed.d181.s1541.e3" seqId="e4928" text="p53" type="protein" />      <interaction e1="AIMed.d181.s1541.e0" e2="AIMed.d181.s1541.e1" id="AIMed.d181.s1541.i0" type="PPI" />    </sentence>    <sentence charOffset="817-1031" id="AIMed.d181.s1542" seqId="s1542" text="The structure of the complex shows that the 53BP2 binding site on the p53 core domain consists of evolutionarily conserved regions that are frequently mutated in cancer and that it overlaps the site of DNA binding.">      <entity charOffset="44-49" id="AIMed.d181.s1542.e0" seqId="e4929" text="53BP2" type="protein" />      <entity charOffset="70-73" id="AIMed.d181.s1542.e1" seqId="e4931" text="p53" type="protein" />      <interaction e1="AIMed.d181.s1542.e0" e2="AIMed.d181.s1542.e1" id="AIMed.d181.s1542.i0" type="PPI" />    </sentence>    <sentence charOffset="1032-1110" id="AIMed.d181.s1543" seqId="s1543" text="The six most frequently observed p53 mutations disrupt 53BP2 binding in vitro.">      <entity charOffset="33-36" id="AIMed.d181.s1543.e0" seqId="e4933" text="p53" type="protein" />      <entity charOffset="55-60" id="AIMed.d181.s1543.e1" seqId="e4935" text="53BP2" type="protein" />      <interaction e1="AIMed.d181.s1543.e0" e2="AIMed.d181.s1543.e1" id="AIMed.d181.s1543.i0" type="PPI" />    </sentence>    <sentence charOffset="1111-1253" id="AIMed.d181.s1544" seqId="s1544" text="The structure provides evidence that the 53BP2-p53 complex forms in vivo and may have a critical role in the p53 pathway of tumor suppression.">      <entity charOffset="41-46" id="AIMed.d181.s1544.e0" seqId="e4937" text="53BP2" type="protein" />      <entity charOffset="47-50" id="AIMed.d181.s1544.e1" seqId="e4939" text="p53" type="protein" />      <entity charOffset="109-112" id="AIMed.d181.s1544.e2" seqId="e4941" text="p53" type="protein" />      <interaction e1="AIMed.d181.s1544.e0" e2="AIMed.d181.s1544.e1" id="AIMed.d181.s1544.i0" type="PPI" />    </sentence>  </document>  <document id="AIMed.d186" origId="8910586" set="test">    <sentence charOffset="0-83" id="AIMed.d186.s1579" seqId="s1579" text="cDNA cloning and characterization of the human interleukin 13 receptor alpha chain.">      <entity charOffset="47-61" id="AIMed.d186.s1579.e0" seqId="e5119" text="interleukin 13" type="protein" />      <entity charOffset="47-70" id="AIMed.d186.s1579.e1" seqId="e5120" text="interleukin 13 receptor" type="protein" />      <entity charOffset="47-82" id="AIMed.d186.s1579.e2" seqId="e5121" text="interleukin 13 receptor alpha chain" type="protein" />    </sentence>    <sentence charOffset="84-182" id="AIMed.d186.s1580" seqId="s1580" text="We have cloned cDNAs corresponding to the human interleukin 13 receptor alpha chain (IL-13Ralpha).">      <entity charOffset="48-62" id="AIMed.d186.s1580.e0" seqId="e5122" text="interleukin 13" type="protein" />      <entity charOffset="48-71" id="AIMed.d186.s1580.e1" seqId="e5123" text="interleukin 13 receptor" type="protein" />      <entity charOffset="48-83" id="AIMed.d186.s1580.e2" seqId="e5124" text="interleukin 13 receptor alpha chain" type="protein" />      <entity charOffset="85-96" id="AIMed.d186.s1580.e3" seqId="e5125" text="IL-13Ralpha" type="protein" />    </sentence>    <sentence charOffset="183-290" id="AIMed.d186.s1581" seqId="s1581" text="The protein has 76% homology to murine IL-13Ralpha, with 95% amino acid identity in the cytoplasmic domain.">      <entity charOffset="39-50" id="AIMed.d186.s1581.e0" seqId="e5126" text="IL-13Ralpha" type="protein" />    </sentence>    <sentence charOffset="291-590" id="AIMed.d186.s1582" seqId="s1582" text="Only weak IL-13 binding activity was found in cells transfected with only IL-13Ralpha; however, the combination of both IL-13Ralpha and IL-4Ralpha resulted in substantial binding activity, with a Kd of approximately 400 pM, indicating that both chains are essential components of the IL-13 receptor.">      <entity charOffset="10-15" id="AIMed.d186.s1582.e0" seqId="e5127" text="IL-13" type="protein" />      <entity charOffset="74-85" id="AIMed.d186.s1582.e1" seqId="e5129" text="IL-13Ralpha" type="protein" />      <entity charOffset="120-131" id="AIMed.d186.s1582.e2" seqId="e5131" text="IL-13Ralpha" type="protein" />      <entity charOffset="136-146" id="AIMed.d186.s1582.e3" seqId="e5132" text="IL-4Ralpha" type="protein" />      <entity charOffset="284-289" id="AIMed.d186.s1582.e4" seqId="e5133" text="IL-13" type="protein" />      <entity charOffset="284-298" id="AIMed.d186.s1582.e5" seqId="e5134" text="IL-13 receptor" type="protein" />      <interaction e1="AIMed.d186.s1582.e0" e2="AIMed.d186.s1582.e1" id="AIMed.d186.s1582.i0" type="PPI" />    </sentence>    <sentence charOffset="591-814" id="AIMed.d186.s1583" seqId="s1583" text="Whereas IL-13Ralpha serves as an alternative accessory protein to the common cytokine receptor gamma chain (gammac) for IL-4 signaling, it could not replace the function of gammac in allowing enhanced IL-2 binding activity.">      <entity charOffset="8-19" id="AIMed.d186.s1583.e0" seqId="e5135" text="IL-13Ralpha" type="protein" />      <entity charOffset="77-106" id="AIMed.d186.s1583.e1" seqId="e5137" text="cytokine receptor gamma chain" type="protein" />      <entity charOffset="108-114" id="AIMed.d186.s1583.e2" seqId="e5138" text="gammac" type="protein" />      <entity charOffset="120-124" id="AIMed.d186.s1583.e3" seqId="e5139" text="IL-4" type="protein" />      <entity charOffset="173-179" id="AIMed.d186.s1583.e4" seqId="e5141" text="gammac" type="protein" />      <entity charOffset="201-205" id="AIMed.d186.s1583.e5" seqId="e5142" text="IL-2" type="protein" />      <interaction e1="AIMed.d186.s1583.e0" e2="AIMed.d186.s1583.e3" id="AIMed.d186.s1583.i0" type="PPI" />    </sentence>    <sentence charOffset="815-978" id="AIMed.d186.s1584" seqId="s1584" text="Nevertheless, the overall size and length of the cytoplasmic domain of IL-13Ralpha and gammac are similar, and like gammac, IL-13Ralpha is located on chromosome X.">      <entity charOffset="71-82" id="AIMed.d186.s1584.e0" seqId="e5143" text="IL-13Ralpha" type="protein" />      <entity charOffset="87-93" id="AIMed.d186.s1584.e1" seqId="e5144" text="gammac" type="protein" />      <entity charOffset="116-122" id="AIMed.d186.s1584.e2" seqId="e5145" text="gammac" type="protein" />      <entity charOffset="124-135" id="AIMed.d186.s1584.e3" seqId="e5146" text="IL-13Ralpha" type="protein" />    </sentence>  </document>  <document id="AIMed.d188" origId="8918891" set="test">    <sentence charOffset="0-96" id="AIMed.d188.s1595" seqId="s1595" text="SREBP transcriptional activity is mediated through an interaction with the CREB-binding protein.">      <entity charOffset="75-79" id="AIMed.d188.s1595.e0" seqId="e5179" text="CREB" type="protein" />      <entity charOffset="75-95" id="AIMed.d188.s1595.e1" seqId="e5180" text="CREB-binding protein" type="protein" />    </sentence>    <sentence charOffset="97-273" id="AIMed.d188.s1596" seqId="s1596" text="The sterol regulatory element binding proteins (SREBP-1 and -2) activate transcription of genes whose products are involved in the cellular uptake and synthesis of cholesterol.">      <entity charOffset="48-55" id="AIMed.d188.s1596.e0" seqId="e5181" text="SREBP-1" type="protein" />    </sentence>    <sentence charOffset="274-457" id="AIMed.d188.s1597" seqId="s1597" text="Although considerable effort has been exerted to define the events regulating the levels of active SREBP, little is known about the transcriptional cofactors mediating SREBP function.">      </sentence>    <sentence charOffset="458-605" id="AIMed.d188.s1598" seqId="s1598" text="In an unbiased search for potential coactivators of SREBP, we isolated a protein of 265 kD from HeLa cells that directly bound SREBP-1 and SREBP-2.">      <entity charOffset="127-134" id="AIMed.d188.s1598.e0" seqId="e5182" text="SREBP-1" type="protein" />      <entity charOffset="139-146" id="AIMed.d188.s1598.e1" seqId="e5183" text="SREBP-2" type="protein" />    </sentence>    <sentence charOffset="606-768" id="AIMed.d188.s1599" seqId="s1599" text="Peptide sequencing and Western blot analysis established that the 265-kD protein was CBP (CREB-binding protein),a recently identified transcriptional coactivator.">      <entity charOffset="85-88" id="AIMed.d188.s1599.e0" seqId="e5184" text="CBP" type="protein" />      <entity charOffset="90-110" id="AIMed.d188.s1599.e1" seqId="e5185" text="CREB-binding protein" type="protein" />    </sentence>    <sentence charOffset="769-918" id="AIMed.d188.s1600" seqId="s1600" text="The putative activation domain of SREBP was shown to bind specifically to amino-terminal domains of recombinant CBP and p300 (a CBP-related protein).">      <entity charOffset="112-115" id="AIMed.d188.s1600.e0" seqId="e5186" text="CBP" type="protein" />      <entity charOffset="120-124" id="AIMed.d188.s1600.e1" seqId="e5187" text="p300" type="protein" />      <entity charOffset="128-131" id="AIMed.d188.s1600.e2" seqId="e5188" text="CBP" type="protein" />    </sentence>    <sentence charOffset="919-1060" id="AIMed.d188.s1601" seqId="s1601" text="Moreover, transfection studies demonstrated that CBP enhances the ability of SREBP to activate transcription of reporter genes in HeLa cells.">      <entity charOffset="49-52" id="AIMed.d188.s1601.e0" seqId="e5189" text="CBP" type="protein" />    </sentence>    <sentence charOffset="1061-1227" id="AIMed.d188.s1602" seqId="s1602" text="Together, these data suggest that CBP mediates SREBP transcriptional activity, thus revealing a new step in the biochemical pathway regulating cholesterol metabolism.">      <entity charOffset="34-37" id="AIMed.d188.s1602.e0" seqId="e5190" text="CBP" type="protein" />    </sentence>  </document>  <document id="AIMed.d189" origId="8921390" set="test">    <sentence charOffset="0-93" id="AIMed.d189.s1603" seqId="s1603" text="Associations of UBE2I with RAD52, UBL1, p53, and RAD51 proteins in a yeast two-hybrid system.">      <entity charOffset="16-21" id="AIMed.d189.s1603.e0" seqId="e5191" text="UBE2I" type="protein" />      <entity charOffset="27-32" id="AIMed.d189.s1603.e1" seqId="e5196" text="RAD52" type="protein" />      <entity charOffset="34-38" id="AIMed.d189.s1603.e2" seqId="e5198" text="UBL1" type="protein" />      <entity charOffset="40-43" id="AIMed.d189.s1603.e3" seqId="e5200" text="p53" type="protein" />      <entity charOffset="49-54" id="AIMed.d189.s1603.e4" seqId="e5202" text="RAD51" type="protein" />      <interaction e1="AIMed.d189.s1603.e0" e2="AIMed.d189.s1603.e1" id="AIMed.d189.s1603.i0" type="PPI" />      <interaction e1="AIMed.d189.s1603.e0" e2="AIMed.d189.s1603.e2" id="AIMed.d189.s1603.i1" type="PPI" />      <interaction e1="AIMed.d189.s1603.e0" e2="AIMed.d189.s1603.e3" id="AIMed.d189.s1603.i2" type="PPI" />      <interaction e1="AIMed.d189.s1603.e0" e2="AIMed.d189.s1603.e4" id="AIMed.d189.s1603.i3" type="PPI" />    </sentence>    <sentence charOffset="94-192" id="AIMed.d189.s1604" seqId="s1604" text="The yeast RAD52-dependent pathway is involved in DNA recombination and double-strand break repair.">      <entity charOffset="10-15" id="AIMed.d189.s1604.e0" seqId="e5204" text="RAD52" type="protein" />    </sentence>    <sentence charOffset="193-303" id="AIMed.d189.s1605" seqId="s1605" text="Yeast ubiquitin-conjugating enzyme UBC9 participates in S- and M-phase cyclin degradation and mitotic control.">      <entity charOffset="35-39" id="AIMed.d189.s1605.e0" seqId="e5205" text="UBC9" type="protein" />    </sentence>    <sentence charOffset="304-519" id="AIMed.d189.s1606" seqId="s1606" text="Using the human RAD52 protein as the &quot;bait&quot; in a yeast two-hybrid system, we have identified a human homolog of yeast UBC9, designated UBE2I, that interacts with RAD52, RAD51, p53, and a ubiquitin-like protein UBL1.">      <entity charOffset="16-21" id="AIMed.d189.s1606.e0" seqId="e5206" text="RAD52" type="protein" />      <entity charOffset="118-122" id="AIMed.d189.s1606.e1" seqId="e5207" text="UBC9" type="protein" />      <entity charOffset="135-140" id="AIMed.d189.s1606.e2" seqId="e5208" text="UBE2I" type="protein" />      <entity charOffset="162-167" id="AIMed.d189.s1606.e3" seqId="e5213" text="RAD52" type="protein" />      <entity charOffset="169-174" id="AIMed.d189.s1606.e4" seqId="e5215" text="RAD51" type="protein" />      <entity charOffset="176-179" id="AIMed.d189.s1606.e5" seqId="e5217" text="p53" type="protein" />      <entity charOffset="210-214" id="AIMed.d189.s1606.e6" seqId="e5219" text="UBL1" type="protein" />      <interaction e1="AIMed.d189.s1606.e2" e2="AIMed.d189.s1606.e3" id="AIMed.d189.s1606.i0" type="PPI" />      <interaction e1="AIMed.d189.s1606.e2" e2="AIMed.d189.s1606.e4" id="AIMed.d189.s1606.i1" type="PPI" />      <interaction e1="AIMed.d189.s1606.e2" e2="AIMed.d189.s1606.e5" id="AIMed.d189.s1606.i2" type="PPI" />      <interaction e1="AIMed.d189.s1606.e2" e2="AIMed.d189.s1606.e6" id="AIMed.d189.s1606.i3" type="PPI" />    </sentence>    <sentence charOffset="520-673" id="AIMed.d189.s1607" seqId="s1607" text="These interactions are UBE2I-specific, since another DNA repair-related ubiquitin-conjugating enzyme, RAD6 (UBC2), does not interact with these proteins.">      <entity charOffset="23-28" id="AIMed.d189.s1607.e0" seqId="e5221" text="UBE2I" type="protein" />      <entity charOffset="102-106" id="AIMed.d189.s1607.e1" seqId="e5222" text="RAD6" type="protein" />      <entity charOffset="108-112" id="AIMed.d189.s1607.e2" seqId="e5223" text="UBC2" type="protein" />    </sentence>    <sentence charOffset="674-757" id="AIMed.d189.s1608" seqId="s1608" text="The interaction of UBE2I with RAD52 is mediated by RAD52's self-association region.">      <entity charOffset="19-24" id="AIMed.d189.s1608.e0" seqId="e5224" text="UBE2I" type="protein" />      <entity charOffset="30-35" id="AIMed.d189.s1608.e1" seqId="e5226" text="RAD52" type="protein" />      <entity charOffset="51-56" id="AIMed.d189.s1608.e2" seqId="e5228" text="RAD52" type="protein" />      <interaction e1="AIMed.d189.s1608.e0" e2="AIMed.d189.s1608.e1" id="AIMed.d189.s1608.i0" type="PPI" />    </sentence>    <sentence charOffset="758-909" id="AIMed.d189.s1609" seqId="s1609" text="These results suggest that the RAD52-dependent processes, cell cycle control, p53-mediated pathway(s), and ubiquitination interact through human UBE2I.">      <entity charOffset="31-36" id="AIMed.d189.s1609.e0" seqId="e5229" text="RAD52" type="protein" />      <entity charOffset="78-81" id="AIMed.d189.s1609.e1" seqId="e5230" text="p53" type="protein" />      <entity charOffset="145-150" id="AIMed.d189.s1609.e2" seqId="e5231" text="UBE2I" type="protein" />    </sentence>  </document>  <document id="AIMed.d191" origId="8976200" set="test">    <sentence charOffset="0-96" id="AIMed.d191.s1621" seqId="s1621" text="Efficient interaction of HIV-1 with purified dendritic cells via multiple chemokine coreceptors.">      </sentence>    <sentence charOffset="97-251" id="AIMed.d191.s1622" seqId="s1622" text="HIV-1 actively replicates in dendritic cell (DC)-T cell cocultures, but it has been difficult to demonstrate substantial infection of purified mature DCs.">      </sentence>    <sentence charOffset="252-411" id="AIMed.d191.s1623" seqId="s1623" text="We now find that HIV-1 begins reverse transcription much more efficiently in DCs than T cells, even though T cells have higher levels of CD4 and gp120 binding.">      <entity charOffset="137-140" id="AIMed.d191.s1623.e0" seqId="e5304" text="CD4" type="protein" />      <entity charOffset="145-150" id="AIMed.d191.s1623.e1" seqId="e5305" text="gp120" type="protein" />    </sentence>    <sentence charOffset="412-477" id="AIMed.d191.s1624" seqId="s1624" text="DCs isolated from skin or from blood precursors behave similarly.">      </sentence>    <sentence charOffset="478-686" id="AIMed.d191.s1625" seqId="s1625" text="Several M-tropic strains and the T-tropic strain IIIB enter DCs efficiently, as assessed by the progressive formation of the early products of reverse transcription after a 90-min virus pulse at 37 degrees C.">      </sentence>    <sentence charOffset="687-792" id="AIMed.d191.s1626" seqId="s1626" text="However, few late gag-containing sequences are detected, so that active viral replication does not occur.">      </sentence>    <sentence charOffset="793-920" id="AIMed.d191.s1627" seqId="s1627" text="The formation of these early transcripts seems to follow entry of HIV-1, rather than binding of virions that contain viral DNA.">      </sentence>    <sentence charOffset="921-1062" id="AIMed.d191.s1628" seqId="s1628" text="Early transcripts are scarce if DCs are exposed to virus on ice for 4 h, or for 90 min at 37 degrees C, conditions which allow virus binding.">      </sentence>    <sentence charOffset="1063-1129" id="AIMed.d191.s1629" seqId="s1629" text="Also the early transcripts once formed are insensitive to trypsin.">      <entity charOffset="58-65" id="AIMed.d191.s1629.e0" seqId="e5306" text="trypsin" type="protein" />    </sentence>    <sentence charOffset="1130-1230" id="AIMed.d191.s1630" seqId="s1630" text="The entry of a M-tropic isolates is blocked by the chemokine RANTES, and the entry of IIIB by SDF-1.">      <entity charOffset="61-67" id="AIMed.d191.s1630.e0" seqId="e5307" text="RANTES" type="protein" />    </sentence>    <sentence charOffset="1231-1289" id="AIMed.d191.s1631" seqId="s1631" text="RANTES interacts with CCR5 and SDF-1 with CXCR4 receptors.">      <entity charOffset="0-6" id="AIMed.d191.s1631.e0" seqId="e5308" text="RANTES" type="protein" />      <entity charOffset="22-26" id="AIMed.d191.s1631.e1" seqId="e5310" text="CCR5" type="protein" />      <entity charOffset="31-36" id="AIMed.d191.s1631.e2" seqId="e5312" text="SDF-1" type="protein" />      <entity charOffset="42-47" id="AIMed.d191.s1631.e3" seqId="e5314" text="CXCR4" type="protein" />      <interaction e1="AIMed.d191.s1631.e0" e2="AIMed.d191.s1631.e1" id="AIMed.d191.s1631.i0" type="PPI" />      <interaction e1="AIMed.d191.s1631.e2" e2="AIMed.d191.s1631.e3" id="AIMed.d191.s1631.i1" type="PPI" />    </sentence>    <sentence charOffset="1290-1402" id="AIMed.d191.s1632" seqId="s1632" text="Entry of M-tropic but not T-tropic virus is ablated in DCs from individuals who lack a functional CCR5 receptor.">      <entity charOffset="98-102" id="AIMed.d191.s1632.e0" seqId="e5316" text="CCR5" type="protein" />    </sentence>    <sentence charOffset="1403-1453" id="AIMed.d191.s1633" seqId="s1633" text="DCs express more CCR5 and CXCR4 mRNA than T cells.">      <entity charOffset="17-21" id="AIMed.d191.s1633.e0" seqId="e5317" text="CCR5" type="protein" />      <entity charOffset="26-31" id="AIMed.d191.s1633.e1" seqId="e5318" text="CXCR4" type="protein" />    </sentence>    <sentence charOffset="1454-1636" id="AIMed.d191.s1634" seqId="s1634" text="Therefore, while HIV-1 does not replicate efficiently in mature DCs, viral entry can be active and can be blocked by chemokines that act on known receptors for M- and T-tropic virus.">      </sentence>  </document>  <document id="AIMed.d200" origId="9050988" set="test">    <sentence charOffset="0-82" id="AIMed.d200.s1716" seqId="s1716" text="Identification of interaction partners for the basic-helix-loop-helix protein E47.">      <entity charOffset="78-81" id="AIMed.d200.s1716.e0" seqId="e5572" text="E47" type="protein" />    </sentence>    <sentence charOffset="83-245" id="AIMed.d200.s1717" seqId="s1717" text="Helix-loop-helix proteins constitute a family of transcription factors with the potential to form homo- and hetero-dimers mediated by the helix-loop-helix domain.">      </sentence>    <sentence charOffset="246-361" id="AIMed.d200.s1718" seqId="s1718" text="Oncogenic mutations in such genes can disrupt the equilibrium of protein-protein interactions in the affected cell.">      </sentence>    <sentence charOffset="362-486" id="AIMed.d200.s1719" seqId="s1719" text="In order to assess the biological consequences of such mutations, the full complement of interacting proteins must be known.">      </sentence>    <sentence charOffset="487-780" id="AIMed.d200.s1720" seqId="s1720" text="To identify proteins interacting with the basic-helix-loop-helix domain of the ubiquitously expressed E47 protein, a 'sandwich'-screening procedure was developed which distinguishes between homo- and hetero-oligomers, and specifically excludes the detection of complexes which cannot bind DNA.">      <entity charOffset="102-105" id="AIMed.d200.s1720.e0" seqId="e5573" text="E47" type="protein" />    </sentence>    <sentence charOffset="781-1032" id="AIMed.d200.s1721" seqId="s1721" text="Nine distinct cDNAs were identified which encode proteins with apparent basic-helix-loop-helix domains, including a novel clone termed eip1 which is distantly related in the basic-helix-loop-helix domain to the Drosophila enhancer-of-split m7 protein.">      <entity charOffset="135-139" id="AIMed.d200.s1721.e0" seqId="e5574" text="eip1" type="protein" />    </sentence>    <sentence charOffset="1033-1218" id="AIMed.d200.s1722" seqId="s1722" text="Using epitope-tagging, interaction of E47 basic-helix-loop-helix protein with the eip1 protein encoded by this novel cDNA was confirmed by immunoprecipitation experiments in COS7 cells.">      <entity charOffset="38-41" id="AIMed.d200.s1722.e0" seqId="e5575" text="E47" type="protein" />      <entity charOffset="82-86" id="AIMed.d200.s1722.e1" seqId="e5577" text="eip1" type="protein" />      <interaction e1="AIMed.d200.s1722.e0" e2="AIMed.d200.s1722.e1" id="AIMed.d200.s1722.i0" type="PPI" />    </sentence>    <sentence charOffset="1219-1280" id="AIMed.d200.s1723" seqId="s1723" text="Interaction was also observed in the yeast two-hybrid system.">      </sentence>    <sentence charOffset="1281-1412" id="AIMed.d200.s1724" seqId="s1724" text="Three cDNAs encoding proteins without basic-helix-loop-helix domains were also found to interact in the sandwich-expression screen.">      </sentence>    <sentence charOffset="1413-1532" id="AIMed.d200.s1725" seqId="s1725" text="Interactions with human PARP and mouse replication factor 1a were confirmed using glutathione transferase-tagged cDNAs.">      <entity charOffset="24-28" id="AIMed.d200.s1725.e0" seqId="e5579" text="PARP" type="protein" />      <entity charOffset="39-60" id="AIMed.d200.s1725.e1" seqId="e5580" text="replication factor 1a" type="protein" />    </sentence>    <sentence charOffset="1533-1679" id="AIMed.d200.s1726" seqId="s1726" text="A cDNA encoding part of the nucleolin protein sequence interacted with the E47 basic-helix-loop-helix only when fused to a beta-galactosidase tag.">      <entity charOffset="28-37" id="AIMed.d200.s1726.e0" seqId="e5581" text="nucleolin" type="protein" />      <entity charOffset="75-78" id="AIMed.d200.s1726.e1" seqId="e5583" text="E47" type="protein" />      <interaction e1="AIMed.d200.s1726.e0" e2="AIMed.d200.s1726.e1" id="AIMed.d200.s1726.i0" type="PPI" />    </sentence>  </document>  <document id="AIMed.d201" origId="9054408" set="test">    <sentence charOffset="0-143" id="AIMed.d201.s1727" seqId="s1727" text="Hepatitis B virus X protein is a transcriptional modulator that communicates with transcription factor IIB and the RNA polymerase II subunit 5.">      <entity charOffset="0-27" id="AIMed.d201.s1727.e0" seqId="e5585" text="Hepatitis B virus X protein" type="protein" />      <entity charOffset="82-106" id="AIMed.d201.s1727.e1" seqId="e5586" text="transcription factor IIB" type="protein" />      <entity charOffset="115-142" id="AIMed.d201.s1727.e2" seqId="e5587" text="RNA polymerase II subunit 5" type="protein" />    </sentence>    <sentence charOffset="144-257" id="AIMed.d201.s1728" seqId="s1728" text="Hepatitis B virus X protein (HBx) transactivates viral and cellular genes through a wide variety of cis-elements.">      <entity charOffset="0-26" id="AIMed.d201.s1728.e0" seqId="e5588" text="Hepatitis B virus X protei" type="protein" />      <entity charOffset="29-32" id="AIMed.d201.s1728.e1" seqId="e5589" text="HBx" type="protein" />    </sentence>    <sentence charOffset="258-298" id="AIMed.d201.s1729" seqId="s1729" text="However, the mechanism is still obscure.">      </sentence>    <sentence charOffset="299-562" id="AIMed.d201.s1730" seqId="s1730" text="Our finding that HBx directly interacts with RNA polymerase II subunit 5 (RPB5), a common subunit of RNA polymerases, implies that HBx directly modulates the function of RNA polymerase (Cheong, J. H., Yi, M., Lin, Y., and Murakami, S. (1995) EMBO J. 14, 142-150).">      <entity charOffset="17-20" id="AIMed.d201.s1730.e0" seqId="e5590" text="HBx" type="protein" />      <entity charOffset="45-72" id="AIMed.d201.s1730.e1" seqId="e5593" text="RNA polymerase II subunit 5" type="protein" />      <entity charOffset="74-78" id="AIMed.d201.s1730.e2" seqId="e5595" text="RPB5" type="protein" />      <entity charOffset="131-134" id="AIMed.d201.s1730.e3" seqId="e5597" text="HBx" type="protein" />      <interaction e1="AIMed.d201.s1730.e0" e2="AIMed.d201.s1730.e1" id="AIMed.d201.s1730.i0" type="PPI" />      <interaction e1="AIMed.d201.s1730.e0" e2="AIMed.d201.s1730.e2" id="AIMed.d201.s1730.i1" type="PPI" />    </sentence>    <sentence charOffset="563-676" id="AIMed.d201.s1731" seqId="s1731" text="In this context, we examined the possibility that HBx and RPB5 interact with other general transcription factors.">      <entity charOffset="50-53" id="AIMed.d201.s1731.e0" seqId="e5598" text="HBx" type="protein" />      <entity charOffset="58-62" id="AIMed.d201.s1731.e1" seqId="e5599" text="RPB5" type="protein" />    </sentence>    <sentence charOffset="677-869" id="AIMed.d201.s1732" seqId="s1732" text="HBx and RPB5 specifically bound to transcription factor IIB (TFIIB) in vitro, both of which were detected by either far-Western blotting or the glutathione S-transferase-resin pull-down assay.">      <entity charOffset="0-3" id="AIMed.d201.s1732.e0" seqId="e5600" text="HBx" type="protein" />      <entity charOffset="8-12" id="AIMed.d201.s1732.e1" seqId="e5601" text="RPB5" type="protein" />      <entity charOffset="35-59" id="AIMed.d201.s1732.e2" seqId="e5602" text="transcription factor IIB" type="protein" />      <entity charOffset="61-66" id="AIMed.d201.s1732.e3" seqId="e5603" text="TFIIB" type="protein" />    </sentence>    <sentence charOffset="870-1020" id="AIMed.d201.s1733" seqId="s1733" text="Delineation of the binding regions of these three proteins revealed that HBx, RPB5, and TFIIB each has two binding regions for the other two proteins.">      <entity charOffset="73-76" id="AIMed.d201.s1733.e0" seqId="e5604" text="HBx" type="protein" />      <entity charOffset="78-82" id="AIMed.d201.s1733.e1" seqId="e5606" text="RPB5" type="protein" />      <entity charOffset="88-93" id="AIMed.d201.s1733.e2" seqId="e5608" text="TFIIB" type="protein" />      <interaction e1="AIMed.d201.s1733.e0" e2="AIMed.d201.s1733.e1" id="AIMed.d201.s1733.i0" type="PPI" />    </sentence>    <sentence charOffset="1021-1128" id="AIMed.d201.s1734" seqId="s1734" text="Co-immunoprecipitation using HepG2 cell lysates that express HBx demonstrated trimeric interaction in vivo.">      <entity charOffset="61-64" id="AIMed.d201.s1734.e0" seqId="e5609" text="HBx" type="protein" />    </sentence>    <sentence charOffset="1129-1388" id="AIMed.d201.s1735" seqId="s1735" text="Some HBx substitution mutants, which had severely impaired transacting activity, exhibited reduced binding affinity with either TFIIB or RPB5 in a mutually exclusive manner, suggesting that HBx transactivation requires the interactions of both RPB5 and TFIIB.">      <entity charOffset="5-8" id="AIMed.d201.s1735.e0" seqId="e5610" text="HBx" type="protein" />      <entity charOffset="128-133" id="AIMed.d201.s1735.e1" seqId="e5612" text="TFIIB" type="protein" />      <entity charOffset="137-141" id="AIMed.d201.s1735.e2" seqId="e5613" text="RPB5" type="protein" />      <entity charOffset="190-193" id="AIMed.d201.s1735.e3" seqId="e5615" text="HBx" type="protein" />      <entity charOffset="244-248" id="AIMed.d201.s1735.e4" seqId="e5617" text="RPB5" type="protein" />      <entity charOffset="253-258" id="AIMed.d201.s1735.e5" seqId="e5619" text="TFIIB" type="protein" />      <interaction e1="AIMed.d201.s1735.e0" e2="AIMed.d201.s1735.e2" id="AIMed.d201.s1735.i0" type="PPI" />      <interaction e1="AIMed.d201.s1735.e3" e2="AIMed.d201.s1735.e4" id="AIMed.d201.s1735.i1" type="PPI" />    </sentence>    <sentence charOffset="1389-1599" id="AIMed.d201.s1736" seqId="s1736" text="These results indicated that HBx is a novel virus modulator that facilitates transcriptional initiation by stabilizing the association between RNA polymerase and TFIIB through communication with RPB5 and TFIIB.">      <entity charOffset="29-32" id="AIMed.d201.s1736.e0" seqId="e5620" text="HBx" type="protein" />      <entity charOffset="162-167" id="AIMed.d201.s1736.e1" seqId="e5621" text="TFIIB" type="protein" />      <entity charOffset="195-199" id="AIMed.d201.s1736.e2" seqId="e5622" text="RPB5" type="protein" />      <entity charOffset="204-209" id="AIMed.d201.s1736.e3" seqId="e5623" text="TFIIB" type="protein" />    </sentence>  </document>  <document id="AIMed.d203" origId="9062194" set="test">    <sentence charOffset="0-111" id="AIMed.d203.s1746" seqId="s1746" text="A new cytokine-receptor binding mode revealed by the crystal structure of the IL-1 receptor with an antagonist.">      <entity charOffset="78-82" id="AIMed.d203.s1746.e0" seqId="e5662" text="IL-1" type="protein" />      <entity charOffset="78-91" id="AIMed.d203.s1746.e1" seqId="e5663" text="IL-1 receptor" type="protein" />    </sentence>    <sentence charOffset="112-380" id="AIMed.d203.s1747" seqId="s1747" text="Inflammation, regardless of whether it is provoked by infection or by tissue damage, starts with the activation of macrophages which initiate a cascade of inflammatory responses by producing the cytokines interleukin-1 (IL-1) and tumour necrosis factor-alpha (ref. 1).">      <entity charOffset="205-218" id="AIMed.d203.s1747.e0" seqId="e5664" text="interleukin-1" type="protein" />      <entity charOffset="220-224" id="AIMed.d203.s1747.e1" seqId="e5665" text="IL-1" type="protein" />      <entity charOffset="230-258" id="AIMed.d203.s1747.e2" seqId="e5666" text="tumour necrosis factor-alpha" type="protein" />    </sentence>    <sentence charOffset="381-535" id="AIMed.d203.s1748" seqId="s1748" text="Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).">      <entity charOffset="42-46" id="AIMed.d203.s1748.e0" seqId="e5667" text="IL-1" type="protein" />      <entity charOffset="42-55" id="AIMed.d203.s1748.e1" seqId="e5668" text="IL-1 receptor" type="protein" />      <entity charOffset="57-61" id="AIMed.d203.s1748.e2" seqId="e5671" text="IL1R" type="protein" />      <entity charOffset="83-92" id="AIMed.d203.s1748.e3" seqId="e5674" text="IL-1alpha" type="protein" />      <entity charOffset="97-105" id="AIMed.d203.s1748.e4" seqId="e5677" text="IL-1beta" type="protein" />      <entity charOffset="114-118" id="AIMed.d203.s1748.e5" seqId="e5680" text="IL-1" type="protein" />      <entity charOffset="114-127" id="AIMed.d203.s1748.e6" seqId="e5681" text="IL-1-receptor" type="protein" />      <entity charOffset="114-138" id="AIMed.d203.s1748.e7" seqId="e5683" text="IL-1-receptor antagonist" type="protein" />      <entity charOffset="139-144" id="AIMed.d203.s1748.e8" seqId="e5684" text="IL1RA" type="protein" />      <interaction e1="AIMed.d203.s1748.e1" e2="AIMed.d203.s1748.e3" id="AIMed.d203.s1748.i0" type="PPI" />      <interaction e1="AIMed.d203.s1748.e2" e2="AIMed.d203.s1748.e4" id="AIMed.d203.s1748.i1" type="PPI" />      <interaction e1="AIMed.d203.s1748.e6" e2="AIMed.d203.s1748.e8" id="AIMed.d203.s1748.i2" type="PPI" />    </sentence>    <sentence charOffset="536-614" id="AIMed.d203.s1749" seqId="s1749" text="IL-1 is the only cytokine for which a naturally occurring antagonist is known.">      <entity charOffset="0-4" id="AIMed.d203.s1749.e0" seqId="e5686" text="IL-1" type="protein" />    </sentence>    <sentence charOffset="615-744" id="AIMed.d203.s1750" seqId="s1750" text="Here we describe the crystal structure at 2.7 A resolution of the soluble extracellular part of type-I IL1R complexed with IL1RA.">      <entity charOffset="103-107" id="AIMed.d203.s1750.e0" seqId="e5687" text="IL1R" type="protein" />      <entity charOffset="96-107" id="AIMed.d203.s1750.e1" seqId="e5688" text="type-I IL1R" type="protein" />      <entity charOffset="123-128" id="AIMed.d203.s1750.e2" seqId="e5690" text="IL1RA" type="protein" />      <interaction e1="AIMed.d203.s1750.e1" e2="AIMed.d203.s1750.e2" id="AIMed.d203.s1750.i0" type="PPI" />    </sentence>    <sentence charOffset="745-804" id="AIMed.d203.s1751" seqId="s1751" text="The receptor consists of three immunoglobulin-like domains.">      </sentence>    <sentence charOffset="805-916" id="AIMed.d203.s1752" seqId="s1752" text="Domains 1 and 2 are tightly linked, but domain three is completely separate and connected by a flexible linker.">      </sentence>    <sentence charOffset="917-1066" id="AIMed.d203.s1753" seqId="s1753" text="Residues of all three domains contact the antagonist and include the five critical IL1RA residues which were identified by site-directed mutagenesis.">      <entity charOffset="83-88" id="AIMed.d203.s1753.e0" seqId="e5692" text="IL1RA" type="protein" />    </sentence>    <sentence charOffset="1067-1223" id="AIMed.d203.s1754" seqId="s1754" text="A region that is important for biological function in IL-1beta, the 'receptor trigger site' is not in direct contact with the receptor in the IL1RA complex.">      <entity charOffset="54-62" id="AIMed.d203.s1754.e0" seqId="e5693" text="IL-1beta" type="protein" />      <entity charOffset="142-147" id="AIMed.d203.s1754.e1" seqId="e5694" text="IL1RA" type="protein" />    </sentence>    <sentence charOffset="1224-1318" id="AIMed.d203.s1755" seqId="s1755" text="Modelling studies suggest that this IL-1beta trigger site might induce a movement of domain 3.">      <entity charOffset="36-44" id="AIMed.d203.s1755.e0" seqId="e5695" text="IL-1beta" type="protein" />    </sentence>  </document>  <document id="AIMed.d210" origId="9160889" set="test">    <sentence charOffset="0-115" id="AIMed.d210.s1817" seqId="s1817" text="Cross-family interaction between the bHLHZip USF and bZip Fra1 proteins results in down-regulation of AP1 activity.">      <entity charOffset="45-48" id="AIMed.d210.s1817.e0" seqId="e5923" text="USF" type="protein" />      <entity charOffset="58-62" id="AIMed.d210.s1817.e1" seqId="e5925" text="Fra1" type="protein" />      <entity charOffset="102-105" id="AIMed.d210.s1817.e2" seqId="e5927" text="AP1" type="protein" />      <interaction e1="AIMed.d210.s1817.e0" e2="AIMed.d210.s1817.e1" id="AIMed.d210.s1817.i0" type="PPI" />    </sentence>    <sentence charOffset="116-331" id="AIMed.d210.s1818" seqId="s1818" text="Heterodimerization among the basic-leucine zipper (bZIP) proteins or among the basic-helix-loop-helix-leucine zipper (bHLHZip) proteins confers a multitude of combinational activities to these transcription factors.">      </sentence>    <sentence charOffset="332-500" id="AIMed.d210.s1819" seqId="s1819" text="To further examine the function of the bHLHZip protein, USF, we screened for cellular proteins which could directly interact with USF using the yeast two-hybrid system.">      <entity charOffset="56-59" id="AIMed.d210.s1819.e0" seqId="e5928" text="USF" type="protein" />      <entity charOffset="130-133" id="AIMed.d210.s1819.e1" seqId="e5929" text="USF" type="protein" />    </sentence>    <sentence charOffset="501-566" id="AIMed.d210.s1820" seqId="s1820" text="A bZip protein, Fra1, was found to efficiently interact with USF.">      <entity charOffset="16-20" id="AIMed.d210.s1820.e0" seqId="e5930" text="Fra1" type="protein" />      <entity charOffset="61-64" id="AIMed.d210.s1820.e1" seqId="e5932" text="USF" type="protein" />      <interaction e1="AIMed.d210.s1820.e0" e2="AIMed.d210.s1820.e1" id="AIMed.d210.s1820.i0" type="PPI" />    </sentence>    <sentence charOffset="567-688" id="AIMed.d210.s1821" seqId="s1821" text="USF specifically interacts with Fra1 but not with other closely related family members, c-Fos, Fra2, FosB, or with c-Jun.">      <entity charOffset="0-3" id="AIMed.d210.s1821.e0" seqId="e5934" text="USF" type="protein" />      <entity charOffset="32-36" id="AIMed.d210.s1821.e1" seqId="e5936" text="Fra1" type="protein" />      <entity charOffset="88-93" id="AIMed.d210.s1821.e2" seqId="e5938" text="c-Fos" type="protein" />      <entity charOffset="95-99" id="AIMed.d210.s1821.e3" seqId="e5939" text="Fra2" type="protein" />      <entity charOffset="101-105" id="AIMed.d210.s1821.e4" seqId="e5940" text="FosB" type="protein" />      <entity charOffset="115-120" id="AIMed.d210.s1821.e5" seqId="e5941" text="c-Jun" type="protein" />      <interaction e1="AIMed.d210.s1821.e0" e2="AIMed.d210.s1821.e1" id="AIMed.d210.s1821.i0" type="PPI" />    </sentence>    <sentence charOffset="689-789" id="AIMed.d210.s1822" seqId="s1822" text="Both the bHLHZip and the N-terminal regions of Fra1 are required for efficient interaction with USF.">      <entity charOffset="47-51" id="AIMed.d210.s1822.e0" seqId="e5942" text="Fra1" type="protein" />      <entity charOffset="96-99" id="AIMed.d210.s1822.e1" seqId="e5944" text="USF" type="protein" />      <interaction e1="AIMed.d210.s1822.e0" e2="AIMed.d210.s1822.e1" id="AIMed.d210.s1822.i0" type="PPI" />    </sentence>    <sentence charOffset="790-879" id="AIMed.d210.s1823" seqId="s1823" text="In vivo association between USF and Fra1 has been demonstrated by co-immunoprecipitation.">      <entity charOffset="28-31" id="AIMed.d210.s1823.e0" seqId="e5946" text="USF" type="protein" />      <entity charOffset="36-40" id="AIMed.d210.s1823.e1" seqId="e5948" text="Fra1" type="protein" />      <interaction e1="AIMed.d210.s1823.e0" e2="AIMed.d210.s1823.e1" id="AIMed.d210.s1823.i0" type="PPI" />    </sentence>    <sentence charOffset="880-969" id="AIMed.d210.s1824" seqId="s1824" text="Expression of exogenous USF led to a decrease in AP1-dependent transcription in F9 cells.">      <entity charOffset="24-27" id="AIMed.d210.s1824.e0" seqId="e5950" text="USF" type="protein" />      <entity charOffset="49-52" id="AIMed.d210.s1824.e1" seqId="e5951" text="AP1" type="protein" />    </sentence>    <sentence charOffset="970-1055" id="AIMed.d210.s1825" seqId="s1825" text="Co-expression of exogenous Fra1 restored the AP1 activity in a dose-dependent manner.">      <entity charOffset="27-31" id="AIMed.d210.s1825.e0" seqId="e5952" text="Fra1" type="protein" />      <entity charOffset="45-48" id="AIMed.d210.s1825.e1" seqId="e5953" text="AP1" type="protein" />    </sentence>    <sentence charOffset="1056-1224" id="AIMed.d210.s1826" seqId="s1826" text="These data show that USF and Fra1 physically and functionally interact demonstrating that cross-talk occurs between factors of distantly related transcription families.">      <entity charOffset="21-24" id="AIMed.d210.s1826.e0" seqId="e5954" text="USF" type="protein" />      <entity charOffset="29-33" id="AIMed.d210.s1826.e1" seqId="e5956" text="Fra1" type="protein" />      <interaction e1="AIMed.d210.s1826.e0" e2="AIMed.d210.s1826.e1" id="AIMed.d210.s1826.i0" type="PPI" />    </sentence>  </document>  <document id="AIMed.d212" origId="9168117" set="test">    <sentence charOffset="0-68" id="AIMed.d212.s1835" seqId="s1835" text="Interaction between ATM protein and c-Abl in response to DNA damage.">      <entity charOffset="20-23" id="AIMed.d212.s1835.e0" seqId="e5986" text="ATM" type="protein" />      <entity charOffset="36-41" id="AIMed.d212.s1835.e1" seqId="e5988" text="c-Abl" type="protein" />      <interaction e1="AIMed.d212.s1835.e0" e2="AIMed.d212.s1835.e1" id="AIMed.d212.s1835.i0" type="PPI" />    </sentence>    <sentence charOffset="69-370" id="AIMed.d212.s1836" seqId="s1836" text="The gene mutated in the autosomal recessive disorder ataxia telangiectasia (AT), designated ATM (for 'AT mutated'), is a member of a family of phosphatidylinositol-3-kinase-like enzymes that are involved in cell-cycle control, meiotic recombination, telomere length monitoring and DNA-damage response.">      <entity charOffset="92-95" id="AIMed.d212.s1836.e0" seqId="e5990" text="ATM" type="protein" />      <entity charOffset="102-112" id="AIMed.d212.s1836.e1" seqId="e5991" text="AT mutated" type="protein" />    </sentence>    <sentence charOffset="371-525" id="AIMed.d212.s1837" seqId="s1837" text="Previous results have demonstrated that AT cells are hypersensitive to ionizing radiation and are defective at the G1/S checkpoint after radiation damage.">      </sentence>    <sentence charOffset="526-732" id="AIMed.d212.s1838" seqId="s1838" text="Because cells lacking the protein tyrosine kinase c-Abl are also defective in radiation-induced G1 arrest, we investigated the possibility that ATM might interact with c-Abl in response to radiation damage.">      <entity charOffset="50-55" id="AIMed.d212.s1838.e0" seqId="e5992" text="c-Abl" type="protein" />      <entity charOffset="144-147" id="AIMed.d212.s1838.e1" seqId="e5993" text="ATM" type="protein" />      <entity charOffset="168-173" id="AIMed.d212.s1838.e2" seqId="e5995" text="c-Abl" type="protein" />      <interaction e1="AIMed.d212.s1838.e1" e2="AIMed.d212.s1838.e2" id="AIMed.d212.s1838.i0" type="PPI" />    </sentence>    <sentence charOffset="733-819" id="AIMed.d212.s1839" seqId="s1839" text="Here we show that ATM binds c-Abl constitutively in control cells but not in AT cells.">      <entity charOffset="18-21" id="AIMed.d212.s1839.e0" seqId="e5997" text="ATM" type="protein" />      <entity charOffset="28-33" id="AIMed.d212.s1839.e1" seqId="e5999" text="c-Abl" type="protein" />      <interaction e1="AIMed.d212.s1839.e0" e2="AIMed.d212.s1839.e1" id="AIMed.d212.s1839.i0" type="PPI" />    </sentence>    <sentence charOffset="820-937" id="AIMed.d212.s1840" seqId="s1840" text="Our results demonstrate that the SH3 domain of c-Abl interacts with a DPAPNPPHFP motif (residues 1,373-1,382) of ATM.">      <entity charOffset="47-52" id="AIMed.d212.s1840.e0" seqId="e6001" text="c-Abl" type="protein" />      <entity charOffset="113-116" id="AIMed.d212.s1840.e1" seqId="e6003" text="ATM" type="protein" />      <interaction e1="AIMed.d212.s1840.e0" e2="AIMed.d212.s1840.e1" id="AIMed.d212.s1840.i0" type="PPI" />    </sentence>    <sentence charOffset="938-1047" id="AIMed.d212.s1841" seqId="s1841" text="The results also reveal that radiation-induction of c-Abl tyrosine kinase activity is diminished in AT cells.">      <entity charOffset="52-57" id="AIMed.d212.s1841.e0" seqId="e6005" text="c-Abl" type="protein" />    </sentence>    <sentence charOffset="1048-1203" id="AIMed.d212.s1842" seqId="s1842" text="These findings indicate that ATM is involved in the activation of c-Abl by DNA damage and this interaction may in part mediate radiation-induced G1 arrest.">      <entity charOffset="29-32" id="AIMed.d212.s1842.e0" seqId="e6006" text="ATM" type="protein" />      <entity charOffset="66-71" id="AIMed.d212.s1842.e1" seqId="e6008" text="c-Abl" type="protein" />      <interaction e1="AIMed.d212.s1842.e0" e2="AIMed.d212.s1842.e1" id="AIMed.d212.s1842.i0" type="PPI" />    </sentence>  </document>  <document id="AIMed.d221" origId="9334213" set="test">    <sentence charOffset="0-184" id="AIMed.d221.s1921" seqId="s1921" text="A region of the beta subunit of the interferon alpha receptor different from box 1 interacts with Jak1 and is sufficient to activate the Jak-Stat pathway and induce an antiviral state.">      <entity charOffset="36-52" id="AIMed.d221.s1921.e0" seqId="e6254" text="interferon alpha" type="protein" />      <entity charOffset="36-61" id="AIMed.d221.s1921.e1" seqId="e6255" text="interferon alpha receptor" type="protein" />      <entity charOffset="98-102" id="AIMed.d221.s1921.e2" seqId="e6257" text="Jak1" type="protein" />      <entity charOffset="137-140" id="AIMed.d221.s1921.e3" seqId="e6259" text="Jak" type="protein" />      <interaction e1="AIMed.d221.s1921.e1" e2="AIMed.d221.s1921.e2" id="AIMed.d221.s1921.i0" type="PPI" />    </sentence>    <sentence charOffset="185-350" id="AIMed.d221.s1922" seqId="s1922" text="Coexpression of the alpha and betaL subunits of the human interferon alpha (IFNalpha) receptor is required for the induction of an antiviral state by human IFNalpha.">      <entity charOffset="58-74" id="AIMed.d221.s1922.e0" seqId="e6260" text="interferon alpha" type="protein" />      <entity charOffset="76-84" id="AIMed.d221.s1922.e1" seqId="e6261" text="IFNalpha" type="protein" />      <entity charOffset="58-94" id="AIMed.d221.s1922.e2" seqId="e6262" text="interferon alpha (IFNalpha) receptor" type="protein" />      <entity charOffset="156-164" id="AIMed.d221.s1922.e3" seqId="e6263" text="IFNalpha" type="protein" />    </sentence>    <sentence charOffset="351-533" id="AIMed.d221.s1923" seqId="s1923" text="To explore the role of the different domains of the betaL subunit in IFNalpha signaling, we coexpressed wild-type alpha subunit and truncated forms of the betaL chain in L-929 cells.">      <entity charOffset="69-77" id="AIMed.d221.s1923.e0" seqId="e6264" text="IFNalpha" type="protein" />    </sentence>    <sentence charOffset="534-773" id="AIMed.d221.s1924" seqId="s1924" text="Our results demonstrated that the first 82 amino acids (AAs) (AAs 265-346) of the cytoplasmic domain of the betaL chain are sufficient to activate the Jak-Stat pathway and trigger an antiviral state after IFNalpha2 binding to the receptor.">      <entity charOffset="151-154" id="AIMed.d221.s1924.e0" seqId="e6265" text="Jak" type="protein" />      <entity charOffset="205-214" id="AIMed.d221.s1924.e1" seqId="e6266" text="IFNalpha2" type="protein" />    </sentence>    <sentence charOffset="774-955" id="AIMed.d221.s1925" seqId="s1925" text="This region of the betaL chain, required for Jak1 binding and activation, contains the Box 1 motif that is important for the interaction of some cytokine receptors with Jak kinases.">      <entity charOffset="45-49" id="AIMed.d221.s1925.e0" seqId="e6267" text="Jak1" type="protein" />      <entity charOffset="169-172" id="AIMed.d221.s1925.e1" seqId="e6268" text="Jak" type="protein" />    </sentence>    <sentence charOffset="956-1244" id="AIMed.d221.s1926" seqId="s1926" text="However, using glutathione S-transferase fusion proteins containing amino- and carboxyl-terminal deletions of the betaL cytoplasmic domain, we demonstrate that the main Jak1-binding region (corresponding to AAs 300-346 on the beta subunit) is distinct from the Box 1 domain (AAs 287-295).">      <entity charOffset="169-173" id="AIMed.d221.s1926.e0" seqId="e6269" text="Jak1" type="protein" />    </sentence>  </document>  <document id="AIMed.d223" origId="9368006" set="test">    <sentence charOffset="0-111" id="AIMed.d223.s1934" seqId="s1934" text="Interaction between cell cycle regulator, E2F-1, and NF-kappaB mediates repression of HIV-1 gene transcription.">      <entity charOffset="42-47" id="AIMed.d223.s1934.e0" seqId="e6296" text="E2F-1" type="protein" />      <entity charOffset="53-62" id="AIMed.d223.s1934.e1" seqId="e6298" text="NF-kappaB" type="protein" />      <interaction e1="AIMed.d223.s1934.e0" e2="AIMed.d223.s1934.e1" id="AIMed.d223.s1934.i0" type="PPI" />    </sentence>    <sentence charOffset="112-253" id="AIMed.d223.s1935" seqId="s1935" text="The NF-kappaB/Rel family of transcription factors is one of the main targets of cytokines and other agents that induce HIV-1 gene expression.">      <entity charOffset="4-13" id="AIMed.d223.s1935.e0" seqId="e6300" text="NF-kappaB" type="protein" />      <entity charOffset="14-17" id="AIMed.d223.s1935.e1" seqId="e6301" text="Rel" type="protein" />    </sentence>    <sentence charOffset="254-432" id="AIMed.d223.s1936" seqId="s1936" text="Some of these extracellular stimuli arrest cells in the G1 phase of the mitotic division cycle and modulate the activity of the tumor suppressor protein Rb and its partner E2F-1.">      <entity charOffset="153-155" id="AIMed.d223.s1936.e0" seqId="e6302" text="Rb" type="protein" />      <entity charOffset="172-177" id="AIMed.d223.s1936.e1" seqId="e6304" text="E2F-1" type="protein" />      <interaction e1="AIMed.d223.s1936.e0" e2="AIMed.d223.s1936.e1" id="AIMed.d223.s1936.i0" type="PPI" />    </sentence>    <sentence charOffset="433-721" id="AIMed.d223.s1937" seqId="s1937" text="Earlier studies indicated that E2F-1, a transcription factor that stimulates expression of S-phase-specific genes, is able to repress transcription directed by the human immunodeficiency virus (HIV-1) type-1 promoter in a variety of cells, including those of glial and lymphocytic origin.">      <entity charOffset="31-36" id="AIMed.d223.s1937.e0" seqId="e6306" text="E2F-1" type="protein" />    </sentence>    <sentence charOffset="722-933" id="AIMed.d223.s1938" seqId="s1938" text="Here, we demonstrate that E2F-1 may regulate the activity of the HIV-1 long terminal repeat through its ability to bind sequences in the NF-kappaB enhancer region and to interact with the NF-kappaB subunit, p50.">      <entity charOffset="26-31" id="AIMed.d223.s1938.e0" seqId="e6307" text="E2F-1" type="protein" />      <entity charOffset="137-146" id="AIMed.d223.s1938.e1" seqId="e6310" text="NF-kappaB" type="protein" />      <entity charOffset="188-197" id="AIMed.d223.s1938.e2" seqId="e6311" text="NF-kappaB" type="protein" />      <entity charOffset="207-210" id="AIMed.d223.s1938.e3" seqId="e6313" text="p50" type="protein" />      <interaction e1="AIMed.d223.s1938.e0" e2="AIMed.d223.s1938.e2" id="AIMed.d223.s1938.i0" type="PPI" />      <interaction e1="AIMed.d223.s1938.e0" e2="AIMed.d223.s1938.e3" id="AIMed.d223.s1938.i1" type="PPI" />    </sentence>    <sentence charOffset="934-1084" id="AIMed.d223.s1939" seqId="s1939" text="Gel retardation and methylation interference assays show that E2F-1 is able to bind specifically to a site embedded within the two NF-kappaB elements.">      <entity charOffset="62-67" id="AIMed.d223.s1939.e0" seqId="e6315" text="E2F-1" type="protein" />      <entity charOffset="131-140" id="AIMed.d223.s1939.e1" seqId="e6316" text="NF-kappaB" type="protein" />    </sentence>    <sentence charOffset="1085-1220" id="AIMed.d223.s1940" seqId="s1940" text="Gel retardation/immunoblot analysis using purified E2F-1 and p50 homodimers reveals the presence of complexes containing both proteins.">      <entity charOffset="51-56" id="AIMed.d223.s1940.e0" seqId="e6317" text="E2F-1" type="protein" />      <entity charOffset="61-64" id="AIMed.d223.s1940.e1" seqId="e6318" text="p50" type="protein" />    </sentence>    <sentence charOffset="1221-1381" id="AIMed.d223.s1941" seqId="s1941" text="Affinity chromatography and co-immunoprecipitation assays provide evidence for direct interaction of E2F-1 and p50 in the absence of their DNA target sequences.">      <entity charOffset="101-106" id="AIMed.d223.s1941.e0" seqId="e6321" text="E2F-1" type="protein" />      <entity charOffset="111-114" id="AIMed.d223.s1941.e1" seqId="e6323" text="p50" type="protein" />      <interaction e1="AIMed.d223.s1941.e0" e2="AIMed.d223.s1941.e1" id="AIMed.d223.s1941.i0" type="PPI" />    </sentence>    <sentence charOffset="1382-1500" id="AIMed.d223.s1942" seqId="s1942" text="In vitro transcription assay demonstrates that E2F-1 represses NF-kappaB mediated transcription in a cell-free system.">      <entity charOffset="47-52" id="AIMed.d223.s1942.e0" seqId="e6325" text="E2F-1" type="protein" />      <entity charOffset="63-72" id="AIMed.d223.s1942.e1" seqId="e6326" text="NF-kappaB" type="protein" />    </sentence>    <sentence charOffset="1501-1674" id="AIMed.d223.s1943" seqId="s1943" text="Functional studies in Jurkat T lymphocytic cells point to the importance of both the E2F and NF-kappaB binding sites in E2F-1 mediated repression of HIV-1 promoter, in vivo.">      <entity charOffset="85-88" id="AIMed.d223.s1943.e0" seqId="e6327" text="E2F" type="protein" />      <entity charOffset="93-102" id="AIMed.d223.s1943.e1" seqId="e6328" text="NF-kappaB" type="protein" />      <entity charOffset="120-125" id="AIMed.d223.s1943.e2" seqId="e6329" text="E2F-1" type="protein" />    </sentence>    <sentence charOffset="1675-1815" id="AIMed.d223.s1944" seqId="s1944" text="The results of this study suggest that NF-kappaB activity may be regulated by its interaction with the cell cycle regulatory protein, E2F-1.">      <entity charOffset="39-48" id="AIMed.d223.s1944.e0" seqId="e6330" text="NF-kappaB" type="protein" />      <entity charOffset="134-139" id="AIMed.d223.s1944.e1" seqId="e6332" text="E2F-1" type="protein" />      <interaction e1="AIMed.d223.s1944.e0" e2="AIMed.d223.s1944.e1" id="AIMed.d223.s1944.i0" type="PPI" />    </sentence>  </document></corpus>